Revvity (RVTY) 10-Q 5 Nov 19 2019 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Sep. 29, 2019	Oct. 31, 2019
Entity Listings [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 29, 2019
Document Transition Report	false
Entity File Number	001-5075
Entity Registrant Name	PERKINELMER INC
Entity Incorporation, State or Country Code	MA
Entity Tax Identification Number	04-2052042
Entity Address, Address Line One	940 Winter Street,
Entity Address, City or Town	Waltham,
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02451
City Area Code	781
Local Phone Number	663-6900
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		111,100,811
Entity Central Index Key	0000031791
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Amendment Flag	false
Current Fiscal Year End Date	--12-29
PKI [Member]
Entity Listings [Line Items]
Trading Symbol	PKI
Trading Symbol	PKI
PKI 21A [Member]
Entity Listings [Line Items]
Trading Symbol	PKI 21A
Trading Symbol	PKI 21A
PKI 21B [Member]
Entity Listings [Line Items]
Trading Symbol	PKI 21B
Trading Symbol	PKI 21B
Common stock, $1 par value per share [Member]
Entity Listings [Line Items]
Title of 12(b) Security	Common stock, $1 par value per share
Title of 12(b) Security	Common stock, $1 par value per share
1.875% Notes due 2026 [Member]
Entity Listings [Line Items]
Title of 12(b) Security	1.875% Notes due 2026
Title of 12(b) Security	1.875% Notes due 2026
0.60% Notes due 2021 [Member]
Entity Listings [Line Items]
Title of 12(b) Security	0.60% Notes due 2021
Title of 12(b) Security	0.60% Notes due 2021
NEW YORK STOCK EXCHANGE, INC. [Member]
Entity Listings [Line Items]
Security Exchange Name	NYSE
Security Exchange Name	NYSE

Condensed Consolidated Income S

Condensed Consolidated Income Statements - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018
Revenue from Contract with Customer, Excluding Assessed Tax	$ 706,923	$ 674,313	$ 2,078,177	$ 2,021,647
Cost of Goods and Services Sold	364,648	341,986	1,080,303	1,056,958
Selling, general and administrative expenses	204,171	196,769	604,581	601,374
Research and development expenses	45,376	48,848	141,700	142,028
Restructuring and contract termination charges, net	14,068	6,508	27,868	13,086
Operating income from continuing operations	78,660	80,202	223,725	208,201
Interest and other expense, net	15,406	2,161	51,879	29,947
Interest And Other Expense Net	15,406	(2,161)	51,879	(29,947)
Income from continuing operations before income taxes	63,254	78,041	171,846	178,254
Provision for income taxes	4,644	2,596	8,642	12,101
Income from continuing operations	58,610	75,445	163,204	166,153
Loss on disposition of discontinued operations before income taxes	0	(308)	0	(859)
Provision for (benefit from) income taxes on discontinued operations and dispositions	52	(1,411)	147	(1,341)
(Loss) income from discontinued operations and dispositions	(52)	1,103	(147)	482
Net income	$ 58,558	$ 76,548	$ 163,057	$ 166,635
Basic earnings (loss) per share:
Income (loss) from continuing operations (per share)	$ 0.53	$ 0.68	$ 1.47	$ 1.50
Gain (loss) on discontinued operations and dispositions (per share)	0	0.01	0	0
Net income (per share)	0.53	0.69	1.47	1.51
Diluted earnings (loss) per share:
Income (loss) from continuing operations (per share)	0.53	0.68	1.46	1.49
Gain (loss) on discontinued operations and dispositions (per share)	0	0.01	0	0
Net income (per share)	$ 0.52	$ 0.69	$ 1.46	$ 1.49
Weighted average shares of common stock outstanding:
Basic (in shares)	110,946	110,724	110,778	110,499
Diluted (in shares)	111,559	111,747	111,460	111,510
Cash dividends per common share	$ 0.07	$ 0.07	$ 0.21	$ 0.21
Product [Member]
Revenue from Contract with Customer, Excluding Assessed Tax	$ 493,320	$ 474,523	$ 1,434,156	$ 1,417,739
Cost of Goods and Services Sold	236,618	213,672	681,349	663,651
Service [Member]
Revenue from Contract with Customer, Excluding Assessed Tax	213,603	199,790	644,021	603,908
Cost of Goods and Services Sold	$ 128,030	$ 128,314	$ 398,954	$ 393,307

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock Amount [Member]	Capital In Excess of Par Value [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
Beginning Balance at Dec. 31, 2017	$ 2,503,188	$ 110,361	$ 58,828	$ 2,380,517	$ (46,518)
Net income	26,024			26,024
Dividends	(7,736)			(7,736)
Exercise of employee stock options and related income tax benefits	7,468	173	7,295
Cost of Repurchased Common Shares, Repurchase Plan and Amount for Statutory Tax Withholding Obligations	(4,502)	(58)	(4,444)
Issuance of common stock for long-term incentive program	(2,885)	(144)	(2,741)
Stock compensation	1,238	0	1,238	0	0
Ending Balance at Apr. 01, 2018	2,555,252	110,620	65,658	2,406,952	(27,978)
New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification | Accounting Standards Update 2016-16 [Member]	(2,062)	0	0		0
Other Comprehensive Income (Loss), after Reclassifications, Net of Tax	18,540				18,540
Beginning Balance at Dec. 31, 2017	2,503,188	110,361	58,828	2,380,517	(46,518)
Net income	166,635
Other comprehensive income (loss)	(114,130)
Ending Balance at Sep. 30, 2018	2,572,469	111,087	89,970	2,532,060	(160,648)
Cumulative Effect of New Accounting Principle in Period of Adoption | Accounting Standards Update 2014-09 [Member]	10,209	0	0		0
Beginning Balance at Apr. 01, 2018	2,555,252	110,620	65,658	2,406,952	(27,978)
Net income	64,063			64,063
Dividends	(7,728)			(7,728)
Exercise of employee stock options and related income tax benefits	880	21	859
Issuance of common stock for employee benefit plans	(1,483)	(21)	(1,462)
Cost of Repurchased Common Shares, Repurchase Plan and Amount for Statutory Tax Withholding Obligations	(94)	(1)	(93)
Issuance of common stock for long-term incentive program	(4,567)	(55)	(4,512)
Stock compensation	1,342	0	1,342	0	0
Ending Balance at Jul. 01, 2018	2,517,177	110,716	73,740	2,463,287	(130,566)
Other Comprehensive Income (Loss), after Reclassifications, Net of Tax	(102,588)				(102,588)
Net income	76,548			76,548
Other comprehensive income (loss)	(30,082)
Dividends	(7,775)			(7,775)
Exercise of employee stock options and related income tax benefits	11,136	359	10,777
Cost of Repurchased Common Shares, Repurchase Plan and Amount for Statutory Tax Withholding Obligations	(463)	(5)	(458)
Issuance of common stock for long-term incentive program	(4,472)	(17)	(4,455)
Stock compensation	1,456	0	1,456	0	0
Ending Balance at Sep. 30, 2018	2,572,469	111,087	89,970	2,532,060	(160,648)
Other Comprehensive Income (Loss), after Reclassifications, Net of Tax	(30,082)				(30,082)
Beginning Balance at Dec. 30, 2018	2,584,955	110,597	48,772	2,602,067	(176,481)
Net income	35,412			35,412
Dividends	(7,742)			(7,742)
Exercise of employee stock options and related income tax benefits	8,610	186	8,424
Issuance of common stock for employee benefit plans	(1,386)	(19)	(1,367)
Cost of Repurchased Common Shares, Repurchase Plan and Amount for Statutory Tax Withholding Obligations	(5,293)	(57)	(5,236)
Issuance of common stock for long-term incentive program	(3,538)	(146)	(3,392)
Stock compensation	1,371	0	1,371	0	0
Ending Balance at Mar. 31, 2019	2,638,472	110,891	58,090	2,643,026	(173,535)
New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification | Accounting Standards Update 2016-02 [Member]	13,289	0	0		0
Other Comprehensive Income (Loss), after Reclassifications, Net of Tax	2,946				2,946
Beginning Balance at Dec. 30, 2018	2,584,955	110,597	48,772	2,602,067	(176,481)
Net income	163,057
Other comprehensive income (loss)	(66,976)
Ending Balance at Sep. 29, 2019	2,706,797	111,093	83,996	2,755,165	(243,457)
Cumulative Effect of New Accounting Principle in Period of Adoption | Accounting Standards Update 2016-02 [Member]				13,289
Beginning Balance at Mar. 31, 2019	2,638,472	110,891	58,090	2,643,026	(173,535)
Net income	69,087			69,087
Dividends	(7,746)			(7,746)
Exercise of employee stock options and related income tax benefits	7,944	167	7,777
Issuance of common stock for employee benefit plans	(1,402)	(15)	(1,387)
Cost of Repurchased Common Shares, Repurchase Plan and Amount for Statutory Tax Withholding Obligations	(764)	(7)	(757)
Issuance of common stock for long-term incentive program	(4,389)	(5)	(4,384)
Stock compensation	1,300	0	1,300	0	0
Ending Balance at Jun. 30, 2019	2,706,867	111,071	72,181	2,704,367	(180,752)
Other Comprehensive Income (Loss), after Reclassifications, Net of Tax	(7,217)				(7,217)
Net income	58,558			58,558
Other comprehensive income (loss)	(62,705)
Dividends	(7,760)			(7,760)
Exercise of employee stock options and related income tax benefits	1,009	19	990
Issuance of common stock for employee benefit plans	(12)	1	11
Cost of Repurchased Common Shares, Repurchase Plan and Amount for Statutory Tax Withholding Obligations	(144)	(2)	(142)
Issuance of common stock for long-term incentive program	(7,896)	(6)	(7,890)
Stock compensation	3,088	0	3,088	0	0
Ending Balance at Sep. 29, 2019	2,706,797	$ 111,093	$ 83,996	$ 2,755,165	(243,457)
Other Comprehensive Income (Loss), after Reclassifications, Net of Tax	$ (62,705)				$ (62,705)

Condensed Consolidated Statemen

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018
Net income	$ 58,558	$ 76,548	$ 163,057	$ 166,635
Other Comprehensive Income (Loss), Net of Tax [Abstract]
Foreign currency translation adjustments	(62,700)	(30,105)	(66,954)	(114,198)
Unrealized (loss) gain on securities, net of tax	(5)	23	(22)	68
Other comprehensive loss	(62,705)	(30,082)	(66,976)	(114,130)
Comprehensive (loss) income	$ (4,147)	$ 46,466	$ 96,081	$ 52,505

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 29, 2019	Dec. 30, 2018
Current assets:
Cash and cash equivalents	$ 392,969	$ 163,111
Accounts receivable, net	646,286	632,669
Inventories	391,820	338,347
Other current assets	117,330	100,507
Total current assets	1,548,405	1,234,634
Property, plant and equipment, net:
At cost	668,835	680,183
Accumulated depreciation	(370,595)	(361,593)
Property, plant and equipment, net	298,240	318,590
Operating Lease, Right-of-Use Asset	174,689	0
Intangible assets, net	1,199,461	1,199,667
Goodwill	2,987,541	2,952,608
Other assets, net	280,745	270,023
Total assets	6,489,081	5,975,522
Current liabilities:
Current portion of long-term debt	506,650	14,856
Accounts payable	190,261	220,949
Accrued expenses and other current liabilities	16,923	4,834
Accrued expenses and other current liabilities	472,156	528,827
Current liabilities of discontinued operations	2,112	2,165
Total current liabilities	1,188,102	771,631
Long-term debt	1,750,925	1,876,624
Long-term liabilities	690,041	742,312
Operating Lease, Liability, Noncurrent	153,216	0
Total liabilities	3,782,284	3,390,567
Commitments and contingencies (see Note 19)
Stockholders' equity:
Preferred stock—$1 par value per share, authorized 1,000,000 shares; none issued or outstanding	0	0
Common stock—$1 par value per share, authorized 300,000,000 shares; issued and outstanding 111,093,000 shares and 110,597,000 shares at September 29, 2019 and at December 30, 2018, respectively	111,093	110,597
Capital in excess of par value	83,996	48,772
Retained earnings	2,755,165	2,602,067
Accumulated other comprehensive loss	(243,457)	(176,481)
Total stockholders’ equity	2,706,797	2,584,955
Total liabilities and stockholders’ equity	$ 6,489,081	$ 5,975,522

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 29, 2019	Dec. 30, 2018
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 1	$ 1
Preferred stock, authorized	1,000,000	1,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value	$ 1	$ 1
Common stock, authorized	300,000,000	300,000,000
Common stock, issued	111,093,000	110,597,000
Common stock, outstanding	111,093,000	110,597,000

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 29, 2019	Sep. 30, 2018
Operating activities:
Net income	$ 163,057	$ 166,635
Loss (gain) from discontinued operations and dispositions, net of income taxes	147	(482)
Income from continuing operations	163,204	166,153
Adjustments to reconcile net income from continuing operations to net cash provided by continuing operations:
Restructuring and contract termination charges, net	27,868	13,086
Depreciation and amortization	157,117	133,386
Gain on disposition of businesses and assets, net	2,469	(13,031)
Gain on Sale of Investments	0	(557)
Gain (Loss) on Extinguishment of Debt	471	0
Stock-based compensation	25,105	23,275
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability	4,399	10,804
Amortization of deferred debt financing costs and accretion of discounts	2,778	2,454
Amortization of acquired inventory revaluation	13,258	18,160
Changes in operating assets and liabilities which provided (used) cash, excluding effects from companies purchased and divested:
Accounts receivable, net	(22,132)	(12,670)
Inventories	(48,367)	(41,313)
Accounts payable	(34,043)	(36,587)
Accrued expenses and other	(143,869)	(111,341)
Net cash provided by operating activities of continuing operations	148,258	151,819
Net cash used in operating activities of discontinued operations	0	(200)
Net cash provided by operating activities	148,258	151,619
Investing activities:
Capital expenditures	(53,082)	(60,443)
Proceeds from surrender of life insurance policies	0	72
Payments to Acquire Investments	(5,387)	(5,500)
Purchases of Licenses	(5,000)	0
Proceeds from Divestiture of Businesses	550	38,027
Activity related to acquisitions, net of cash and cash equivalents acquired	(252,620)	(44,057)
Net cash used in investing activities of continuing operations	(315,539)	(71,901)
Net cash provided by investing activities of discontinued operations	0	0
Net cash used in investing activities	(315,539)	(71,901)
Financing activities:
Payments on borrowings	(1,419,489)	(1,019,000)
Proceeds from borrowings	1,034,416	605,000
Proceeds from sale of senior debt	847,195	369,340
Payments of debt financing costs	(7,922)	(2,634)
Settlement of cash flow hedges	(1,587)	(30,285)
Net payments on other credit facilities	(11,166)	(22,871)
Payments for acquisition-related contingent consideration	(28,200)	(12,800)
Proceeds from issuance of common stock under stock plans	17,563	19,484
Purchases of common stock	(6,201)	(4,974)
Dividends paid	(23,282)	(23,222)
Net Cash Provided by (Used in) Financing Activities, Continuing Operations	401,327	(121,962)
Cash Provided by (Used in) Financing Activities, Discontinued Operations	0	0
Net cash provided by (used in) financing activities	401,327	(121,962)
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	(4,384)	(7,410)
Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalent	229,662	(49,654)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents at beginning of period	166,315	202,371
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents at end of period	395,977	152,717
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$ 166,315	$ 202,371

Basis of Presentation

Basis of Presentation	9 Months Ended
	Sep. 29, 2019
Accounting Policies [Abstract]
Basis of Accounting [Text Block]	Basis of Presentation The condensed consolidated financial statements included herein have been prepared by PerkinElmer, Inc. (the “Company”), in accordance with accounting principles generally accepted in the United States of America (the “U.S.” or the "United States") and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information in the footnote disclosures of the financial statements has been condensed or omitted where it substantially duplicates information provided in the Company’s latest audited consolidated financial statements, in accordance with the rules and regulations of the SEC. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes included in its Annual Report on Form 10-K for the fiscal year ended December 30, 2018 , filed with the SEC (the “ 2018 Form 10-K”). The balance sheet amounts at December 30, 2018 in this report were derived from the Company’s audited 2018 consolidated financial statements included in the 2018 Form 10-K. The condensed consolidated financial statements reflect all adjustments that, in the opinion of management, are necessary to present fairly the Company’s financial position, results of operations and cash flows for the periods indicated. The preparation of financial statements in conformity with U.S. Generally Accepted Accounting Principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts and classifications of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The results of operations for the three and nine months ended September 29, 2019 and September 30, 2018 , respectively, are not necessarily indicative of the results for the entire fiscal year or any future period. The Company’s fiscal year ends on the Sunday nearest December 31. The Company reports fiscal years under a 52/53 week format and as a result, certain fiscal years will contain 53 weeks. The fiscal year ending December 29, 2019 (" fiscal year 2019 ") will include 52 weeks, and the fiscal year ended December 30, 2018 (" fiscal year 2018 ") included 52 weeks. Recently Adopted and Issued Accounting Pronouncements: From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (the "FASB") and are adopted by the Company as of the specified effective dates. Unless otherwise discussed, such pronouncements did not have or will not have a significant impact on the Company’s consolidated financial position, results of operations and cash flows or do not apply to the Company’s operations. In April 2019, the FASB issued Accounting Standards Update No. 2019-04, Codification Improvements to Topic 326, Financial Instruments - Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments ("ASU 2019-04"). ASU 2019-04 clarifies certain aspects of previously issued accounting standards related to: (1) ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Statements ("ASU 2016-13"), in areas of accrued interest receivable, transfers of loans and debt securities between classifications, recoveries and prepayments, (2) ASU 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities ("ASU 2017-12"), in areas of partial-term fair value hedges, fair value hedge basis adjustments, certain disclosures and transition requirements and (3) ASU 2016-01, Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities ("ASU 2016-01"), in areas of remeasurement of equity securities under ASC 820, Fair Value Measurement , when using the measurement alternative and remeasurement of equity securities at historical exchange rates. The amendments related to ASU 2016-13 are required to be adopted in conjunction with that accounting standards update, as further described below. Since the Company has already adopted ASU 2017-12 and ASU 2016-01, the related amendments in ASU 2019-04 are effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years, with early adoption permitted in any interim period. The amendments to ASU 2017-12 can either be adopted retrospectively as of the date of adoption of ASU 2017-12 or they can be adopted prospectively. The amendments to ASU 2016-01 are required to be applied using a modified-retrospective adoption approach with a cumulative-effect adjustment to retained earnings as of the date of adoption of ASU 2016-01, except for those related to equity securities without readily determinable fair values that are measured using the measurement alternative, which are required to be applied prospectively. The Company is currently evaluating the requirements of ASU 2019-04 and has not yet determined the impact of its adoption on the Company's consolidated financial position, results of operations and cash flows. In August 2018, the FASB issued Accounting Standards Update No. 2018-15, Intangibles-Goodwill and Other- Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract ("ASU 2018-15"). ASU 2018-15 aligns the accounting for implementation costs incurred in a hosting arrangement that is a service contract with the guidance on capitalizing costs associated with developing or obtaining internal-use software (and hosting arrangements that include an internal-use software license). The provisions of this guidance are to be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. ASU 2018-15 is effective for annual reporting periods beginning after December 15, 2019, and interim periods within those years with early adoption permitted. The Company is currently evaluating the requirements of this guidance and has not yet determined the impact of its adoption on the Company's consolidated financial position, results of operations and cash flows. In August 2018, the FASB issued Accounting Standards Update No. 2018-14, Compensation - Retirement Benefits - Defined Benefit Plans - General (Subtopic 715-20): Disclosure Framework - Changes to the Disclosure Requirements for Defined Benefit Plans ("ASU 2018-14"). ASU 2018-14 adds, removes, and clarifies disclosure requirements related to defined benefit pension and other postretirement plans. ASU 2018-14 adds requirements for an entity to disclose the weighted-average interest crediting rates used in the entity’s cash balance pension plans and other similar plans; and an explanation of the reasons for significant gains and losses related to changes in the benefit obligation for the period . Further, ASU 2018-14 removes guidance that currently requires the following disclosures: the amounts in accumulated other comprehensive income expected to be recognized as part of net periodic benefit cost over the next year; the amount and timing of plan assets expected to be returned to the employer; information about (1) benefits covered by related-party insurance and annuity contracts and (2) significant transactions between the plan and related parties; and the effects of a one-percentage-point change on the assumed health care costs and the effect of this change in rates on service cost, interest cost, and the benefit obligation for postretirement health care benefits. ASU 2018-14 also clarifies the guidance in Compensation-Retirement Benefits (Topic 715-20-50-3) on defined benefit plans to require disclosure of (1) the projected benefit obligation ("PBO") and fair value of plan assets for pension plans with PBOs in excess of plan assets (the same disclosure with reference to the accumulated postretirement benefit obligation rather than the PBO is required for other postretirement benefit plans) and (2) the accumulated benefit obligation ("ABO") and fair value of plan assets for pension plans with ABOs in excess of plan assets. The provisions of this guidance are to be applied retrospectively to all periods presented upon their effective date. ASU 2018-14 is effective for annual reporting periods beginning after December 15, 2020, and interim periods within those years with early adoption permitted. The Company is currently evaluating the requirements of this guidance and has not yet determined the impact of its adoption on the Company's consolidated financial position, results of operations and cash flows. In August 2018, the FASB issued Accounting Standards Update No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement ("ASU 2018-13"). ASU 2018-13 adds, removes, and modifies certain disclosures related to fair value measurements. ASU 2018-13 adds requirements for an entity to disclose the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period; and the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. Further, ASU 2018-13 removes the requirement to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy; the policy for timing of transfers between levels; and the valuation processes for Level 3 fair value measurements. ASU 2018-13 also modifies existing disclosure requirements related to measurement uncertainty. The amendments regarding changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty are to be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments are to be applied retrospectively to all periods presented upon their effective date. ASU 2018-13 is effective for annual reporting periods beginning after December 15, 2019, and interim periods within those years. Early adoption is permitted for any removed or modified disclosures. The Company is currently evaluating the requirements of this guidance and has not yet determined the impact of its adoption on the Company's consolidated financial position, results of operations and cash flows. In June 2016, the FASB issued Accounting Standards Update No. 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments . ASU 2016-13 changes how entities will measure credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. The standard requires entities to use the expected loss impairment model and will apply to most financial assets measured at amortized cost and certain other instruments, including trade and other receivables, loans, held-to-maturity debt securities, net investments in leases and off-balance sheet credit exposures. Entities are required to estimate the lifetime “expected credit loss” for each applicable financial asset and record an allowance that, when deducted from the amortized cost basis of the financial asset, presents the net amount expected to be collected on the financial asset. The standard also amends the impairment model for available-for-sale (“AFS”) debt securities and requires entities to determine whether all or a portion of the unrealized loss on an AFS debt security is a credit loss. An entity will recognize an allowance for credit losses on an AFS debt security as a contra-account to the amortized cost basis rather than as a direct reduction of the amortized cost basis of the investment. The provisions of this guidance are to be applied using a modified-retrospective approach. A prospective transition approach is required for debt securities for which an other-than-temporary impairment had been recognized before the effective date. Subsequent to the issuance of ASU 2016-13, in November 2018, the FASB issued Accounting Standards Update No. 2018-19, Codification Improvements to Topic 326, Financial Instruments - Credit Losses ("ASU 2018-19"), in April 2019, the FASB issued ASU 2019-04, and in May 2019, the FASB issued Accounting Standards Update No. 2019-05, Financial Instruments - Credit Losses (Topic 326), Targeted Transition Relief ("ASU 2019-05") . The amendments in ASU 2018-19 clarify that receivables arising from operating leases are not within the scope of Subtopic 326-20, Financial Instruments - Credit Losses - Measured at Amortized Cost . Instead, impairment of receivables arising from operating leases should be accounted for in accordance with Topic 842, Leases . The amendments in ASU 2019-04 clarify the measurement of allowance for credit losses on accrued interest receivable; the inclusion of expected recoveries in the allowance for credit losses; the permission of a prepayment-adjusted effective interest rate when determining the allowance for credit losses; and the steps entities should take when recording the transfer of loans or debt securities between measurement classifications. The amendments in ASU 2019-05 provide an option to irrevocably elect the fair value option in Subtopic 825-10, Financial Instruments-Overall , on an instrument-by-instrument basis, for eligible financial assets measured at amortized cost basis upon adoption of ASU 2016-13, but this fair value option election does not apply to held-to-maturity debt securities. The effective date and transition requirements for the amendments in ASU 2018-19, ASU 2019-04 and ASU 2019-05 are the same as the effective date and transition requirements of ASU 2016-13, which is effective for annual reporting periods beginning after December 15, 2019, and interim periods within those years. Early adoption is permitted for annual periods beginning after December 15, 2018, and interim periods therein. The Company is currently evaluating the requirements of this guidance and has not yet determined the impact of its adoption on the Company's consolidated financial position, results of operations and cash flows. In February 2016, the FASB issued Accounting Standards Update No. 2016-02, Leases ("ASU 2016-02"). ASU 2016-02 requires organizations that lease assets to recognize assets and liabilities on the balance sheet related to the rights and obligations created by those leases, regardless of whether they are classified as finance or operating leases. Consistent with current guidance, the recognition, measurement, and presentation of expenses and cash flows arising from a lease of assets will primarily depend on its classification as a finance or operating lease. ASU 2016-02 also requires new disclosures to help financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. The provisions of this guidance are effective for annual periods beginning after December 15, 2018, and interim periods within those years, with early adoption permitted. ASU 2016-02 is to be applied using a modified retrospective approach. Subsequent to the issuance of ASU 2016-02, in July 2018, the FASB issued Accounting Standards Update No. 2018-10, Codification Improvements to Topic 842, Leases ("ASU 2018-10") and Accounting Standards Update No. 2018-11, Leases (Topic 842): Targeted Improvements ("ASU 2018-11"), and in March 2019, the FASB issued Accounting Standards Update No. 2019-01, Leases (Topic 842): Codification Improvements ("ASU 2019-01"). The amendments in ASU 2018-10 clarify, correct or remove inconsistencies in the guidance provided under ASU 2016-02 related to sixteen specific issues identified. The amendments in ASU 2018-11 provide entities with an additional (and optional) transition method to adopt the new leases standard. Under the new transition method, an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. Consequently, an entity's reporting for the comparative periods presented in the financial statements in the period of adoption will continue to be in accordance with Accounting Standards Codification (“ASC”) 840, Leases ("ASC 840"). An entity that elects this additional (and optional) transition method must provide the required disclosures under ASC 840 for all periods that continue to be in accordance with ASC 840. ASU 2018-11 also provides lessors with a practical expedient, by class of underlying asset, to not separate nonlease components from the associated lease component and, instead, to account for those components as a single component if certain criteria are met. ASU 2019-01 provides clarification on implementation issues associated with adopting ASU 2016-02. ASU 2019-01 provides guidance on transition disclosures related to Topic 250, Accounting Changes and Error Corrections , specifically paragraph 205-10-50-3, which requires entities to provide in the fiscal year in which a new accounting principle is adopted the identical disclosures for interim periods after the date of adoption. The guidance in ASU 2019-01 explicitly provides an exception to the paragraph 250-10-50-3 interim disclosure requirements in the Topic 842 transition disclosure requirements. The effective date and transition requirements for these standards are the same as the effective date and transition requirements of ASU 2016-02. The standards were effective for the Company beginning on December 31, 2018, the first day of the Company's fiscal year 2019. The Company did not early adopt these standards and adopted these standards using the optional transition method. The Company applied the modified retrospective approach, and applied the new leases standards at December 31, 2018, with a cumulative effect adjustment recognized in the opening balance of retained earnings in fiscal year 2019. As a lessee, the most significant impact of the standards relates to the recognition of the right-of-use assets and lease liabilities for the operating leases in the balance sheet. In addition, the Company had deferred gains from sale-leaseback transactions that are being amortized in operating expenses over the lease terms and the leases are accounted for as operating leases under ASC 840. Under the new standards, the Company recognized the deferred gains from the sales as a cumulative effect adjustment in retained earnings at December 31, 2018. The Company also derecognized the impact of its build-to-suit arrangements in which the Company was the deemed owner during the construction period, for which the construction is complete and the lease commenced before the initial date of adoption. The adoption of the standards resulted in an increase in retained earnings at December 31, 2018 of approximately $13.3 million for the cumulative effect of initially applying the standards as of that date. In addition, the adoption of the standards resulted in the recognition of right-of-use assets of approximately $199.5 million and lease liabilities of approximately $147.1 million , primarily related to the facilities operating leases, a decrease in property and equipment of approximately $34.6 million and an increase in deferred tax liabilities of $4.6 million for the tax impact of the cumulative adjustments. The adoption did not have an impact to cash from or used in operating, investing or financing activities in the Company's consolidated statement of cash flows at December 31, 2018.

Revenue (Notes)

Revenue (Notes) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer [Text Block]			Revenue Disaggregation of revenue In the following tables, revenue is disaggregated by primary geographical markets, primary end-markets and timing of revenue recognition. The tables also include a reconciliation of the disaggregated revenue with the reportable segments' revenue. Reportable Segments Three Months Ended September 29, 2019 September 30, 2018 Discovery & Analytical Solutions Diagnostics Total Discovery & Analytical Solutions Diagnostics Total (In thousands) Primary geographical markets Americas $ 178,493 $ 96,759 $ 275,252 $ 169,366 $ 95,607 $ 264,973 Europe 119,801 70,225 190,026 110,747 68,480 179,227 Asia 128,610 113,035 241,645 126,053 104,060 230,113 $ 426,904 $ 280,019 $ 706,923 $ 406,166 $ 268,147 $ 674,313 Primary end-markets Diagnostics $ — $ 280,019 $ 280,019 $ — $ 268,147 $ 268,147 Life sciences 243,167 — 243,167 222,191 — 222,191 Applied markets 183,737 — 183,737 183,975 — 183,975 $ 426,904 $ 280,019 $ 706,923 $ 406,166 $ 268,147 $ 674,313 Timing of revenue recognition Products and services transferred at a point in time $ 311,123 $ 259,161 $ 570,284 $ 290,929 $ 247,189 $ 538,118 Services transferred over time 115,781 20,858 136,639 115,237 20,958 136,195 $ 426,904 $ 280,019 $ 706,923 $ 406,166 $ 268,147 $ 674,313 Reportable Segments Nine Months Ended September 29, 2019 September 30, 2018 Discovery & Analytical Solutions Diagnostics Total Discovery & Analytical Solutions Diagnostics Total (In thousands) Primary geographical markets Americas $ 518,884 $ 300,403 $ 819,287 $ 497,833 $ 282,536 $ 780,369 Europe 351,216 208,729 559,945 357,766 205,892 563,658 Asia 379,604 319,341 698,945 377,720 299,900 677,620 $ 1,249,704 $ 828,473 $ 2,078,177 $ 1,233,319 $ 788,328 $ 2,021,647 Primary end-markets Diagnostics $ — $ 828,473 $ 828,473 $ — $ 788,328 $ 788,328 Life sciences 702,406 — 702,406 675,807 — 675,807 Applied markets 547,298 — 547,298 557,512 — 557,512 $ 1,249,704 $ 828,473 $ 2,078,177 $ 1,233,319 $ 788,328 $ 2,021,647 Timing of revenue recognition Products and services transferred at a point in time $ 903,274 $ 765,858 $ 1,669,132 $ 886,007 $ 725,483 $ 1,611,490 Services transferred over time 346,430 62,615 409,045 347,312 62,845 410,157 $ 1,249,704 $ 828,473 $ 2,078,177 $ 1,233,319 $ 788,328 $ 2,021,647 Contract Balances Contract assets: The unbilled receivables (contract assets) primarily relate to the Company's right to consideration for work completed but not billed at the reporting date. The unbilled receivables are transferred to trade receivables when billed to customers. Contract assets are generally classified as current assets and are included in "Accounts receivable, net" in the consolidated balance sheets. The balance of contract assets as of September 29, 2019 and December 30, 2018 were $42.1 million and $31.9 million , respectively. The amount of unbilled receivables recognized at the beginning of the period that were transferred to trade receivables during the nine months ended September 29, 2019 was $16.3 million . The increase in unbilled receivables during the nine months ended September 29, 2019 as a result of recognition of revenue before billing to customers, excluding amounts transferred to trade receivables during the period, amounted to $26.5 million . Contract liabilities: The contract liabilities primarily relate to the advance consideration received from customers for products and related installation for which transfer of control has not occurred at the balance sheet date. Contract liabilities are classified as either current in "Accounts payable" or long-term in "Long-term liabilities" in the consolidated balance sheets based on the timing of when the Company expects to recognize revenue. The balance of contract liabilities as of September 29, 2019 and December 30, 2018 were $26.2 million and $30.8 million , respectively. The increase in contract liabilities during the nine months ended September 29, 2019 due to cash received, excluding amounts recognized as revenue during the period, was $15.6 million . The amount of revenue recognized during the nine months ended September 29, 2019 that was included in the contract liability balance at the beginning of the period was $20.2 million . Contract costs: The Company recognizes the incremental costs of obtaining a contract with a customer as an asset if it expects the benefit of those costs to be longer than one year. The Company determined that certain sales incentive programs meet the requirements to be capitalized. Total capitalized costs to obtain a contract were immaterial during the period and are included in other current and long-term assets on the consolidated balance sheets. The Company applies a practical expedient to expense costs as incurred for costs to obtain a contract with a customer when the amortization period would have been one year or less. These costs include the Company's internal sales force compensation program, as the Company determined that annual compensation is commensurate with annual sales activities. Transaction price allocated to the remaining performance obligations
Revenue from Contract with Customer, Excluding Assessed Tax	$ 706,923	$ 674,313	$ 2,078,177	$ 2,021,647
Transferred at Point in Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	570,284	538,118	1,669,132	1,611,490
Transferred over Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	136,639	136,195	409,045	410,157
Americas [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	275,252	264,973	819,287	780,369
Europe [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	190,026	179,227	559,945	563,658
Asia [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	241,645	230,113	698,945	677,620
Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	280,019	268,147	828,473	788,328
Life Sciences [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	243,167	222,191	702,406	675,807
Applied Markets [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	183,737	183,975	547,298	557,512
Discovery & Analytical Solutions [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	426,904	406,166	1,249,704	1,233,319
Discovery & Analytical Solutions [Member] | Transferred at Point in Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	311,123	290,929	903,274	886,007
Discovery & Analytical Solutions [Member] | Transferred over Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	115,781	115,237	346,430	347,312
Discovery & Analytical Solutions [Member] | Americas [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	178,493	169,366	518,884	497,833
Discovery & Analytical Solutions [Member] | Europe [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	119,801	110,747	351,216	357,766
Discovery & Analytical Solutions [Member] | Asia [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	128,610	126,053	379,604	377,720
Discovery & Analytical Solutions [Member] | Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	0	0	0	0
Discovery & Analytical Solutions [Member] | Life Sciences [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	243,167	222,191	702,406	675,807
Discovery & Analytical Solutions [Member] | Applied Markets [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	183,737	183,975	547,298	557,512
Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	280,019	268,147	828,473	788,328
Diagnostics [Member] | Transferred at Point in Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	259,161	247,189	765,858	725,483
Diagnostics [Member] | Transferred over Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	20,858	20,958	62,615	62,845
Diagnostics [Member] | Americas [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	96,759	95,607	300,403	282,536
Diagnostics [Member] | Europe [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	70,225	68,480	208,729	205,892
Diagnostics [Member] | Asia [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	113,035	104,060	319,341	299,900
Diagnostics [Member] | Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	280,019	268,147	828,473	788,328
Diagnostics [Member] | Life Sciences [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	0	0	0	0
Diagnostics [Member] | Applied Markets [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	$ 0	$ 0	$ 0	$ 0

Business Combinations

Business Combinations	9 Months Ended
	Sep. 29, 2019
Business Combinations [Abstract]
Business Combinations	Business Combinations Acquisitions in fiscal year 2019 During the first three quarters of fiscal year 2019, the Company completed the acquisition of three businesses for aggregate consideration of $258.4 million in cash. Cisbio Bioassays SAS (“Cisbio”), a company based in Codolet, France, was acquired for a total consideration of $219.9 million in cash, and two other businesses were acquired for a total consideration of $38.5 million in cash. The excess of the purchase price over the fair value of the acquired businesses' net assets represents cost and revenue synergies specific to the Company, as well as non-capitalizable intangible assets, such as the employee workforces acquired, and has been allocated to goodwill, which is not tax deductible. The Company has reported the operations for these acquisitions within the results of the Company's Diagnostics and Discovery & Analytical Solutions segments, from the acquisition dates. Identifiable definite-lived intangible assets, such as core technology, trade names and customer relationships, acquired as part of these acquisitions had a weighted average amortization period of 10.1 years . The total purchase price for the acquisitions in fiscal year 2019 has been allocated to the estimated fair values of assets acquired and liabilities assumed as follows: 2019 Acquisitions (In thousands) Fair value of business combination: Cash payments $ 257,970 Working capital and other adjustments 438 Less: cash acquired (13,866 ) Total $ 244,542 Identifiable assets acquired and liabilities assumed: Current assets $ 46,003 Property, plant and equipment 5,309 Other assets 529 Identifiable intangible assets: Core technology 115,467 Trade names 5,600 Customer relationships 40,200 Goodwill 79,659 Deferred taxes (39,878 ) Deferred revenue (83 ) Liabilities assumed (8,264 ) Total $ 244,542 Subsequent to September 29, 2019 , the Company completed the acquisition of Shangdong Meizheng Bio-Tech Co., Ltd. ("Meizheng Group"), a company headquartered in Beijing, China, for a total consideration of $152.0 million in cash, as of the closing date. The Company has a potential obligation to pay the former shareholder of the Meizheng Group additional contingent consideration of up to $26.0 million . The operations for this acquisition will be reported within the results of the Company's Discovery & Analytical Solutions segment from the acquisition date. Acquisitions in fiscal year 2018 During fiscal year 2018, the Company completed the acquisition of four businesses for aggregate consideration of $105.8 million . The excess of the purchase price over the fair value of the acquired businesses' net assets represents cost and revenue synergies specific to the Company, as well as non-capitalizable intangible assets, such as the employee workforces acquired, and has been allocated to goodwill, which is not tax deductible. The Company has reported the operations for these acquisitions within the results of the Company's Diagnostics and Discovery & Analytical Solutions segments from the acquisition dates. Identifiable definite-lived intangible assets, such as core technology, trade names and customer relationships, acquired as part of these acquisitions had a weighted average amortization period of 11.2 years . The total purchase price for the acquisitions in fiscal year 2018 has been allocated to the estimated fair values of assets acquired and liabilities assumed as follows: 2018 Acquisitions (In thousands) Fair value of business combination: Cash payments $ 95,950 Other liability 3,354 Contingent consideration 6,200 Working capital and other adjustments 262 Less: cash acquired (1,132 ) Total $ 104,634 Identifiable assets acquired and liabilities assumed: Current assets $ 6,079 Property, plant and equipment 1,166 Other assets 891 Identifiable intangible assets: Core technology 34,021 Trade names 1,070 Customer relationships 10,200 Goodwill 65,129 Deferred taxes (9,049 ) Debt assumed (461 ) Liabilities assumed (4,412 ) Total $ 104,634 The preliminary allocations of the purchase prices for acquisitions are based upon initial valuations. The Company's estimates and assumptions underlying the initial valuations are subject to the collection of information necessary to complete its valuations within the measurement periods, which are up to one year from the respective acquisition dates. The primary areas of the preliminary purchase price allocations that are not yet finalized relate to the fair value of certain tangible and intangible assets acquired and liabilities assumed, assets and liabilities related to income taxes and related valuation allowances, and residual goodwill. The Company expects to continue to obtain information to assist in determining the fair values of the net assets acquired at the acquisition dates during the measurement periods. During the measurement periods, the Company will adjust assets or liabilities if new information is obtained about facts and circumstances that existed as of the acquisition dates that, if known, would have resulted in the recognition of those assets and liabilities as of those dates. These adjustments will be made in the periods in which the amounts are determined and the cumulative effect of such adjustments will be calculated as if the adjustments had been completed as of the acquisition dates. All changes that do not qualify as adjustments made during the measurement periods are also included in current period earnings. Allocations of the purchase price for acquisitions are based on estimates of the fair value of the net assets acquired and are subject to adjustment upon finalization of the purchase price allocations. The accounting for business combinations requires estimates and judgments as to expectations for future cash flows of the acquired business, and the allocation of those cash flows to identifiable intangible assets, in determining the estimated fair values for assets acquired and liabilities assumed. The fair values assigned to tangible and intangible assets acquired and liabilities assumed, including contingent consideration, are based on management’s estimates and assumptions, as well as other information compiled by management, including valuations that utilize customary valuation procedures and techniques. Contingent consideration is measured at fair value at the acquisition date, based on the probability that revenue thresholds or product development milestones will be achieved during the earnout period, with changes in the fair value after the acquisition date affecting earnings to the extent it is to be settled in cash. Increases or decreases in the fair value of contingent consideration liabilities primarily result from changes in the estimated probabilities of achieving revenue thresholds, changes in discount rates or product development milestones during the earnout period. As of September 29, 2019 , the Company may have to pay contingent consideration related to acquisitions with open contingency periods of up to $28.0 million . As of September 29, 2019 , the Company has recorded contingent consideration obligations with an estimated fair value of $25.5 million , of which $21.6 million was recorded in accrued expenses and other current liabilities, and $3.9 million was recorded in long-term liabilities. As of December 30, 2018 , the Company had recorded contingent consideration obligations with an estimated fair value of $69.7 million , of which $67.0 million was recorded in accrued expenses and other current liabilities, and $2.7 million was recorded in long-term liabilities. The expected maximum earnout period for acquisitions with open contingency periods does not exceed 2.8 years from September 29, 2019 , and the remaining weighted average expected earnout period at September 29, 2019 was 9 months . If the actual results differ from the estimates and judgments used in these fair values, the amounts recorded in the condensed consolidated financial statements could result in a possible impairment of the intangible assets and goodwill, require acceleration of the amortization expense of definite-lived intangible assets or the recognition of additional contingent consideration which would be recognized as a component of operating expenses from continuing operations. Total acquisition and divestiture-related costs for the three and nine months ended September 29, 2019 were $0.8 million and $5.9 million , respectively. Net foreign exchange loss related mainly to the Company's acquisition of Cisbio for the nine months ended September 29, 2019 amounted to $2.6 million . Total acquisition and divestiture-related costs for the three and nine months ended September 30, 2018 were $1.7 million and $5.5 million , respectively. These amounts included $0.1 million and $1.0 million of net foreign exchange gain related to the foreign currency denominated stay bonus associated with the Company's acquisition of Tulip Diagnostics Private Limited for the three and nine months ended September 30, 2018 , respectively. These acquisition and divestiture-related costs were expensed as incurred and recorded in selling, general and administrative expenses and interest and other expense, net in the Company's consolidated statements of operations.

Restructuring and Lease Charges

Restructuring and Lease Charges, Net	9 Months Ended
	Sep. 29, 2019
Restructuring and Related Activities [Abstract]
Restructuring and Lease Charges, Net	Restructuring and Contract Termination Charges, Net The Company has undertaken a series of restructuring actions related to the impact of acquisitions and divestitures, the alignment of the Company's operations with its growth strategy, the integration of its business units and its productivity initiatives. The current portion of restructuring and contract termination charges is recorded in accrued restructuring and contract termination charges and the long-term portion of restructuring and contract termination charges is recorded in operating lease liabilities and long-term liabilities. The activities associated with these plans have been reported as restructuring and contract termination charges, net, as applicable, and are included as a component of income from continuing operations. The Company implemented a restructuring plan in the third quarter of fiscal year 2019 consisting of workforce reductions principally intended to realign resources to emphasize growth initiatives (the "Q3 2019 Plan"). The Company implemented a restructuring plan in the second quarter of fiscal year 2019 consisting of workforce reductions principally intended to realign resources to emphasize growth initiatives (the "Q2 2019 Plan"). The Company implemented a restructuring plan in the first quarter of fiscal year 2019 consisting of workforce reductions principally intended to realign resources to emphasize growth initiatives (the "Q1 2019 Plan"). The Company implemented a restructuring plan in each of the first, third and fourth quarters of fiscal year 2018 consisting of workforce reductions principally intended to realign resources to emphasize growth initiatives (the "Q1 2018 Plan", "Q3 2018 Plan" and "Q4 2018 Plan", respectively). Details of the plans initiated in previous years (the “Previous Plans”) are discussed more fully in Note 6 to the audited consolidated financial statements in the 2018 Form 10-K. The following table summarizes the reductions in headcount, the initial restructuring or contract termination charges by reporting segment, and the dates by which payments were substantially completed, or the dates by which payments are expected to be substantially completed, for restructuring actions implemented during fiscal years 2019 and 2018 in continuing operations: Workforce Reductions Total (Expected) Date Payments Substantially Completed by Headcount Reduction Discovery & Analytical Solutions Diagnostics Severance (In thousands, except headcount data) Q3 2019 Plan 259 $ 11,156 $ 2,641 $ 13,797 Q2 FY2020 Q2 2019 Plan 44 4,461 1,129 5,590 Q1 FY2020 Q1 2019 Plan 105 6,001 1,459 7,460 Q4 FY2019 Q4 2018 Plan 1 348 — 348 Q1 FY2019 Q3 2018 Plan 61 1,146 618 1,764 Q4 FY2019 Q1 2018 Plan 47 5,096 902 5,998 Q4 FY2019 The Company does not currently expect to incur any future charges for these plans. The Company expects to make payments under the Previous Plans for remaining residual lease obligations, with terms varying in length, through fiscal year 2022 . In connection with the termination of various contractual commitments, the Company recorded additional pre-tax charges of $0.3 million and $0.2 million during the nine months ended September 29, 2019 , in the Discovery & Analytical Solutions and Diagnostics segments, respectively. At September 29, 2019 , the Company had $18.1 million recorded for accrued restructuring and contract termination charges, of which $16.9 million was recorded in short-term accrued restructuring and contract termination charges and $1.2 million was recorded in operating lease liabilities. At December 30, 2018 , the Company had $6.2 million recorded for accrued restructuring and contract termination charges, of which $4.8 million was recorded in short-term accrued restructuring and contract termination charges, and $1.4 million was recorded in long-term liabilities. The following table summarizes the Company's restructuring and contract termination accrual balances and related activity by restructuring plan, as well as contract termination accrual balances and related activity, during the nine months ended September 29, 2019 : Balance at December 30, 2018 2019 Charges 2019 Changes in Estimates, Net 2019 Amounts Paid Balance at September 29, 2019 (In thousands) Severance: Q3 2019 Plan $ — $ 13,797 $ — $ (4,810 ) $ 8,987 Q2 2019 Plan — 5,590 — (2,701 ) 2,889 Q1 2019 Plan — 7,460 23 (5,150 ) 2,333 Q4 2018 Plan 348 — — (348 ) — Q3 2018 Plan 1,415 — 401 (1,196 ) 620 Q1 2018 Plan 1,609 — — (283 ) 1,326 Previous Plans 2,671 — 145 (1,060 ) 1,756 Restructuring 6,043 26,847 — 569 (15,548 ) 17,911 Contract Termination 137 402 50 (401 ) 188 Total Restructuring and Contract Termination $ 6,180 $ 27,249 $ 619 $ (15,949 ) $ 18,099

Interest and Other Expense (Inc

Interest and Other Expense (Income), Net	9 Months Ended
	Sep. 29, 2019
Other Income and Expenses [Abstract]
Interest and Other Expense (Income), Net	Interest and Other Expense, Net Interest and other expense, net, consisted of the following: Three Months Ended Nine Months Ended September 29, September 30, September 29, September 30, (In thousands) Interest income $ (292 ) $ (316 ) $ (925 ) $ (754 ) Interest expense 16,149 16,684 49,206 50,745 (Gain) loss on disposition of businesses and assets, net — (13,031 ) 2,469 (13,031 ) Debt extinguishment costs 471 — 471 — Other (income) expense, net (922 ) (1,176 ) 658 (7,013 ) Total interest and other expense, net $ 15,406 $ 2,161 $ 51,879 $ 29,947 Foreign currency transaction losses were $4.7 million and $9.2 million for the three and nine months ended September 29, 2019 , respectively. Foreign currency transaction losses (gains) were $4.3 million and $(8.8) million for the three and nine months ended September 30, 2018 , respectively. Net gains from forward currency hedge contracts were $4.2 million for each of the three and nine months ended September 29, 2019 . Net (gains) losses from forward currency hedge contracts were $(2.5) million and $9.8 million for the three and nine months ended September 30, 2018 , respectively. The other components of net periodic pension credit were $1.4 million and $4.4 million for the three and nine months ended September 29, 2019 , respectively. The other components of net periodic pension credit were $2.5 million and $7.5 million for the three and nine months ended September 30, 2018 , respectively. These amounts were included in other income, net.

Inventories, Net

Inventories, Net	9 Months Ended
	Sep. 29, 2019
Inventory Disclosure [Abstract]
Inventories, Net	Inventories Inventories as of September 29, 2019 and December 30, 2018 consisted of the following: September 29, December 30, (In thousands) Raw materials $ 136,102 $ 119,115 Work in progress 31,192 18,110 Finished goods 224,526 201,122 Total inventories $ 391,820 $ 338,347

Income Taxes

Income Taxes	9 Months Ended
	Sep. 29, 2019
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The Company regularly reviews its tax positions in each significant taxing jurisdiction in the process of evaluating its unrecognized tax benefits. The Company makes adjustments to its unrecognized tax benefits when: (i) facts and circumstances regarding a tax position change, causing a change in management’s judgment regarding that tax position; (ii) a tax position is effectively settled with a tax authority at a differing amount; and/or (iii) the statute of limitations expires regarding a tax position. The total provision for income taxes included in the condensed consolidated statements of operations consisted of the following: Three Months Ended Nine Months Ended September 29, September 30, September 29, September 30, (In thousands) Continuing operations $ 4,644 $ 2,596 $ 8,642 $ 12,101 Discontinued operations 52 (1,411 ) 147 (1,341 ) Total $ 4,696 $ 1,185 $ 8,789 $ 10,760 At September 29, 2019 , the Company had gross tax effected unrecognized tax benefits of $31.1 million , of which $29.4 million , if recognized, would affect the continuing operations effective tax rate. The remaining amount, if recognized, would affect discontinued operations. The Company believes that it is reasonably possible that approximately $1.3 million of its uncertain tax positions at September 29, 2019 , including accrued interest and penalties, and net of tax benefits, may be resolved over the next twelve months as a result of lapses in applicable statutes of limitations and potential settlements. Various tax years after 2009 remain open to examination by certain jurisdictions in which the Company has significant business operations, such as Finland, Germany, Italy, Netherlands, Singapore, the United Kingdom and the United States. The tax years under examination vary by jurisdiction. During the first nine months of fiscal years 2019 and 2018 , the Company recorded net discrete income tax benefit s of $12.7 million and $7.1 million , respectively. The most significant discrete tax benefits recorded in the first nine months of fiscal year 2019 include recognition of excess tax benefits on stock compensation of $4.6 million , U.S. federal return to provision adjustments of $6.5 million and $3.7 million associated with a tax election made during fiscal year 2019, partially offset by the tax expense of $2.7 million related to a change in tax reform transition tax. The most significant discrete tax benefits recorded in the first nine months of fiscal year 2018 include recognition of excess tax benefits on stock compensation of $5.4 million and change in tax reform estimates of $5.4 million , partially offset by the tax expense of $7.1 million related to the sale of the multispectral imaging business.

Debt

Debt	9 Months Ended
	Sep. 29, 2019
Debt Disclosure [Abstract]
Debt	Debt Senior Unsecured Revolving Credit Facility. On September 17, 2019, the Company terminated its previous senior unsecured revolving credit facility and entered into a new senior unsecured revolving credit facility with a five-year term and a borrowing capacity of $1.0 billion . The new senior unsecured revolving credit facility provides for revolving loans that may be either US Dollar Base Rate loans or Eurocurrency Rate loans, as those terms are defined in the new credit agreement. As of September 29, 2019 , undrawn letters of credit in the aggregate amount of $11.4 million were treated as issued and outstanding when calculating the borrowing availability under the facility. As of September 29, 2019 , the Company had $957.3 million available for additional borrowing under the facility. The Company plans to use the new senior unsecured revolving credit facility for general corporate purposes, which may include working capital, refinancing existing indebtedness, capital expenditures, share repurchases, acquisitions and strategic alliances. The interest rates on the Eurocurrency Rate loans are based on the Eurocurrency Rate at the time of borrowing, plus a percentage spread based on the credit rating of the Company's debt. The interest rates on the US Dollar Base Rate loans are based on the US Dollar Base Rate at the time of borrowing, plus a percentage spread based on the credit rating of the Company's debt. The base rate is the higher of (i) the Federal Funds Rate (as defined in the new credit agreement) plus 50 basis points (ii) the rate of interest in effect for such day as publicly announced from time to time by Bank of America as its "prime rate," or (iii) the Eurocurrency Rate plus 1.00%. The Eurocurrency margin as of September 29, 2019 was 101.5 basis points. The weighted average Eurocurrency interest rate as of September 29, 2019 was 0.75%, resulting in a weighted average effective Eurocurrency Rate, including the margin, of 1.77%, which was the interest applicable to the borrowings outstanding as of September 29, 2019 . As of September 29, 2019 , the new senior unsecured revolving credit facility had outstanding borrowings of $31.3 million , and $3.5 million of unamortized debt issuance costs. As of December 30, 2018 , the previous senior unsecured revolving credit facility had outstanding borrowings of $418.0 million , and $2.4 million of unamortized debt issuance costs. The credit agreement for the new facility contains affirmative, negative and financial covenants and events of default. The financial covenants include a debt-to-capital ratio that remains applicable for so long as the Company's debt is rated as investment grade. In the event that the Company's debt is not rated as investment grade, the debt-to-capital ratio covenant is replaced with a maximum consolidated leverage ratio covenant and a minimum consolidated interest coverage ratio covenant. 5% Senior Unsecured Notes due in 2021. On October 25, 2011, the Company issued $500.0 million aggregate principal amount of senior unsecured notes due in 2021 (the “November 2021 Notes”) in a registered public offering and received $493.6 million of net proceeds from the issuance. The November 2021 Notes were issued at 99.4% of the principal amount, which resulted in a discount of $3.1 million . As of September 29, 2019 , the November 2021 Notes had an aggregate carrying value of $498.0 million , net of $0.8 million of unamortized original issue discount and $1.2 million of unamortized debt issuance costs. As of December 30, 2018 , the November 2021 Notes had an aggregate carrying value of $497.4 million , net of $1.1 million of unamortized original issue discount and $1.6 million of unamortized debt issuance costs. The November 2021 Notes were scheduled to mature in November 2021 and bore interest at an annual rate of 5% . Interest on the November 2021 Notes was payable semi-annually on May 15th and November 15th each year. On October 13, 2019, the Company redeemed all of its outstanding November 2021 Notes. The redemption of the November 2021 Notes resulted in a pre-tax, non-operating charge of $32.3 million . The non-operating charge consists of a cash make-whole premium payment of $31.3 million , net of $1.0 million from a reverse treasury rate lock settlement, to call the November 2021 Notes and $2.0 million associated with existing deferred costs and original issue discount. 1.875% Senior Unsecured Notes due 2026. On July 19, 2016, the Company issued €500.0 million aggregate principal amount of senior unsecured notes due in 2026 (the “2026 Notes”) in a registered public offering and received approximately €492.3 million of net proceeds from the issuance. The 2026 Notes were issued at 99.118% of the principal amount, which resulted in a discount of €4.4 million . The 2026 Notes mature in July 2026 and bear interest at an annual rate of 1.875% . Interest on the 2026 Notes is payable annually on July 19th each year. The proceeds from the 2026 Notes were used to pay in full the outstanding balance of the Company's previous senior unsecured revolving credit facility. As of September 29, 2019 , the 2026 Notes had an aggregate carrying value of $540.1 million , net of $3.5 million of unamortized original issue discount and $3.4 million of unamortized debt issuance costs. As of December 30, 2018 , the 2026 Notes had an aggregate carrying value of $564.5 million , net of $4.0 million of unamortized original issue discount and $3.8 million of unamortized debt issuance costs. Prior to April 19, 2026 (three months prior to their maturity date), the Company may redeem the 2026 Notes in whole at any time or in part from time to time, at its option, at a redemption price equal to the greater of (i) 100% of the principal amount of the 2026 Notes to be redeemed, or (ii) the sum of the present values of the remaining scheduled payments of principal and interest in respect to the 2026 Notes being redeemed, discounted on an annual basis, at the applicable Comparable Government Bond Rate (as defined in the indenture governing the 2026 Notes) plus 35 basis points; plus, in each case, accrued and unpaid interest. In addition, at any time on or after April 19, 2026 (three months prior to their maturity date), the Company may redeem the 2026 Notes, at its option, at a redemption price equal to 100% of the principal amount of the 2026 Notes due to be redeemed plus accrued and unpaid interest. Upon a change of control (as defined in the indenture governing the 2026 Notes) and a contemporaneous downgrade of the 2026 Notes below investment grade, the Company will, in certain circumstances, make an offer to purchase the 2026 Notes at a price equal to 101% of their principal amount plus any accrued and unpaid interest. 0.6% Senior Unsecured Notes due in 2021. On April 11, 2018, the Company issued €300.0 million aggregate principal amount of senior unsecured notes due in 2021 (the “April 2021 Notes”) in a registered public offering and received approximately €298.7 million of net proceeds from the issuance. The April 2021 Notes were issued at 99.95% of the principal amount, which resulted in a discount of €0.2 million . As of September 29, 2019 , the April 2021 Notes had an aggregate carrying value of $326.8 million , net of $0.1 million of unamortized original issue discount and $1.3 million of unamortized debt issuance costs. As of December 30, 2018 , the April 2021 Notes had an aggregate carrying value of $341.3 million , net of $0.1 million of unamortized original issue discount and $2.0 million of unamortized debt issuance costs. The April 2021 Notes mature in April 2021 and bear interest at an annual rate of 0.6% . Interest on the April 2021 Notes is payable annually on April 9th each year. Prior to the maturity date of the April 2021 Notes, the Company may redeem them in whole at any time or in part from time to time, at its option, at a redemption price equal to the greater of (i) 100% of the principal amount of the April 2021 Notes to be redeemed, or (ii) the sum of the present values of the remaining scheduled payments of principal and interest in respect to the April 2021 Notes being redeemed, discounted on an annual basis, at the applicable Comparable Government Bond Rate (as defined in the indenture governing the April 2021 Notes) plus 15 basis points; plus, in each case, accrued and unpaid interest. Upon a change of control (as defined in the indenture governing the April 2021 Notes) and a contemporaneous downgrade of the April 2021 Notes below investment grade, the Company will, in certain circumstances, make an offer to purchase the April 2021 Notes at a price equal to 101% of their principal amount, plus accrued and unpaid interest. 3.3% Senior Unsecured Notes due in 2029. On September 12, 2019, the Company issued $850.0 million aggregate principal amount of senior unsecured notes due in 2029 (the "2029 Notes”) in a registered public offering and received $847.2 million of net proceeds from the issuance. The 2029 Notes were issued at 99.67% of the principal amount, which resulted in a discount of $2.8 million . As of September 29, 2019 , the 2029 Notes had an aggregate carrying value of $839.1 million , net of $2.8 million of unamortized original issue discount and $8.1 million of unamortized debt issuance costs. The 2029 Notes mature in September 2029 and bear interest at an annual rate of 3.3% . Interest on the 2029 Notes is payable semi-annually on March 15th and September 15th each year. Proceeds from the 2029 Notes were used to repay all outstanding borrowings under the Company’s previous senior unsecured revolving credit facility with the remaining proceeds used in the redemption of the November 2021 Notes. Prior to June 15, 2029 (three months prior to their maturity date), the Company may redeem the 2029 Notes in whole or in part, at its option, at a redemption price equal to the greater of (i) 100% of the principal amount of the 2029 Notes to be redeemed, and (ii) the sum of the present values of the remaining scheduled payments of principal and interest in respect to the 2029 Notes being redeemed (not including any portion of such payments of interest accrued but unpaid as of the date of redemption) assuming that such 2029 Notes matured on June 15, 2029, discounted at the date of redemption on a semi-annual basis (assuming a 360-day year of twelve 30-day months), at the Treasury Rate (as defined in the indenture governing the 2029 Notes) plus 25 basis points, plus accrued and unpaid interest. At any time on or after June 15, 2029 (three months prior to their maturity date), the Company may redeem the 2029 Notes, at its option, at a redemption price equal to 100% of the principal amount of the 2029 Notes to be redeemed plus accrued and unpaid interest. Upon a change of control (as defined in the indenture governing the 2029 Notes) and a contemporaneous downgrade of the 2029 Notes below investment grade, each holder of 2029 Notes will have the right to require the Company to repurchase such holder's 2029 Notes for 101% of their principal amount, plus accrued and unpaid interest. Other Debt Facilities. The Company's other debt facilities include Euro-denominated bank loans with an aggregate carrying value of $25.4 million (or €23.2 million ) and $32.1 million (or €28.0 million ) as of September 29, 2019 and December 30, 2018 , respectively. These bank loans are primarily utilized for financing fixed assets and are required to be repaid in monthly or quarterly installments with maturity dates extending to 2028. Of these bank loans, loans in the aggregate amount of $25.3 million bear fixed interest rates between 1.1% and 4.5% and a loan in the amount of $0.1 million bears a variable interest rate based on the Euribor rate plus a margin of 1.5% . An aggregate amount of $4.0 million of the bank loans are secured by mortgages on real property and the remaining $21.4 million are unsecured. Certain credit agreements for the unsecured bank loans include financial covenants which are based on an equity ratio or an equity ratio and minimum interest coverage ratio. In addition, the Company had secured bank loans in the aggregate amount of $0.3 million as of September 29, 2019 , and unsecured revolving credit facilities and a secured bank loan in the amount of $5.8 million and $0.3 million , respectively, as of December 30, 2018 . The unsecured revolving debt facilities had fixed interest at a rate of 2.3% . The secured bank loans of $0.3 million bear fixed annual interest rates between 1.95% and 5.0% and are required to be repaid in monthly installments until 2027. Financing Lease Obligations. In fiscal year 2012, the Company entered into agreements with the lessors of certain buildings that the Company is currently occupying and leasing to expand those buildings. The Company provided a portion of the funds needed for the construction of the additions to the buildings, and as a result the Company was considered the owner of the buildings during the construction period. At the end of the construction period, the Company was not reimbursed by the lessors for all of the construction costs. The Company is therefore deemed to have continuing involvement and the leases qualify as financing leases under sale-leaseback accounting guidance, representing debt obligations for the Company and non-cash investing and financing activities. As a result, the Company capitalized $29.3 million in property, plant and equipment, net, representing the fair value of the buildings with a corresponding increase to debt. The Company has also capitalized $11.5 million in additional construction costs necessary to complete the renovations to the buildings, which were funded by the lessors, with a corresponding increase to debt. At December 30, 2018 , the Company had $34.5 million recorded for these financing lease obligations, of which $1.5 million was recorded as short-term debt and $33.0 million was recorded as long-term debt. Prior to adoption of ASC 842, Leases

Earnings Per Share

Earnings Per Share	9 Months Ended
	Sep. 29, 2019
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share Basic earnings per share was computed by dividing net income by the weighted-average number of common shares outstanding during the period less restricted unvested shares. Diluted earnings per share was computed by dividing net income by the weighted-average number of common shares outstanding plus all potentially dilutive common stock equivalents, primarily shares issuable upon the exercise of stock options using the treasury stock method. The following table reconciles the number of shares utilized in the earnings per share calculations: Three Months Ended Nine Months Ended September 29, September 30, September 29, September 30, (In thousands) Number of common shares—basic 110,946 110,724 110,778 110,499 Effect of dilutive securities: Stock options 484 791 558 813 Restricted stock awards 129 232 124 198 Number of common shares—diluted 111,559 111,747 111,460 111,510 Number of potentially dilutive securities excluded from calculation due to antidilutive impact 413 358 396 346 Antidilutive securities include outstanding stock options with exercise prices and average unrecognized compensation cost in excess of the average fair market value of common stock for the related period. Antidilutive options were excluded from the calculation of diluted net income per share and could become dilutive in the future.

Industry Segment Information

Industry Segment Information	9 Months Ended
	Sep. 29, 2019
Segment Reporting [Abstract]
Industry Segment Information	Industry Segment Information The Company discloses information about its operating segments based on the way that management organizes the segments within the Company for making operating decisions and assessing financial performance. The Company evaluates the performance of its operating segments based on revenue and operating income. Intersegment revenue and transfers are not significant. The accounting policies of the operating segments are the same as those described in Note 1 to the audited consolidated financial statements in the 2018 Form 10-K. The principal products and services of the Company's two operating segments are: • Discovery & Analytical Solutions . Provides products and services targeted towards the life sciences and applied markets. • Diagnostics . Develops diagnostics, tools and applications focused on clinically-oriented customers, especially within the reproductive health, immunodiagnostics and applied genomics markets. The Diagnostics segment serves the diagnostics market. The Company has included the expenses for its corporate headquarters, such as legal, tax, audit, human resources, information technology, and other management and compliance costs, as well as the activity related to the mark-to-market adjustment on postretirement benefit plans, as “Corporate” below. The Company has a process to allocate and recharge expenses to the reportable segments when these costs are administered or paid by the corporate headquarters based on the extent to which the segment benefited from the expenses. These amounts have been calculated in a consistent manner and are included in the Company’s calculations of segment results to internally plan and assess the performance of each segment for all purposes, including determining the compensation of the business leaders for each of the Company’s operating segments. Revenue and operating income (loss) from continuing operations by operating segment are shown in the table below: Three Months Ended Nine Months Ended September 29, September 30, September 29, September 30, (In thousands) Discovery & Analytical Solutions Product revenue $ 256,118 $ 247,250 $ 738,422 $ 748,270 Service revenue 170,786 158,916 511,282 485,049 Total revenue 426,904 406,166 1,249,704 1,233,319 Operating income from continuing operations 52,347 48,381 146,963 149,243 Diagnostics Product revenue 237,202 227,273 695,734 669,469 Service revenue 42,817 40,874 132,739 118,859 Total revenue 280,019 268,147 828,473 788,328 Operating income from continuing operations 47,443 47,411 128,184 104,585 Corporate Operating loss from continuing operations (21,130 ) (15,590 ) (51,422 ) (45,627 ) Continuing Operations Product revenue 493,320 474,523 1,434,156 1,417,739 Service revenue 213,603 199,790 644,021 603,908 Total revenue 706,923 674,313 2,078,177 2,021,647 Operating income from continuing operations 78,660 80,202 223,725 208,201 Interest and other expense, net (see Note 5) 15,406 2,161 51,879 29,947 Income from continuing operations before income taxes $ 63,254 $ 78,041 $ 171,846 $ 178,254

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 29, 2019
Stockholders' Equity Note [Abstract]
Stockholders' Equity	Stockholders’ Equity Comprehensive Income: The components of accumulated other comprehensive loss consisted of the following: September 29, December 30, (In thousands) Foreign currency translation adjustments $ (243,413 ) $ (176,459 ) Unrecognized prior service costs, net of income taxes 245 245 Unrealized net losses on securities, net of income taxes (289 ) (267 ) Accumulated other comprehensive loss $ (243,457 ) $ (176,481 ) Stock Repurchases: On July 23, 2018, the Board of Directors (the "Board") authorized the Company to repurchase shares of common stock for an aggregate amount up to $250.0 million under a stock repurchase program (the "Repurchase Program"). The Repurchase Program will expire on July 23, 2020 unless terminated earlier by the Board and may be suspended or discontinued at any time. During the nine months ended September 29, 2019 , the Company had no stock repurchases under the Repurchase Program. As of September 29, 2019 , $197.8 million remained available for aggregate repurchases of shares under the Repurchase Program. In addition, the Board has authorized the Company to repurchase shares of common stock to satisfy minimum statutory tax withholding obligations in connection with the vesting of restricted stock awards and restricted stock unit awards granted pursuant to the Company’s equity incentive plans and to satisfy obligations related to the exercise of stock options made pursuant to the Company's equity incentive plans. During the three months ended September 29, 2019 , the Company repurchased 1,654 shares of common stock for this purpose at an aggregate cost of $0.1 million . During the nine months ended September 29, 2019 , the Company repurchased 67,222 shares of common stock for this purpose at an aggregate cost of $6.2 million. The repurchased shares have been reflected as additional authorized but unissued shares, with the payments reflected in common stock and capital in excess of par value. Dividends: The Board declared a regular quarterly cash dividend of $0.07 per share for the first three quarters of fiscal year 2019 and in each quarter of fiscal year 2018 . At September 29, 2019 , the Company has accrued $7.8 million for dividends declared on July 25, 2019 for the third quarter of fiscal year 2019 that will be payable in November 2019 . On October 24, 2019 , the Company announced that the Board had declared a quarterly dividend of $0.07 per share for the fourth quarter of fiscal year 2019 that will be payable in February 2020 . In the future, the Board may determine to reduce or eliminate the Company’s common stock dividend in order to fund investments for growth, repurchase shares or conserve capital resources.

Stock Plans

Stock Plans	9 Months Ended
	Sep. 29, 2019
Share-based Payment Arrangement [Abstract]
Stock Plans	Stock Plans The Company’s 2019 Incentive Plan (the “2019 Plan”) authorizes the issuance of incentive stock options intended to qualify under Section 422 of the Internal Revenue Code of 1986, as amended, non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units, other stock-based awards and cash awards as part of the Company’s compensation programs. The 2019 Plan was approved by the Company’s Board on January 24, 2019 and by the Company’s shareholders on April 23, 2019. The 2019 Plan replaced the Company’s 2009 Incentive Plan (the “2009 Plan”), under which the Company’s common stock was made available for stock option grants, restricted stock awards, performance restricted stock units, performance units and stock awards as part of the Company’s compensation programs. Upon shareholder approval of the 2019 Plan, 6.25 million shares of the Company’s common stock, as well as shares of the Company’s common stock previously granted under the 2009 Plan that expire, terminate or are otherwise surrendered, canceled, forfeited or repurchased by the Company at their original issuance price subject to a contractual repurchase right, became available for grant under the 2019 Plan. Awards granted under the 2009 Plan prior to its expiration remain outstanding. As part of the Company’s compensation programs, the Company also offers shares of its common stock under its Employee Stock Purchase Plan. The following table summarizes total pre-tax compensation expense recognized related to the Company’s stock option grants, restricted stock awards, performance restricted stock units, performance units and stock awards, included in the Company’s condensed consolidated statements of operations for the three and nine months ended September 29, 2019 and September 30, 2018 : Three Months Ended Nine Months Ended September 29, September 30, September 29, September 30, (In thousands) Cost of revenue $ 477 $ 430 $ 1,188 $ 1,093 Research and development expenses 178 335 802 1,029 Selling, general and administrative expenses 11,649 10,362 23,115 21,153 Total stock-based compensation expense $ 12,304 $ 11,127 $ 25,105 $ 23,275 The total income tax benefit recognized in the condensed consolidated statements of operations for stock-based compensation was $2.8 million and $10.0 million for the three and nine months ended September 29, 2019 , respectively. The total income tax benefit recognized in the condensed consolidated statements of operations for stock-based compensation was $6.1 million and $10.6 million for the three and nine months ended September 30, 2018 , respectively. Stock-based compensation costs capitalized as part of inventory was $0.4 million as of each of September 29, 2019 and September 30, 2018 . Stock Options : The fair value of each option grant is estimated using the Black-Scholes option pricing model. The Company’s weighted-average assumptions used in the Black-Scholes option pricing model were as follows: Three and Nine Months Ended September 29, September 30, Risk-free interest rate 1.9 % 2.9 % Expected dividend yield 0.3 % 0.4 % Expected term 5 years 5 years Expected stock volatility 22.8 % 20.7 % The following table summarizes stock option activity for the nine months ended September 29, 2019 : Number of Shares Weighted- Average Exercise Price Weighted-Average Remaining Contractual Term Total Intrinsic Value (In thousands) (In years) (In millions) Outstanding at December 30, 2018 1,765 $ 52.91 Granted 302 93.67 Exercised (371 ) 47.30 Forfeited (112 ) 78.29 Outstanding at September 29, 2019 1,584 $ 60.20 4.0 $ 39.5 Exercisable at September 29, 2019 997 $ 48.75 3.1 $ 36.3 The weighted-average per-share grant-date fair value of options granted during the nine months ended September 29, 2019 was $22.64 . The weighted-average per-share grant-date fair value of options granted during the three and nine months ended September 30, 2018 was $18.65 and $17.56 , respectively. The total intrinsic value of options exercised during the three and nine months ended September 29, 2019 was $0.6 million and $17.3 million , respectively. The total intrinsic value of options exercised during the three and nine months ended September 30, 2018 was $18.9 million and $25.3 million , respectively. Cash received from option exercises for the nine months ended September 29, 2019 and September 30, 2018 was $17.6 million and $19.5 million , respectively. The total compensation expense recognized related to the Company’s outstanding options was $3.1 million and $5.7 million for the three and nine months ended September 29, 2019 , respectively, and $1.4 million and $4.0 million for the three and nine months ended September 30, 2018 , respectively. There was $7.7 million of total unrecognized compensation cost related to nonvested stock options granted as of September 29, 2019 . This cost is expected to be recognized over a weighted-average period of 1.9 years. Restricted Stock Awards : The following table summarizes restricted stock award activity for the nine months ended September 29, 2019 : Number of Shares Weighted- Average Grant- Date Fair Value (In thousands) Nonvested at December 30, 2018 465 $ 61.72 Granted 161 94.88 Vested (214 ) 54.91 Forfeited (57 ) 75.90 Nonvested at September 29, 2019 355 $ 78.57 The fair value of restricted stock awards vested during the three and nine months ended September 29, 2019 was $0.4 million and $11.7 million , respectively. The fair value of restricted stock awards vested during the three and nine months ended September 30, 2018 was $1.1 million and $10.0 million , respectively. The total compensation expense recognized related to the Company’s outstanding restricted stock awards was $4.7 million and $10.2 million for the three and nine months ended September 29, 2019 , respectively, and $3.0 million and $8.7 million for the three and nine months ended September 30, 2018 , respectively. As of September 29, 2019 , there was $18.2 million of total unrecognized compensation cost related to nonvested restricted stock awards. This cost is expected to be recognized over a weighted-average period of 1.5 years. Performance Restricted Stock Units: As part of the Company's executive compensation program, the Company granted 76,218 performance restricted stock units during the nine months ended September 29, 2019 that will vest based on performance of the Company. The weighted-average per-share grant date fair value of performance restricted stock units granted during the nine months ended September 29, 2019 was $92.95 . During the nine months ended September 29, 2019 , 18,777 performance restricted stock units were forfeited. The total compensation expense recognized related to performance restricted stock units was $3.2 million and $4.8 million for the three and nine months ended September 29, 2019 , respectively, and $1.3 million and $2.2 million for the three and nine months ended September 30, 2018 , respectively. As of September 29, 2019 , there were 145,114 performance restricted stock units outstanding. Performance Units : No performance units were granted during the nine months ended September 29, 2019 . During the nine months ended September 29, 2019 , 10,116 performance units were forfeited. The total compensation expense recognized related to performance units was $1.3 million and $3.7 million for the three and nine months ended September 29, 2019 , respectively, and $5.3 million and $7.6 million for the three and nine months ended September 30, 2018 , respectively. As of September 29, 2019 , there were 71,213 performance units outstanding and subject to forfeiture, with a corresponding liability of $8.5 million recorded in accrued expenses and other current liabilities. Stock Awards : The Company’s stock award program provides an annual equity award to non-employee directors. During the nine months ended September 29, 2019 , the Company awarded 7,301 shares to non-employee directors. The weighted-average per-share grant-date fair value of the stock awards granted during the nine months ended September 29, 2019 was $95.84 . The total compensation expense recognized related to the stock awards was $0.7 million and $0.8 million for the nine months ended September 29, 2019 and September 30, 2018 , respectively. Employee Stock Purchase Plan : During the nine months ended September 29, 2019 , the Company issued 33,843 shares of common stock under the Company's Employee Stock Purchase Plan at a weighted-average price of $82.25 per share. During the nine months ended September 30, 2018 , the Company issued 21,321 shares of common stock under the Company's Employee Stock Purchase Plan at a weighted-average price of $69.57 per share. At September 29, 2019 , an aggregate of 0.8 million shares of the Company’s common stock remained available for sale to employees out of the 5.0 million shares authorized by shareholders for issuance under this plan.

Goodwill and Intangible Assets,

Goodwill and Intangible Assets, Net	9 Months Ended
	Sep. 29, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets, Net	Goodwill and Intangible Assets, Net The Company tests goodwill and non-amortizing intangible assets at least annually for possible impairment. Accordingly, the Company completes the annual testing of impairment for goodwill and non-amortizing intangible assets on the later of January 1 or the first day of each fiscal year. In addition to its annual test, the Company regularly evaluates whether events or circumstances have occurred that may indicate a potential impairment of goodwill or non-amortizing intangible assets. The process of testing goodwill for impairment involves the determination of the fair value of the applicable reporting units. The test consists of the comparison of the fair value to the carrying value of the reporting unit to determine if the carrying value exceeds the fair value. If the carrying value of the reporting unit exceeds its fair value, an impairment loss in an amount equal to that excess is recognized up to the amount of goodwill . The Company performed its annual impairment testing for its reporting units as of January 1, 2019 , its annual impairment testing date for fiscal year 2019 . The Company concluded that there was no goodwill impairment. The range of the long-term terminal growth rates for the Company’s reporting units was 3% to 5% for the fiscal year 2019 impairment analysis. The range for the discount rates for the reporting units was 10.5% to 15% . Keeping all other variables constant, a 10% change in any one of these input assumptions for the various reporting units would still allow the Company to conclude that there was no impairment of goodwill. The Company has consistently employed the income approach to estimate the current fair value when testing for impairment of goodwill. A number of significant assumptions and estimates are involved in the application of the income approach to forecast operating cash flows, including markets and market share, sales volumes and prices, costs to produce, tax rates, capital spending, discount rates and working capital changes. Cash flow forecasts are based on approved business unit operating plans for the early years’ cash flows and historical relationships in later years. The income approach is sensitive to changes in long-term terminal growth rates and the discount rates. The long-term terminal growth rates are consistent with the Company’s historical long-term terminal growth rates, as the current economic trends are not expected to affect the long-term terminal growth rates of the Company. The Company corroborates the income approach with a market approach. Non-amortizing intangibles are also subject to an annual impairment test. The Company has consistently employed the relief from royalty model to estimate the current fair value when testing for impairment of non-amortizing intangible assets. The impairment test consists of a comparison of the fair value of the non-amortizing intangible asset with its carrying amount. If the carrying amount of a non-amortizing intangible asset exceeds its fair value, an impairment loss in an amount equal to that excess is recognized up to the amount of the amortizing intangible asset. In addition, the Company evaluates the remaining useful life of its non-amortizing intangible asset at least annually to determine whether events or circumstances continue to support an indefinite useful life. If events or circumstances indicate that the useful life of the Company's non-amortizing intangible asset is no longer indefinite, the asset will be tested for impairment. This intangible asset will then be amortized prospectively over its estimated remaining useful life and accounted for in the same manner as other intangible assets that are subject to amortization. The Company performed its annual impairment testing as of January 1, 2019 and concluded that there was no impairment of its non-amortizing intangible asset. An assessment of the recoverability of amortizing intangible assets takes place when events have occurred that may give rise to an impairment. No such events occurred during the first nine months of fiscal year 2019 . The changes in the carrying amount of goodwill for the nine months ended September 29, 2019 were as follows: Discovery & Analytical Solutions Diagnostics Consolidated (In thousands) Balance at December 30, 2018 $ 1,334,992 $ 1,617,616 $ 2,952,608 Foreign currency translation (22,342 ) (27,941 ) (50,283 ) Acquisitions, earn-outs and other 17,970 67,246 85,216 Balance at September 29, 2019 $ 1,330,620 $ 1,656,921 $ 2,987,541 Identifiable intangible asset balances by category were as follows: September 29, December 30, (In thousands) Patents $ 30,816 $ 42,646 Less: Accumulated amortization (27,136 ) (37,753 ) Net patents 3,680 4,893 Trade names and trademarks 81,103 78,146 Less: Accumulated amortization (38,138 ) (33,801 ) Net trade names and trademarks 42,965 44,345 Licenses 58,728 53,305 Less: Accumulated amortization (48,664 ) (45,550 ) Net licenses 10,064 7,755 Core technology 637,051 540,911 Less: Accumulated amortization (302,709 ) (265,744 ) Net core technology 334,342 275,167 Customer relationships 1,084,801 1,089,527 Less: Accumulated amortization (348,275 ) (293,964 ) Net customer relationships 736,526 795,563 IPR&D 1,300 1,360 Net amortizable intangible assets 1,128,877 1,129,083 Non-amortizing intangible asset: Trade name 70,584 70,584 Total $ 1,199,461 $ 1,199,667 Total amortization expense related to definite-lived intangible assets was $41.3 million and $121.2 million for the three and nine months ended September 29, 2019 , respectively, and $35.3 million and $100.7 million for the three and nine months ended September 30, 2018 , respectively. Estimated amortization expense related to amortizable intangible assets for each of the next five years is $40.5 million for the remainder of fiscal year 2019 , $172.1 million for fiscal year 2020 , $157.2 million for fiscal year 2021 , $141.6 million for fiscal year 2022 , and $118.6 million for fiscal year 2023

Warranty Reserves

Warranty Reserves	9 Months Ended
	Sep. 29, 2019
Product Warranties Disclosures [Abstract]
Warranty Reserves	Warranty Reserves The Company provides warranty protection for certain products usually for a period of one year beyond the date of sale. The majority of costs associated with warranty obligations include the replacement of parts and the time for service personnel to respond to repair and replacement requests. A warranty reserve is recorded based upon historical results, supplemented by management’s expectations of future costs. Warranty reserves are included in “Accrued expenses and other current liabilities” on the condensed consolidated balance sheets. A summary of warranty reserve activity is as follows: Three Months Ended Nine Months Ended September 29, September 30, September 29, September 30, (In thousands) Balance at beginning of period $ 7,985 $ 8,943 $ 8,393 $ 9,050 Provision charged to income 2,899 3,327 8,601 10,012 Payments (3,999 ) (3,547 ) (10,536 ) (10,514 ) Adjustments to previously provided warranties, net 1,239 (226 ) 1,658 110 Foreign currency translation and acquisitions (169 ) (49 ) (161 ) (210 ) Balance at end of period $ 7,955 $ 8,448 $ 7,955 $ 8,448

Employee Benefit Plans

Employee Benefit Plans	9 Months Ended
	Sep. 29, 2019
Retirement Benefits [Abstract]
Employee Benefit Plans	Employee Postretirement Benefit Plans The following table summarizes the components of net periodic pension credit for the Company’s various defined benefit employee pension and postretirement plans: Defined Benefit Pension Benefits Postretirement Medical Benefits Three Months Ended September 29, September 30, September 29, September 30, (In thousands) Service and administrative costs $ 1,698 $ 1,712 $ 22 $ 27 Interest cost 4,136 4,051 29 30 Expected return on plan assets (6,132 ) (7,270 ) (294 ) (314 ) Amortization of prior service costs (38 ) (41 ) — — Net periodic pension credit $ (336 ) $ (1,548 ) $ (243 ) $ (257 ) Defined Benefit Pension Benefits Postretirement Medical Benefits Nine Months Ended September 29, September 30, September 29, September 30, (In thousands) Service cost $ 4,960 $ 5,180 $ 66 $ 80 Interest cost 12,445 12,212 87 90 Expected return on plan assets (18,469 ) (21,926 ) (882 ) (941 ) Amortization of prior service costs (115 ) (123 ) — — Net periodic benefit credit $ (1,179 ) $ (4,657 ) $ (729 ) $ (771 ) During the nine months ended September 29, 2019 and September 30, 2018 , the Company contributed $6.1 million and $6.4 million , respectively, in the aggregate, to pension plans outside of the United States. The Company recognizes actuarial gains and losses, unless an interim remeasurement is required, in the fourth quarter of the year in which the gains and losses occur, in accordance with the Company's accounting method for defined benefit pension plans and other postretirement benefits as described in Note 1 of the Company's audited consolidated financial statements and notes included in its 2018 Form 10-K. Such adjustments for gains and losses are primarily driven by events and circumstances beyond the Company's control, including changes in interest rates, the performance of the financial markets and mortality assumptions. Service costs for plans in active accrual are included in operating expenses.

Derivatives And Hedging Activit

Derivatives And Hedging Activities	9 Months Ended
	Sep. 29, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives and Hedging Activities	Derivatives and Hedging Activities The Company uses derivative instruments as part of its risk management strategy only, and includes derivatives utilized as economic hedges that are not designated as hedging instruments. By nature, all financial instruments involve market and credit risks. The Company enters into derivative instruments with major investment grade financial institutions and has policies to monitor the credit risk of those counterparties. The Company does not enter into derivative contracts for trading or other speculative purposes, nor does the Company use leveraged financial instruments. Approximately 70% of the Company’s business is conducted outside of the United States, generally in foreign currencies. As a result, fluctuations in foreign currency exchange rates can increase the costs of financing, investing and operating the business. In the ordinary course of business, the Company enters into foreign exchange contracts for periods consistent with its committed exposures to mitigate the effect of foreign currency movements on transactions denominated in foreign currencies. The intent of these economic hedges is to offset gains and losses that occur on the underlying exposures from these currencies, with gains and losses resulting from the forward currency contracts that hedge these exposures. Transactions covered by hedge contracts include intercompany and third-party receivables and payables. The contracts are primarily in European and Asian currencies, have maturities that do not exceed 12 months, have no cash requirements until maturity, and are recorded at fair value on the Company’s condensed consolidated balance sheets. The unrealized gains and losses on the Company’s foreign currency contracts are recognized immediately in interest and other expense, net. The cash flows related to the settlement of these hedges are included in cash flows from operating activities within the Company’s condensed consolidated statement of cash flows. Principal hedged currencies include the Chinese Yuan, Euro, British Pound, Swedish Krona, and Singapore Dollar. The Company held forward foreign exchange contracts, designated as economic hedges, with U.S. dollar equivalent notional amounts totaling $282.3 million , $223.3 million and $180.4 million at September 29, 2019 , December 30, 2018 and September 30, 2018 , respectively, and the fair value of these foreign currency derivative contracts was insignificant. The gains and losses realized on these foreign currency derivative contracts are not material. The duration of these contracts was generally 30 days or less during each of the nine months ended September 29, 2019 and September 30, 2018 . In addition, in connection with certain intercompany loan agreements utilized to finance its acquisitions and stock repurchase program, the Company enters into forward foreign exchange contracts intended to hedge movements in foreign exchange rates prior to settlement of such intercompany loans denominated in foreign currencies. The Company records these hedges at fair value on the Company’s condensed consolidated balance sheets. The unrealized gains and losses on these hedges, as well as the gains and losses associated with the remeasurement of the intercompany loans, are recognized immediately in interest and other expense, net. The cash flows related to the settlement of these hedges are included in cash flows from financing activities within the Company’s condensed consolidated statement of cash flows. The outstanding forward exchange contracts designated as economic hedges, which were intended to hedge movements in foreign exchange rates prior to the settlement of certain intercompany loan agreements included combined Euro notional amounts of €14.9 million and combined U.S. Dollar notional amounts of $8.7 million as of September 29, 2019 , combined Euro notional amounts of €37.3 million and combined U.S. Dollar notional amounts of $5.7 million as of December 30, 2018 , and combined Euro notional amounts of €48.7 million and combined U.S. Dollar notional amounts of $28.0 million as of September 30, 2018 . The net gains and losses on these derivatives, combined with the gains and losses on the remeasurement of the hedged intercompany loans were not material for each of the three and nine months ended September 29, 2019 and September 30, 2018 . The Company paid $1.6 million and $30.3 million during the nine months ended September 29, 2019 and September 30, 2018 , respectively, from the settlement of these hedges. In April 2018, the Company designated a portion of the 2026 Notes to hedge its investments in certain foreign subsidiaries. Unrealized translation adjustments from a portion of the 2026 Notes were included in the foreign currency translation component of AOCI, which offsets translation adjustments on the underlying net assets of foreign subsidiaries. The cumulative translation gains or losses will remain in AOCI until the foreign subsidiaries are liquidated or sold. As of September 29, 2019 , the total notional amount of the 2026 Notes that was designated to hedge investments in foreign subsidiaries was €134.3 million . The unrealized foreign exchange gains recorded in AOCI related to the net investment hedge was $5.8 million and $8.9 million for the three and nine months ended September 29, 2019 , respectively, and $0.8 million and $7.7 million for the three and nine months ended September 30, 2018 , respectively. During fiscal year 2018, the Company designated the April 2021 Notes to hedge its investments in certain foreign subsidiaries. Unrealized translation adjustments from the April 2021 Notes were included in the foreign currency translation component of AOCI, which offsets translation adjustments on the underlying net assets of foreign subsidiaries. The cumulative translation gains or losses will remain in AOCI until the foreign subsidiaries are liquidated or sold. As of September 29, 2019 , the total notional amount of the April 2021 Notes that was designated to hedge investments in foreign subsidiaries was €299.9 million . The unrealized foreign exchange gains recorded in AOCI related to the net investment hedge were $12.8 million and $15.1 million for the three and nine months ended September 29, 2019 , respectively, and $1.8 million and $22.6 million for the three and nine months ended September 30, 2018 . On May 31, 2019, the Company entered into a cross-currency swap designated as a net investment hedge to hedge the Euro currency exposure of the Company’s net investment in certain foreign subsidiaries. This agreement is a contract to exchange fixed-rate payments in one currency for fixed-rate payments in another currency. Changes in the fair value of this swap are recorded in equity as a component of AOCI in the same manner as foreign currency translation adjustments. In assessing the effectiveness of this hedge, the Company uses a method based on changes in spot rates to measure the impact of the foreign currency exchange rate fluctuations on both its foreign subsidiary net investment and the related swap. Under this method, changes in the fair value of the hedging instrument other than those due to changes in the spot rate are initially recorded in AOCI as a translation adjustment, and then are amortized into other (income) expense, net in the condensed consolidated statement of operations using a systematic and rational method over the instrument’s term. Changes in the fair value associated with the effective portion (i.e. those changes due to the spot rate) are recorded in AOCI as a translation adjustment and are released and recognized in earnings only upon the sale or liquidation of the hedged net investment. The cross-currency swap has an initial notional value of €197.4 million or $220.0 million and matures on November 15, 2021. Interest on the cross-currency swap is payable semi-annually, in Euro, on May 15th and November 15th of each year based on the Euro notional value and a fixed rate of 2.47% . The Company receives interest in U.S. dollars on May 15th and November 15th of each year based on the U.S. dollar equivalent of the Euro notional value and a fixed rate of 5.00% . On September 29, 2019 , the fair value of the cross-currency swap was $4.7 million which was recorded in AOCI. In connection with the early redemption of the November 2021 Notes, on September 11, 2019, the Company entered into a reverse treasury rate lock agreement with a financial intermediary with a notional amount of $500.0 million . The Company entered into the reverse treasury rate lock agreement in order to hedge the variability in the redemption payment on the entire principal amount of the November 2021 Notes. The reverse treasury rate lock substantively fixed the present value of the forecasted debt make-whole payment, which was priced on October 10, 2019, to mitigate risk associated with the changes in the 2-year U.S. treasury yield. As of September 29, 2019 , the Company recognized a mark-to-market loss of $0.2 million . The Company received $1.0 million upon settlement of the reverse treasury rate lock. The Company does no t expect any material net pre-tax gains or losses to be reclassified from accumulated other comprehensive loss into interest and other expense, net within the next twelve months.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 29, 2019
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash equivalents, derivatives, marketable securities and accounts receivable. The Company believes it had no significant concentrations of credit risk as of September 29, 2019 . The Company uses the market approach technique to value its financial instruments and there were no changes in valuation techniques during the nine months ended September 29, 2019 . The Company’s financial assets and liabilities carried at fair value are primarily comprised of marketable securities, derivative contracts used to hedge the Company’s currency risk, and acquisition-related contingent consideration. The Company has not elected to measure any additional financial instruments or other items at fair value. Valuation Hierarchy: The following summarizes the three levels of inputs required to measure fair value. For Level 1 inputs, the Company utilizes quoted market prices as these instruments have active markets. For Level 2 inputs, the Company utilizes quoted market prices in markets that are not active, broker or dealer quotations, or utilizes alternative pricing sources with reasonable levels of price transparency. For Level 3 inputs, the Company utilizes unobservable inputs based on the best information available, including estimates by management primarily based on information provided by third-party fund managers, independent brokerage firms and insurance companies. A financial asset’s or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The following tables show the assets and liabilities carried at fair value measured on a recurring basis as of September 29, 2019 and December 30, 2018 classified in one of the three classifications described above: Fair Value Measurements at September 29, 2019 Using: Total Carrying Value at September 29, 2019 Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable (Level 3) (In thousands) Marketable securities $ 2,708 $ 2,708 $ — $ — Foreign exchange derivative assets 272 — 272 — Foreign exchange derivative liabilities (646 ) — (646 ) — Contingent consideration (25,502 ) — — (25,502 ) Fair Value Measurements at December 30, 2018 Using: Total Carrying Value at December 30, 2018 Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (In thousands) Marketable securities $ 2,447 $ 2,447 $ — $ — Foreign exchange derivative assets 750 — 750 — Foreign exchange derivative liabilities (594 ) — (594 ) — Contingent consideration (69,661 ) — — (69,661 ) Level 1 and Level 2 Valuation Techniques: The Company’s Level 1 and Level 2 assets and liabilities are comprised of investments in equity and fixed-income securities as well as derivative contracts. For financial assets and liabilities that utilize Level 1 and Level 2 inputs, the Company utilizes both direct and indirect observable price quotes, including common stock price quotes, foreign exchange forward prices and bank price quotes. Below is a summary of valuation techniques for Level 1 and Level 2 financial assets and liabilities. Marketable securities: Include equity and fixed-income securities measured at fair value using the quoted market prices in active markets at the reporting date. Foreign exchange derivative assets and liabilities: Include foreign exchange derivative contracts that are valued using quoted forward foreign exchange prices at the reporting date. The Company’s foreign exchange derivative contracts are subject to master netting arrangements that allow the Company and its counterparties to net settle amounts owed to each other. Derivative assets and liabilities that can be net settled under these arrangements have been presented in the Company's condensed consolidated balance sheet on a net basis and are recorded in other assets. As of both September 29, 2019 and December 30, 2018 , none of the master netting arrangements involved collateral. Level 3 Valuation Techniques: The Company’s Level 3 liabilities are comprised of contingent consideration related to acquisitions. For liabilities that utilize Level 3 inputs, the Company uses significant unobservable inputs. Below is a summary of valuation techniques for Level 3 liabilities. Contingent consideration: Contingent consideration is measured at fair value at the acquisition date using projected milestone dates, discount rates, probabilities of success and projected revenues (for revenue-based considerations). Projected risk-adjusted contingent payments are discounted back to the current period using a discounted cash flow model. During fiscal year 2015, the Company acquired certain assets and assumed certain liabilities from Vanadis Diagnostics AB. Under the terms of the acquisition, the initial purchase consideration was $32.0 million , net of cash and the Company will be obligated to make potential future milestone payments, based on completion of a proof of concept, regulatory approvals and product sales, of up to $93.0 million ranging from 2016 to 2019. The fair value of the contingent consideration as of the acquisition date was estimated at $56.9 million . During the third quarter of fiscal year 2019 , the Company updated the fair value of the contingent consideration and recorded a liability of $19.2 million as of September 29, 2019 . The key assumptions used to determine the fair value of the contingent consideration as of September 29, 2019 included projected milestone dates within fiscal year 2020 , discount rates ranging from 0.6% to 1.6% and conditional and cumulative probabilities of success of each individual milestone ranging from 95% to 98% . A significant delay in the product development (including projected regulatory milestone) achievement date in isolation could result in a significantly lower fair value measurement; a significant acceleration in the product development (including projected regulatory milestone) achievement date in isolation would not have a material impact on the fair value measurement; a significant change in the discount rate in isolation would not have a material impact on the fair value measurement; and a significant change in the probabilities of success in isolation could result in a significant change in fair value measurement. During the nine months ended September 29, 2019 , the Company paid $48.5 million of contingent consideration, of which $28.2 million was included in financing activities and $20.3 million was included in operating activities in the consolidated statements of cash flows. The fair values of contingent consideration are calculated on a quarterly basis based on a collaborative effort of the Company’s regulatory, research and development, operations, finance and accounting groups, as appropriate. Potential valuation adjustments are made as additional information becomes available, including the progress towards achieving proof of concept, regulatory approvals and revenue targets as compared to initial projections, the impact of market competition and market landscape shifts from non-invasive prenatal testing products, with the impact of such adjustments being recorded in the Company's consolidated statements of operations. As of September 29, 2019 , the Company may have to pay contingent consideration, related to acquisitions with open contingency periods, of up to $28.0 million . The expected maximum earnout period for the acquisitions with open contingency periods does not exceed 2.8 years from September 29, 2019 , and the remaining weighted average expected earnout period at September 29, 2019 was 9 months . A reconciliation of the beginning and ending Level 3 net liabilities for contingent consideration is as follows: Three Months Ended Nine Months Ended September 29, September 30, September 29, September 30, (In thousands) Balance at beginning of period $ (34,261 ) $ (74,093 ) $ (69,661 ) $ (65,328 ) Additions — (5,800 ) — (7,500 ) Amounts paid and foreign currency translation 9,997 16,507 48,558 16,507 Change in fair value (included within selling, general and administrative expenses) (1,238 ) (3,740 ) (4,399 ) (10,805 ) Balance at end of period $ (25,502 ) $ (67,126 ) $ (25,502 ) $ (67,126 ) The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate fair value due to the short-term maturities of these assets and liabilities. If measured at fair value, cash and cash equivalents would be classified as Level 1. As of September 29, 2019 , the Company’s new senior unsecured revolving credit facility, which provides for $1.0 billion of revolving loans, had a carrying value of $27.8 million , net of $3.5 million of unamortized debt issuance costs. As of December 30, 2018 , the Company’s previous senior unsecured revolving credit facility had a carrying value of $415.6 million , net of $2.4 million of unamortized debt issuance costs. The interest rate on the Company’s new senior unsecured revolving credit facility is reset at least monthly to correspond to variable rates that reflect currently available terms and conditions for similar debt. The Company had no change in credit standing during the first nine months of fiscal year 2019 . Consequently, the carrying value approximates fair value and were classified as Level 2. The Company's November 2021 Notes, with a face value of $500.0 million , had an aggregate carrying value of $498.0 million , net of $0.8 million of unamortized original issue discount and $1.2 million of unamortized debt issuance costs as of September 29, 2019 . The November 2021 Notes had an aggregate carrying value of $497.4 million , net of $1.1 million of unamortized original issue discount and $1.6 million of unamortized debt issuance costs as of December 30, 2018 . The November 2021 Notes had a fair value of $526.2 million and $516.1 million as of September 29, 2019 and December 30, 2018 , respectively. The fair value of the November 2021 Notes is estimated using market quotes from brokers and is based on current rates offered for similar debt. On October 13, 2019, the Company redeemed all of its outstanding November 2021 Notes. The Company's 2026 Notes, with a face value of €500.0 million , had an aggregate carrying value of $540.1 million , net of $3.5 million of unamortized original issue discount and $3.4 million of unamortized debt issuance costs as of September 29, 2019 . The 2026 Notes had an aggregate carrying value of $564.5 million , net of $4.0 million of unamortized original issue discount and $3.8 million of unamortized debt issuance costs as of December 30, 2018 . The 2026 Notes had a fair value of €526.0 million and €496.1 million as of September 29, 2019 and December 30, 2018 , respectively. The fair value of the 2026 Notes is estimated using market quotes from brokers and is based on current rates offered for similar debt. The Company's April 2021 Notes, with a face value of €300.0 million , had an aggregate carrying value of $326.8 million , net of $0.1 million of unamortized original issue discount and $1.3 million of unamortized debt issuance costs as of September 29, 2019 . The April 2021 Notes had an aggregate carrying value of $341.3 million , net of $0.1 million of unamortized original issue discount and $2.0 million of unamortized debt issuance costs as of December 30, 2018 . The April 2021 Notes had a fair value of €302.8 million and €300.5 million as of September 29, 2019 and December 30, 2018 , respectively. The fair value of the April 2021 Notes is estimated using market quotes from brokers and is based on current rates offered for similar debt. The Company's 2029 Notes, with a face value of $850.0 million , had an aggregate carrying value of $839.1 million , net of $2.8 million of unamortized original issue discount and $8.1 million of unamortized debt issuance costs as of September 29, 2019 . The 2029 Notes had a fair value of $851.0 million as of September 29, 2019 . The fair value of the 2029 Notes is estimated using market quotes from brokers and is based on current rates offered for similar debt. As of September 29, 2019 , the April 2021 Notes, November 2021 Notes, 2026 Notes and 2029 Notes were classified as Level 2. The Company’s other debt facilities had an aggregate carrying value of $25.7 million and $38.2 million as of September 29, 2019 and December 30, 2018 , respectively. As of September 29, 2019 , these consisted of bank loans in the aggregate amount of $25.6 million bearing fixed interest rates between 1.1% and 5.0% and a bank loan in the amount of $0.1 million bearing a variable interest rate based on the Euribor rate plus a margin of 1.5% . The Company had no change in credit standing during the first nine months of fiscal year 2019 . Consequently, the carrying value approximates fair value and were classified as Level 2. As of September 29, 2019 , there has not been any significant impact to the fair value of the Company’s derivative liabilities due to credit risk. Similarly, there has not been any significant adverse impact to the Company’s derivative assets based on the evaluation of its counterparties’ credit risks.

Contingencies

Contingencies	9 Months Ended
	Sep. 29, 2019
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Contingencies The Company is conducting a number of environmental investigations and remedial actions at current and former locations of the Company and, along with other companies, has been named a potentially responsible party (“PRP”) for certain waste disposal sites. The Company accrues for environmental issues in the accounting period that the Company’s responsibility is established and when the cost can be reasonably estimated. The Company has accrued $7.9 million as of each of September 29, 2019 and December 30, 2018 , which represents its management’s estimate of the cost of the remediation of known environmental matters and does not include any potential liability for related personal injury or property damage claims. These amounts were included in accrued expenses and other current liabilities. The Company's environmental accrual is not discounted and does not reflect the recovery of any material amounts through insurance or indemnification arrangements. The cost estimates are subject to a number of variables, including the stage of the environmental investigations, the magnitude of the possible contamination, the nature of the potential remedies, possible joint and several liability, the time period over which remediation may occur, and the possible effects of changing laws and regulations. For sites where the Company has been named a PRP, management does not currently anticipate any additional liability to result from the inability of other significant named parties to contribute. The Company expects that the majority of such accrued amounts could be paid out over a period of up to ten years. As assessment and remediation activities progress at each individual site, these liabilities are reviewed and adjusted to reflect additional information as it becomes available. There have been no environmental problems to date that have had, or are expected to have, a material adverse effect on the Company’s condensed consolidated financial statements. While it is possible that a loss exceeding the amounts recorded in the condensed consolidated financial statements may be incurred, the potential exposure is not expected to be materially different from those amounts recorded. The Company is subject to various claims, legal proceedings and investigations covering a wide range of matters that arise in the ordinary course of its business activities. Although the Company has established accruals for potential losses that it believes are probable and reasonably estimable, in the opinion of the Company’s management, based on its review of the information available at this time, the total cost of resolving these contingencies at September 29, 2019 would not have a material adverse effect on the Company’s condensed consolidated financial statements. However, each of these matters is subject to uncertainties, and it is possible that some of these matters may be resolved unfavorably to the Company.

Leases (Notes)

Leases (Notes)	9 Months Ended
	Sep. 29, 2019
Disclosure Text Block [Abstract]
Leases [Text Block]	Leases Changes in significant accounting policies Except for the changes below, the Company consistently applied the accounting policies to all periods presented in these condensed consolidated financial statements. The Company adopted ASC 842 with a date of initial application of December 31, 2018 ("transition date"). As a result, the Company has changed its accounting policy for leases as detailed below. The Company applied ASC 842 using the modified retrospective method and applied the new leases standard at transition date, with a cumulative effect adjustment recognized in the opening balance of retained earnings in fiscal year 2019. Therefore, the comparative information has not been adjusted and continues to be reported under ASC 840. As a lessee, the Company recognized operating leases in the consolidated balance sheet under ASC 842. Operating leases are included in operating lease right-of-use (“ROU”) assets, other current liabilities, and operating lease liabilities in the Company's consolidated balance sheet. ROU assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities were recognized at the transition date based on the present value of the remaining lease payments over the lease term. As most of the Company's leases as of the transition date did not provide an implicit rate, the Company used its incremental borrowing rate based on the information available at transition date in determining the present value of lease payments. The Company used the implicit rate when readily determinable. The operating lease ROU asset excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company has lease agreements with lease and non-lease components, which are generally accounted for separately. For certain equipment leases, such as cars, the Company accounts for the lease and non-lease components as a single lease component. Additionally, for certain equipment leases, the Company applies a portfolio approach to effectively account for the operating lease ROU assets and liabilities. The Company has made an accounting policy election not to recognize ROU assets and lease liabilities that arise from short-term leases for facilities and equipment. Instead, the Company recognizes the lease payments in the consolidated statement of operations on a straight-line basis over the lease term and variable lease payments in the period in which the obligation for those payments is incurred. As a lessor, the Company applies the practical expedient to not separate non-lease components from the associated lease component, instead to account for those components as a single component if the non-lease components otherwise would be accounted for under ASC 606, Revenue From Contracts With Customers (“ASC 606”), and both of the following criteria are met: 1) the timing and pattern of transfer of the non-lease component or components and associated lease component are the same; and 2) the lease component, if accounted for separately, would be classified as an operating lease. If the non-lease component or components associated with the lease component are the predominant component of the combined component, the Company accounts for the combined component in accordance with ASC 606. Otherwise, the Company accounts for the combined component as an operating lease in accordance with ASC 842. Lessee Disclosures The Company leases certain property and equipment under operating and finance leases. The Company's leases have remaining lease terms of less than 1 year to 41 years, some of which include options to extend the lease for up to 5 years, and some of which include options to terminate the lease within 1 year. Finance leases are not material to the Company. The components of lease expense were as follows: Three Months Ended Nine Months Ended September 29, September 29, (In thousands) Lease cost: Operating lease cost $ 14,846 44,766 Supplemental cash flow information related to leases was as follows: Three Months Ended Nine Months Ended September 29, September 29, (In thousands) Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 12,938 37,663 Supplemental balance sheet information related to leases was as follows: September 29, (In thousands, except lease term and discount rate) Operating Leases: Operating lease right-of-use assets $ 174,689 Accrued expenses and other current liabilities $ 37,453 Operating lease liabilities 153,216 Total operating liabilities $ 190,669 Weighted Average Remaining Lease Term in Years Operating leases 7.6 Weighted Average Remaining Discount Rate Operating leases 3.3% Maturities of lease liabilities as of September 29, 2019 were as follows: Operating Leases (In thousands) 2019 $ 12,284 2020 43,049 2021 35,771 2022 24,964 2023 20,021 2024 17,843 2025 and thereafter 65,505 Total lease payments 219,437 Less imputed interest (28,768 ) Total $ 190,669 Under ASC 840, minimum rental commitments under noncancelable operating leases as of December 30, 2018 were as follows: $56.4 million in fiscal year 2019 , $46.6 million in fiscal year 2020 , $33.5 million in fiscal year 2021 , $22.1 million in fiscal year 2022 , $15.6 million in fiscal year 2023 and $67.6 million in fiscal year 2024 and thereafter . Lessor Disclosures
Leases of Lessee Disclosure [Text Block]	Lessee Disclosures The Company leases certain property and equipment under operating and finance leases. The Company's leases have remaining lease terms of less than 1 year to 41 years, some of which include options to extend the lease for up to 5 years, and some of which include options to terminate the lease within 1 year. Finance leases are not material to the Company. The components of lease expense were as follows: Three Months Ended Nine Months Ended September 29, September 29, (In thousands) Lease cost: Operating lease cost $ 14,846 44,766 Supplemental cash flow information related to leases was as follows: Three Months Ended Nine Months Ended September 29, September 29, (In thousands) Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 12,938 37,663 Supplemental balance sheet information related to leases was as follows: September 29, (In thousands, except lease term and discount rate) Operating Leases: Operating lease right-of-use assets $ 174,689 Accrued expenses and other current liabilities $ 37,453 Operating lease liabilities 153,216 Total operating liabilities $ 190,669 Weighted Average Remaining Lease Term in Years Operating leases 7.6 Weighted Average Remaining Discount Rate Operating leases 3.3% Maturities of lease liabilities as of September 29, 2019 were as follows: Operating Leases (In thousands) 2019 $ 12,284 2020 43,049 2021 35,771 2022 24,964 2023 20,021 2024 17,843 2025 and thereafter 65,505 Total lease payments 219,437 Less imputed interest (28,768 ) Total $ 190,669 Under ASC 840, minimum rental commitments under noncancelable operating leases as of December 30, 2018 were as follows: $56.4 million in fiscal year 2019 , $46.6 million in fiscal year 2020 , $33.5 million in fiscal year 2021 , $22.1 million in fiscal year 2022 , $15.6 million in fiscal year 2023 and $67.6 million in fiscal year 2024 and thereafter
Leases of Lessor Disclosure [Text Block]	Lessor Disclosures

Basis of Presentation (Policies

Basis of Presentation (Policies)	9 Months Ended
	Sep. 29, 2019
Accounting Policies [Abstract]
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted and Issued Accounting Pronouncements: From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (the "FASB") and are adopted by the Company as of the specified effective dates. Unless otherwise discussed, such pronouncements did not have or will not have a significant impact on the Company’s consolidated financial position, results of operations and cash flows or do not apply to the Company’s operations. In April 2019, the FASB issued Accounting Standards Update No. 2019-04, Codification Improvements to Topic 326, Financial Instruments - Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments ("ASU 2019-04"). ASU 2019-04 clarifies certain aspects of previously issued accounting standards related to: (1) ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Statements ("ASU 2016-13"), in areas of accrued interest receivable, transfers of loans and debt securities between classifications, recoveries and prepayments, (2) ASU 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities ("ASU 2017-12"), in areas of partial-term fair value hedges, fair value hedge basis adjustments, certain disclosures and transition requirements and (3) ASU 2016-01, Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities ("ASU 2016-01"), in areas of remeasurement of equity securities under ASC 820, Fair Value Measurement , when using the measurement alternative and remeasurement of equity securities at historical exchange rates. The amendments related to ASU 2016-13 are required to be adopted in conjunction with that accounting standards update, as further described below. Since the Company has already adopted ASU 2017-12 and ASU 2016-01, the related amendments in ASU 2019-04 are effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years, with early adoption permitted in any interim period. The amendments to ASU 2017-12 can either be adopted retrospectively as of the date of adoption of ASU 2017-12 or they can be adopted prospectively. The amendments to ASU 2016-01 are required to be applied using a modified-retrospective adoption approach with a cumulative-effect adjustment to retained earnings as of the date of adoption of ASU 2016-01, except for those related to equity securities without readily determinable fair values that are measured using the measurement alternative, which are required to be applied prospectively. The Company is currently evaluating the requirements of ASU 2019-04 and has not yet determined the impact of its adoption on the Company's consolidated financial position, results of operations and cash flows. In August 2018, the FASB issued Accounting Standards Update No. 2018-15, Intangibles-Goodwill and Other- Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract ("ASU 2018-15"). ASU 2018-15 aligns the accounting for implementation costs incurred in a hosting arrangement that is a service contract with the guidance on capitalizing costs associated with developing or obtaining internal-use software (and hosting arrangements that include an internal-use software license). The provisions of this guidance are to be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. ASU 2018-15 is effective for annual reporting periods beginning after December 15, 2019, and interim periods within those years with early adoption permitted. The Company is currently evaluating the requirements of this guidance and has not yet determined the impact of its adoption on the Company's consolidated financial position, results of operations and cash flows. In August 2018, the FASB issued Accounting Standards Update No. 2018-14, Compensation - Retirement Benefits - Defined Benefit Plans - General (Subtopic 715-20): Disclosure Framework - Changes to the Disclosure Requirements for Defined Benefit Plans ("ASU 2018-14"). ASU 2018-14 adds, removes, and clarifies disclosure requirements related to defined benefit pension and other postretirement plans. ASU 2018-14 adds requirements for an entity to disclose the weighted-average interest crediting rates used in the entity’s cash balance pension plans and other similar plans; and an explanation of the reasons for significant gains and losses related to changes in the benefit obligation for the period . Further, ASU 2018-14 removes guidance that currently requires the following disclosures: the amounts in accumulated other comprehensive income expected to be recognized as part of net periodic benefit cost over the next year; the amount and timing of plan assets expected to be returned to the employer; information about (1) benefits covered by related-party insurance and annuity contracts and (2) significant transactions between the plan and related parties; and the effects of a one-percentage-point change on the assumed health care costs and the effect of this change in rates on service cost, interest cost, and the benefit obligation for postretirement health care benefits. ASU 2018-14 also clarifies the guidance in Compensation-Retirement Benefits (Topic 715-20-50-3) on defined benefit plans to require disclosure of (1) the projected benefit obligation ("PBO") and fair value of plan assets for pension plans with PBOs in excess of plan assets (the same disclosure with reference to the accumulated postretirement benefit obligation rather than the PBO is required for other postretirement benefit plans) and (2) the accumulated benefit obligation ("ABO") and fair value of plan assets for pension plans with ABOs in excess of plan assets. The provisions of this guidance are to be applied retrospectively to all periods presented upon their effective date. ASU 2018-14 is effective for annual reporting periods beginning after December 15, 2020, and interim periods within those years with early adoption permitted. The Company is currently evaluating the requirements of this guidance and has not yet determined the impact of its adoption on the Company's consolidated financial position, results of operations and cash flows. In August 2018, the FASB issued Accounting Standards Update No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement ("ASU 2018-13"). ASU 2018-13 adds, removes, and modifies certain disclosures related to fair value measurements. ASU 2018-13 adds requirements for an entity to disclose the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period; and the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. Further, ASU 2018-13 removes the requirement to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy; the policy for timing of transfers between levels; and the valuation processes for Level 3 fair value measurements. ASU 2018-13 also modifies existing disclosure requirements related to measurement uncertainty. The amendments regarding changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty are to be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments are to be applied retrospectively to all periods presented upon their effective date. ASU 2018-13 is effective for annual reporting periods beginning after December 15, 2019, and interim periods within those years. Early adoption is permitted for any removed or modified disclosures. The Company is currently evaluating the requirements of this guidance and has not yet determined the impact of its adoption on the Company's consolidated financial position, results of operations and cash flows. In June 2016, the FASB issued Accounting Standards Update No. 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments . ASU 2016-13 changes how entities will measure credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. The standard requires entities to use the expected loss impairment model and will apply to most financial assets measured at amortized cost and certain other instruments, including trade and other receivables, loans, held-to-maturity debt securities, net investments in leases and off-balance sheet credit exposures. Entities are required to estimate the lifetime “expected credit loss” for each applicable financial asset and record an allowance that, when deducted from the amortized cost basis of the financial asset, presents the net amount expected to be collected on the financial asset. The standard also amends the impairment model for available-for-sale (“AFS”) debt securities and requires entities to determine whether all or a portion of the unrealized loss on an AFS debt security is a credit loss. An entity will recognize an allowance for credit losses on an AFS debt security as a contra-account to the amortized cost basis rather than as a direct reduction of the amortized cost basis of the investment. The provisions of this guidance are to be applied using a modified-retrospective approach. A prospective transition approach is required for debt securities for which an other-than-temporary impairment had been recognized before the effective date. Subsequent to the issuance of ASU 2016-13, in November 2018, the FASB issued Accounting Standards Update No. 2018-19, Codification Improvements to Topic 326, Financial Instruments - Credit Losses ("ASU 2018-19"), in April 2019, the FASB issued ASU 2019-04, and in May 2019, the FASB issued Accounting Standards Update No. 2019-05, Financial Instruments - Credit Losses (Topic 326), Targeted Transition Relief ("ASU 2019-05") . The amendments in ASU 2018-19 clarify that receivables arising from operating leases are not within the scope of Subtopic 326-20, Financial Instruments - Credit Losses - Measured at Amortized Cost . Instead, impairment of receivables arising from operating leases should be accounted for in accordance with Topic 842, Leases . The amendments in ASU 2019-04 clarify the measurement of allowance for credit losses on accrued interest receivable; the inclusion of expected recoveries in the allowance for credit losses; the permission of a prepayment-adjusted effective interest rate when determining the allowance for credit losses; and the steps entities should take when recording the transfer of loans or debt securities between measurement classifications. The amendments in ASU 2019-05 provide an option to irrevocably elect the fair value option in Subtopic 825-10, Financial Instruments-Overall , on an instrument-by-instrument basis, for eligible financial assets measured at amortized cost basis upon adoption of ASU 2016-13, but this fair value option election does not apply to held-to-maturity debt securities. The effective date and transition requirements for the amendments in ASU 2018-19, ASU 2019-04 and ASU 2019-05 are the same as the effective date and transition requirements of ASU 2016-13, which is effective for annual reporting periods beginning after December 15, 2019, and interim periods within those years. Early adoption is permitted for annual periods beginning after December 15, 2018, and interim periods therein. The Company is currently evaluating the requirements of this guidance and has not yet determined the impact of its adoption on the Company's consolidated financial position, results of operations and cash flows. In February 2016, the FASB issued Accounting Standards Update No. 2016-02, Leases ("ASU 2016-02"). ASU 2016-02 requires organizations that lease assets to recognize assets and liabilities on the balance sheet related to the rights and obligations created by those leases, regardless of whether they are classified as finance or operating leases. Consistent with current guidance, the recognition, measurement, and presentation of expenses and cash flows arising from a lease of assets will primarily depend on its classification as a finance or operating lease. ASU 2016-02 also requires new disclosures to help financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. The provisions of this guidance are effective for annual periods beginning after December 15, 2018, and interim periods within those years, with early adoption permitted. ASU 2016-02 is to be applied using a modified retrospective approach. Subsequent to the issuance of ASU 2016-02, in July 2018, the FASB issued Accounting Standards Update No. 2018-10, Codification Improvements to Topic 842, Leases ("ASU 2018-10") and Accounting Standards Update No. 2018-11, Leases (Topic 842): Targeted Improvements ("ASU 2018-11"), and in March 2019, the FASB issued Accounting Standards Update No. 2019-01, Leases (Topic 842): Codification Improvements ("ASU 2019-01"). The amendments in ASU 2018-10 clarify, correct or remove inconsistencies in the guidance provided under ASU 2016-02 related to sixteen specific issues identified. The amendments in ASU 2018-11 provide entities with an additional (and optional) transition method to adopt the new leases standard. Under the new transition method, an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. Consequently, an entity's reporting for the comparative periods presented in the financial statements in the period of adoption will continue to be in accordance with Accounting Standards Codification (“ASC”) 840, Leases ("ASC 840"). An entity that elects this additional (and optional) transition method must provide the required disclosures under ASC 840 for all periods that continue to be in accordance with ASC 840. ASU 2018-11 also provides lessors with a practical expedient, by class of underlying asset, to not separate nonlease components from the associated lease component and, instead, to account for those components as a single component if certain criteria are met. ASU 2019-01 provides clarification on implementation issues associated with adopting ASU 2016-02. ASU 2019-01 provides guidance on transition disclosures related to Topic 250, Accounting Changes and Error Corrections , specifically paragraph 205-10-50-3, which requires entities to provide in the fiscal year in which a new accounting principle is adopted the identical disclosures for interim periods after the date of adoption. The guidance in ASU 2019-01 explicitly provides an exception to the paragraph 250-10-50-3 interim disclosure requirements in the Topic 842 transition disclosure requirements. The effective date and transition requirements for these standards are the same as the effective date and transition requirements of ASU 2016-02. The standards were effective for the Company beginning on December 31, 2018, the first day of the Company's fiscal year 2019. The Company did not early adopt these standards and adopted these standards using the optional transition method. The Company applied the modified retrospective approach, and applied the new leases standards at December 31, 2018, with a cumulative effect adjustment recognized in the opening balance of retained earnings in fiscal year 2019. As a lessee, the most significant impact of the standards relates to the recognition of the right-of-use assets and lease liabilities for the operating leases in the balance sheet. In addition, the Company had deferred gains from sale-leaseback transactions that are being amortized in operating expenses over the lease terms and the leases are accounted for as operating leases under ASC 840. Under the new standards, the Company recognized the deferred gains from the sales as a cumulative effect adjustment in retained earnings at December 31, 2018. The Company also derecognized the impact of its build-to-suit arrangements in which the Company was the deemed owner during the construction period, for which the construction is complete and the lease commenced before the initial date of adoption. The adoption of the standards resulted in an increase in retained earnings at December 31, 2018 of approximately $13.3 million for the cumulative effect of initially applying the standards as of that date. In addition, the adoption of the standards resulted in the recognition of right-of-use assets of approximately $199.5 million and lease liabilities of approximately $147.1 million , primarily related to the facilities operating leases, a decrease in property and equipment of approximately $34.6 million and an increase in deferred tax liabilities of $4.6 million for the tax impact of the cumulative adjustments. The adoption did not have an impact to cash from or used in operating, investing or financing activities in the Company's consolidated statement of cash flows at December 31, 2018.

Leases (Policies)

Leases (Policies)	9 Months Ended
	Sep. 29, 2019
Leases [Abstract]
Leases [Policy Text Block]	Changes in significant accounting policies Except for the changes below, the Company consistently applied the accounting policies to all periods presented in these condensed consolidated financial statements. The Company adopted ASC 842 with a date of initial application of December 31, 2018 ("transition date"). As a result, the Company has changed its accounting policy for leases as detailed below. The Company applied ASC 842 using the modified retrospective method and applied the new leases standard at transition date, with a cumulative effect adjustment recognized in the opening balance of retained earnings in fiscal year 2019. Therefore, the comparative information has not been adjusted and continues to be reported under ASC 840. As a lessee, the Company recognized operating leases in the consolidated balance sheet under ASC 842. Operating leases are included in operating lease right-of-use (“ROU”) assets, other current liabilities, and operating lease liabilities in the Company's consolidated balance sheet. ROU assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities were recognized at the transition date based on the present value of the remaining lease payments over the lease term. As most of the Company's leases as of the transition date did not provide an implicit rate, the Company used its incremental borrowing rate based on the information available at transition date in determining the present value of lease payments. The Company used the implicit rate when readily determinable. The operating lease ROU asset excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company has lease agreements with lease and non-lease components, which are generally accounted for separately. For certain equipment leases, such as cars, the Company accounts for the lease and non-lease components as a single lease component. Additionally, for certain equipment leases, the Company applies a portfolio approach to effectively account for the operating lease ROU assets and liabilities. The Company has made an accounting policy election not to recognize ROU assets and lease liabilities that arise from short-term leases for facilities and equipment. Instead, the Company recognizes the lease payments in the consolidated statement of operations on a straight-line basis over the lease term and variable lease payments in the period in which the obligation for those payments is incurred. As a lessor, the Company applies the practical expedient to not separate non-lease components from the associated lease component, instead to account for those components as a single component if the non-lease components otherwise would be accounted for under ASC 606, Revenue From Contracts With Customers (“ASC 606”), and both of the following criteria are met: 1) the timing and pattern of transfer of the non-lease component or components and associated lease component are the same; and 2) the lease component, if accounted for separately, would be classified as an operating lease. If the non-lease component or components associated with the lease component are the predominant component of the combined component, the Company accounts for the combined component in accordance with ASC 606. Otherwise, the Company accounts for the combined component as an operating lease in accordance with ASC 842.
Lessee, Leases [Policy Text Block]	As a lessee, the Company recognized operating leases in the consolidated balance sheet under ASC 842. Operating leases are included in operating lease right-of-use (“ROU”) assets, other current liabilities, and operating lease liabilities in the Company's consolidated balance sheet. ROU assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities were recognized at the transition date based on the present value of the remaining lease payments over the lease term. As most of the Company's leases as of the transition date did not provide an implicit rate, the Company used its incremental borrowing rate based on the information available at transition date in determining the present value of lease payments. The Company used the implicit rate when readily determinable. The operating lease ROU asset excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company has lease agreements with lease and non-lease components, which are generally accounted for separately. For certain equipment leases, such as cars, the Company accounts for the lease and non-lease components as a single lease component. Additionally, for certain equipment leases, the Company applies a portfolio approach to effectively account for the operating lease ROU assets and liabilities. The Company has made an accounting policy election not to recognize ROU assets and lease liabilities that arise from short-term leases for facilities and equipment. Instead, the Company recognizes the lease payments in the consolidated statement of operations on a straight-line basis over the lease term and variable lease payments in the period in which the obligation for those payments is incurred.
Lessor, Leases [Policy Text Block]	As a lessor, the Company applies the practical expedient to not separate non-lease components from the associated lease component, instead to account for those components as a single component if the non-lease components otherwise would be accounted for under ASC 606, Revenue From Contracts With Customers (“ASC 606”), and both of the following criteria are met: 1) the timing and pattern of transfer of the non-lease component or components and associated lease component are the same; and 2) the lease component, if accounted for separately, would be classified as an operating lease. If the non-lease component or components associated with the lease component are the predominant component of the combined component, the Company accounts for the combined component in accordance with ASC 606. Otherwise, the Company accounts for the combined component as an operating lease in accordance with ASC 842.

Revenue (Tables)

Revenue (Tables)	9 Months Ended
	Sep. 29, 2019
Disaggregation of Revenue [Line Items]
Disaggregation of Revenue [Table Text Block]	In the following tables, revenue is disaggregated by primary geographical markets, primary end-markets and timing of revenue recognition. The tables also include a reconciliation of the disaggregated revenue with the reportable segments' revenue. Reportable Segments Three Months Ended September 29, 2019 September 30, 2018 Discovery & Analytical Solutions Diagnostics Total Discovery & Analytical Solutions Diagnostics Total (In thousands) Primary geographical markets Americas $ 178,493 $ 96,759 $ 275,252 $ 169,366 $ 95,607 $ 264,973 Europe 119,801 70,225 190,026 110,747 68,480 179,227 Asia 128,610 113,035 241,645 126,053 104,060 230,113 $ 426,904 $ 280,019 $ 706,923 $ 406,166 $ 268,147 $ 674,313 Primary end-markets Diagnostics $ — $ 280,019 $ 280,019 $ — $ 268,147 $ 268,147 Life sciences 243,167 — 243,167 222,191 — 222,191 Applied markets 183,737 — 183,737 183,975 — 183,975 $ 426,904 $ 280,019 $ 706,923 $ 406,166 $ 268,147 $ 674,313 Timing of revenue recognition Products and services transferred at a point in time $ 311,123 $ 259,161 $ 570,284 $ 290,929 $ 247,189 $ 538,118 Services transferred over time 115,781 20,858 136,639 115,237 20,958 136,195 $ 426,904 $ 280,019 $ 706,923 $ 406,166 $ 268,147 $ 674,313 Reportable Segments Nine Months Ended September 29, 2019 September 30, 2018 Discovery & Analytical Solutions Diagnostics Total Discovery & Analytical Solutions Diagnostics Total (In thousands) Primary geographical markets Americas $ 518,884 $ 300,403 $ 819,287 $ 497,833 $ 282,536 $ 780,369 Europe 351,216 208,729 559,945 357,766 205,892 563,658 Asia 379,604 319,341 698,945 377,720 299,900 677,620 $ 1,249,704 $ 828,473 $ 2,078,177 $ 1,233,319 $ 788,328 $ 2,021,647 Primary end-markets Diagnostics $ — $ 828,473 $ 828,473 $ — $ 788,328 $ 788,328 Life sciences 702,406 — 702,406 675,807 — 675,807 Applied markets 547,298 — 547,298 557,512 — 557,512 $ 1,249,704 $ 828,473 $ 2,078,177 $ 1,233,319 $ 788,328 $ 2,021,647 Timing of revenue recognition Products and services transferred at a point in time $ 903,274 $ 765,858 $ 1,669,132 $ 886,007 $ 725,483 $ 1,611,490 Services transferred over time 346,430 62,615 409,045 347,312 62,845 410,157 $ 1,249,704 $ 828,473 $ 2,078,177 $ 1,233,319 $ 788,328 $ 2,021,647

Business Combinations (Tables)

Business Combinations (Tables)	9 Months Ended
	Sep. 29, 2019
Business Acquisition [Line Items]
Schedule of Business Acquisitions, by Acquisition1 [Table Text Block]	The total purchase price for the acquisitions in fiscal year 2019 has been allocated to the estimated fair values of assets acquired and liabilities assumed as follows: 2019 Acquisitions (In thousands) Fair value of business combination: Cash payments $ 257,970 Working capital and other adjustments 438 Less: cash acquired (13,866 ) Total $ 244,542 Identifiable assets acquired and liabilities assumed: Current assets $ 46,003 Property, plant and equipment 5,309 Other assets 529 Identifiable intangible assets: Core technology 115,467 Trade names 5,600 Customer relationships 40,200 Goodwill 79,659 Deferred taxes (39,878 ) Deferred revenue (83 ) Liabilities assumed (8,264 ) Total $ 244,542
Schedule of Business Acquisitions, by Acquisition [Table Text Block]	The total purchase price for the acquisitions in fiscal year 2018 has been allocated to the estimated fair values of assets acquired and liabilities assumed as follows: 2018 Acquisitions (In thousands) Fair value of business combination: Cash payments $ 95,950 Other liability 3,354 Contingent consideration 6,200 Working capital and other adjustments 262 Less: cash acquired (1,132 ) Total $ 104,634 Identifiable assets acquired and liabilities assumed: Current assets $ 6,079 Property, plant and equipment 1,166 Other assets 891 Identifiable intangible assets: Core technology 34,021 Trade names 1,070 Customer relationships 10,200 Goodwill 65,129 Deferred taxes (9,049 ) Debt assumed (461 ) Liabilities assumed (4,412 ) Total $ 104,634

Restructuring and Lease Charg_2

Restructuring and Lease Charges, Net (Tables)	9 Months Ended
	Sep. 29, 2019
Restructuring Cost and Reserve [Line Items]
Schedule of Restructuring Plan Activity [Table Text Block]	The following table summarizes the reductions in headcount, the initial restructuring or contract termination charges by reporting segment, and the dates by which payments were substantially completed, or the dates by which payments are expected to be substantially completed, for restructuring actions implemented during fiscal years 2019 and 2018 in continuing operations: Workforce Reductions Total (Expected) Date Payments Substantially Completed by Headcount Reduction Discovery & Analytical Solutions Diagnostics Severance (In thousands, except headcount data) Q3 2019 Plan 259 $ 11,156 $ 2,641 $ 13,797 Q2 FY2020 Q2 2019 Plan 44 4,461 1,129 5,590 Q1 FY2020 Q1 2019 Plan 105 6,001 1,459 7,460 Q4 FY2019 Q4 2018 Plan 1 348 — 348 Q1 FY2019 Q3 2018 Plan 61 1,146 618 1,764 Q4 FY2019 Q1 2018 Plan 47 5,096 902 5,998 Q4 FY2019
Schedule of Restructuring Reserve by Type of Cost [Table Text Block]	The following table summarizes the Company's restructuring and contract termination accrual balances and related activity by restructuring plan, as well as contract termination accrual balances and related activity, during the nine months ended September 29, 2019 : Balance at December 30, 2018 2019 Charges 2019 Changes in Estimates, Net 2019 Amounts Paid Balance at September 29, 2019 (In thousands) Severance: Q3 2019 Plan $ — $ 13,797 $ — $ (4,810 ) $ 8,987 Q2 2019 Plan — 5,590 — (2,701 ) 2,889 Q1 2019 Plan — 7,460 23 (5,150 ) 2,333 Q4 2018 Plan 348 — — (348 ) — Q3 2018 Plan 1,415 — 401 (1,196 ) 620 Q1 2018 Plan 1,609 — — (283 ) 1,326 Previous Plans 2,671 — 145 (1,060 ) 1,756 Restructuring 6,043 26,847 — 569 (15,548 ) 17,911 Contract Termination 137 402 50 (401 ) 188 Total Restructuring and Contract Termination $ 6,180 $ 27,249 $ 619 $ (15,949 ) $ 18,099

Interest and Other Expense (I_2

Interest and Other Expense (Income), Net (Tables)	9 Months Ended
	Sep. 29, 2019
Other Income and Expenses [Abstract]
Interest and Other Expense (Income), Net	Interest and other expense, net, consisted of the following: Three Months Ended Nine Months Ended September 29, September 30, September 29, September 30, (In thousands) Interest income $ (292 ) $ (316 ) $ (925 ) $ (754 ) Interest expense 16,149 16,684 49,206 50,745 (Gain) loss on disposition of businesses and assets, net — (13,031 ) 2,469 (13,031 ) Debt extinguishment costs 471 — 471 — Other (income) expense, net (922 ) (1,176 ) 658 (7,013 ) Total interest and other expense, net $ 15,406 $ 2,161 $ 51,879 $ 29,947

Inventories, Net (Tables)

Inventories, Net (Tables)	9 Months Ended
	Sep. 29, 2019
Inventory Disclosure [Abstract]
Schedule of Net Inventories	Inventories as of September 29, 2019 and December 30, 2018 consisted of the following: September 29, December 30, (In thousands) Raw materials $ 136,102 $ 119,115 Work in progress 31,192 18,110 Finished goods 224,526 201,122 Total inventories $ 391,820 $ 338,347

Income Taxes (Tables)

Income Taxes (Tables)	9 Months Ended
	Sep. 29, 2019
Income Tax Disclosure [Abstract]
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]	The total provision for income taxes included in the condensed consolidated statements of operations consisted of the following: Three Months Ended Nine Months Ended September 29, September 30, September 29, September 30, (In thousands) Continuing operations $ 4,644 $ 2,596 $ 8,642 $ 12,101 Discontinued operations 52 (1,411 ) 147 (1,341 ) Total $ 4,696 $ 1,185 $ 8,789 $ 10,760

Earnings Per Share (Tables)

Earnings Per Share (Tables)	9 Months Ended
	Sep. 29, 2019
Earnings Per Share [Abstract]
Schedule of Reconciliation of Number of Shares Utilized in Earnings Per Share Calculations	The following table reconciles the number of shares utilized in the earnings per share calculations: Three Months Ended Nine Months Ended September 29, September 30, September 29, September 30, (In thousands) Number of common shares—basic 110,946 110,724 110,778 110,499 Effect of dilutive securities: Stock options 484 791 558 813 Restricted stock awards 129 232 124 198 Number of common shares—diluted 111,559 111,747 111,460 111,510 Number of potentially dilutive securities excluded from calculation due to antidilutive impact 413 358 396 346

Industry Segment Information (T

Industry Segment Information (Tables)	9 Months Ended
	Sep. 29, 2019
Segment Reporting [Abstract]
Schedule of Sales and Operating Income by Operating Segment, Excluding Discontinued Operations	Revenue and operating income (loss) from continuing operations by operating segment are shown in the table below: Three Months Ended Nine Months Ended September 29, September 30, September 29, September 30, (In thousands) Discovery & Analytical Solutions Product revenue $ 256,118 $ 247,250 $ 738,422 $ 748,270 Service revenue 170,786 158,916 511,282 485,049 Total revenue 426,904 406,166 1,249,704 1,233,319 Operating income from continuing operations 52,347 48,381 146,963 149,243 Diagnostics Product revenue 237,202 227,273 695,734 669,469 Service revenue 42,817 40,874 132,739 118,859 Total revenue 280,019 268,147 828,473 788,328 Operating income from continuing operations 47,443 47,411 128,184 104,585 Corporate Operating loss from continuing operations (21,130 ) (15,590 ) (51,422 ) (45,627 ) Continuing Operations Product revenue 493,320 474,523 1,434,156 1,417,739 Service revenue 213,603 199,790 644,021 603,908 Total revenue 706,923 674,313 2,078,177 2,021,647 Operating income from continuing operations 78,660 80,202 223,725 208,201 Interest and other expense, net (see Note 5) 15,406 2,161 51,879 29,947 Income from continuing operations before income taxes $ 63,254 $ 78,041 $ 171,846 $ 178,254

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 29, 2019
Stockholders' Equity Note [Abstract]
Components of Accumulated Other Comprehensive Loss	The components of accumulated other comprehensive loss consisted of the following: September 29, December 30, (In thousands) Foreign currency translation adjustments $ (243,413 ) $ (176,459 ) Unrecognized prior service costs, net of income taxes 245 245 Unrealized net losses on securities, net of income taxes (289 ) (267 ) Accumulated other comprehensive loss $ (243,457 ) $ (176,481 )

Stock Plans (Tables)

Stock Plans (Tables)	9 Months Ended
	Sep. 29, 2019
Share-based Payment Arrangement [Abstract]
Summary of Total Compensation Recognized Related to Outstanding Equity Awards	The following table summarizes total pre-tax compensation expense recognized related to the Company’s stock option grants, restricted stock awards, performance restricted stock units, performance units and stock awards, included in the Company’s condensed consolidated statements of operations for the three and nine months ended September 29, 2019 and September 30, 2018 : Three Months Ended Nine Months Ended September 29, September 30, September 29, September 30, (In thousands) Cost of revenue $ 477 $ 430 $ 1,188 $ 1,093 Research and development expenses 178 335 802 1,029 Selling, general and administrative expenses 11,649 10,362 23,115 21,153 Total stock-based compensation expense $ 12,304 $ 11,127 $ 25,105 $ 23,275 The total income tax benefit recognized in the condensed consolidated statements of operations for stock-based compensation was $2.8 million and $10.0 million for the three and nine months ended September 29, 2019 , respectively. The total income tax benefit recognized in the condensed consolidated statements of operations for stock-based compensation was $6.1 million and $10.6 million for the three and nine months ended September 30, 2018 , respectively. Stock-based compensation costs capitalized as part of inventory was $0.4 million as of each of September 29, 2019 and September 30, 2018
Weighted-Average Assumptions Used in the Black-Scholes Option Pricing Model	The Company’s weighted-average assumptions used in the Black-Scholes option pricing model were as follows: Three and Nine Months Ended September 29, September 30, Risk-free interest rate 1.9 % 2.9 % Expected dividend yield 0.3 % 0.4 % Expected term 5 years 5 years Expected stock volatility 22.8 % 20.7 %
Summary of Stock Option Activity	The following table summarizes stock option activity for the nine months ended September 29, 2019 : Number of Shares Weighted- Average Exercise Price Weighted-Average Remaining Contractual Term Total Intrinsic Value (In thousands) (In years) (In millions) Outstanding at December 30, 2018 1,765 $ 52.91 Granted 302 93.67 Exercised (371 ) 47.30 Forfeited (112 ) 78.29 Outstanding at September 29, 2019 1,584 $ 60.20 4.0 $ 39.5 Exercisable at September 29, 2019 997 $ 48.75 3.1 $ 36.3
Summary of Restricted Stock Award Activity	The following table summarizes restricted stock award activity for the nine months ended September 29, 2019 : Number of Shares Weighted- Average Grant- Date Fair Value (In thousands) Nonvested at December 30, 2018 465 $ 61.72 Granted 161 94.88 Vested (214 ) 54.91 Forfeited (57 ) 75.90 Nonvested at September 29, 2019 355 $ 78.57

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets, Net (Tables)	9 Months Ended
	Sep. 29, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Changes in the Carrying Amount of Goodwill	The changes in the carrying amount of goodwill for the nine months ended September 29, 2019 were as follows: Discovery & Analytical Solutions Diagnostics Consolidated (In thousands) Balance at December 30, 2018 $ 1,334,992 $ 1,617,616 $ 2,952,608 Foreign currency translation (22,342 ) (27,941 ) (50,283 ) Acquisitions, earn-outs and other 17,970 67,246 85,216 Balance at September 29, 2019 $ 1,330,620 $ 1,656,921 $ 2,987,541
Identifiable Intangible Asset Balances	Identifiable intangible asset balances by category were as follows: September 29, December 30, (In thousands) Patents $ 30,816 $ 42,646 Less: Accumulated amortization (27,136 ) (37,753 ) Net patents 3,680 4,893 Trade names and trademarks 81,103 78,146 Less: Accumulated amortization (38,138 ) (33,801 ) Net trade names and trademarks 42,965 44,345 Licenses 58,728 53,305 Less: Accumulated amortization (48,664 ) (45,550 ) Net licenses 10,064 7,755 Core technology 637,051 540,911 Less: Accumulated amortization (302,709 ) (265,744 ) Net core technology 334,342 275,167 Customer relationships 1,084,801 1,089,527 Less: Accumulated amortization (348,275 ) (293,964 ) Net customer relationships 736,526 795,563 IPR&D 1,300 1,360 Net amortizable intangible assets 1,128,877 1,129,083 Non-amortizing intangible asset: Trade name 70,584 70,584 Total $ 1,199,461 $ 1,199,667

Warranty Reserves (Tables)

Warranty Reserves (Tables)	9 Months Ended
	Sep. 29, 2019
Product Warranties Disclosures [Abstract]
Warranty Reserve Activity	A summary of warranty reserve activity is as follows: Three Months Ended Nine Months Ended September 29, September 30, September 29, September 30, (In thousands) Balance at beginning of period $ 7,985 $ 8,943 $ 8,393 $ 9,050 Provision charged to income 2,899 3,327 8,601 10,012 Payments (3,999 ) (3,547 ) (10,536 ) (10,514 ) Adjustments to previously provided warranties, net 1,239 (226 ) 1,658 110 Foreign currency translation and acquisitions (169 ) (49 ) (161 ) (210 ) Balance at end of period $ 7,955 $ 8,448 $ 7,955 $ 8,448

Employee Benefit Plans (Tables)

Employee Benefit Plans (Tables)	9 Months Ended
	Sep. 29, 2019
Retirement Benefits [Abstract]
Components of Net Periodic Benefit Cost (Credit)	The following table summarizes the components of net periodic pension credit for the Company’s various defined benefit employee pension and postretirement plans: Defined Benefit Pension Benefits Postretirement Medical Benefits Three Months Ended September 29, September 30, September 29, September 30, (In thousands) Service and administrative costs $ 1,698 $ 1,712 $ 22 $ 27 Interest cost 4,136 4,051 29 30 Expected return on plan assets (6,132 ) (7,270 ) (294 ) (314 ) Amortization of prior service costs (38 ) (41 ) — — Net periodic pension credit $ (336 ) $ (1,548 ) $ (243 ) $ (257 ) Defined Benefit Pension Benefits Postretirement Medical Benefits Nine Months Ended September 29, September 30, September 29, September 30, (In thousands) Service cost $ 4,960 $ 5,180 $ 66 $ 80 Interest cost 12,445 12,212 87 90 Expected return on plan assets (18,469 ) (21,926 ) (882 ) (941 ) Amortization of prior service costs (115 ) (123 ) — — Net periodic benefit credit $ (1,179 ) $ (4,657 ) $ (729 ) $ (771 )

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 29, 2019
Fair Value Disclosures [Abstract]
Assets and Liabilities Carried at Fair Value Measured on a Recurring Basis	The following tables show the assets and liabilities carried at fair value measured on a recurring basis as of September 29, 2019 and December 30, 2018 classified in one of the three classifications described above: Fair Value Measurements at September 29, 2019 Using: Total Carrying Value at September 29, 2019 Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable (Level 3) (In thousands) Marketable securities $ 2,708 $ 2,708 $ — $ — Foreign exchange derivative assets 272 — 272 — Foreign exchange derivative liabilities (646 ) — (646 ) — Contingent consideration (25,502 ) — — (25,502 ) Fair Value Measurements at December 30, 2018 Using: Total Carrying Value at December 30, 2018 Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (In thousands) Marketable securities $ 2,447 $ 2,447 $ — $ — Foreign exchange derivative assets 750 — 750 — Foreign exchange derivative liabilities (594 ) — (594 ) — Contingent consideration (69,661 ) — — (69,661 )
Reconciliation of Beginning and Ending Level 3 Net Liabilities	A reconciliation of the beginning and ending Level 3 net liabilities for contingent consideration is as follows: Three Months Ended Nine Months Ended September 29, September 30, September 29, September 30, (In thousands) Balance at beginning of period $ (34,261 ) $ (74,093 ) $ (69,661 ) $ (65,328 ) Additions — (5,800 ) — (7,500 ) Amounts paid and foreign currency translation 9,997 16,507 48,558 16,507 Change in fair value (included within selling, general and administrative expenses) (1,238 ) (3,740 ) (4,399 ) (10,805 ) Balance at end of period $ (25,502 ) $ (67,126 ) $ (25,502 ) $ (67,126 )

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 29, 2019
Leases [Abstract]
Lease, Cost [Table Text Block]	The components of lease expense were as follows: Three Months Ended Nine Months Ended September 29, September 29, (In thousands) Lease cost: Operating lease cost $ 14,846 44,766
Supplemental Cash Flow Information Related To Leases [Table Text Block]	Supplemental cash flow information related to leases was as follows: Three Months Ended Nine Months Ended September 29, September 29, (In thousands) Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 12,938 37,663
Supplemental Balance Sheet Information Related To Leases [Table Text Block]	Supplemental balance sheet information related to leases was as follows: September 29, (In thousands, except lease term and discount rate) Operating Leases: Operating lease right-of-use assets $ 174,689 Accrued expenses and other current liabilities $ 37,453 Operating lease liabilities 153,216 Total operating liabilities $ 190,669 Weighted Average Remaining Lease Term in Years Operating leases 7.6 Weighted Average Remaining Discount Rate Operating leases 3.3%
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Maturities of lease liabilities as of September 29, 2019 were as follows: Operating Leases (In thousands) 2019 $ 12,284 2020 43,049 2021 35,771 2022 24,964 2023 20,021 2024 17,843 2025 and thereafter 65,505 Total lease payments 219,437 Less imputed interest (28,768 ) Total $ 190,669

Basis of Presentation (Basis of

Basis of Presentation (Basis of Presentation) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2018	Apr. 01, 2018
Basis of Presentation [Line Items]
Defined Benefit Plan, Other Cost (Credit)	$ (1,400)	$ (2,500)	$ (4,400)	$ (7,500)
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents			(4,384)	$ (7,410)
Operating Cycle						52
Operating Lease, Right-of-Use Asset	174,689		174,689			$ 0	$ 199,500
Operating Lease, Liability	$ (190,669)		$ (190,669)				(147,100)
Impact of New Accounting Principle, Property and Equipment							(34,600)
Tax Impact of Cumulative Adjustments,, Deferred Tax Liabilities							(4,600)
Accounting Standards Update 2014-09 [Member]
Basis of Presentation [Line Items]
Cumulative Effect of New Accounting Principle in Period of Adoption								$ 10,209
Accounting Standards Update 2016-02 [Member]
Basis of Presentation [Line Items]
Cumulative Effect of New Accounting Principle in Period of Adoption							$ (13,300)
Forecast [Member]
Basis of Presentation [Line Items]
Operating Cycle					52

Revenue (Details)

Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018	Dec. 30, 2018
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	$ 706,923	$ 674,313	$ 2,078,177	$ 2,021,647
Contract with Customer, Asset and Liability [Abstract]
Contract with Customer, Asset, Net, Current	42,100		42,100		$ 31,900
Contract with Customer, Liability, Current	26,200		26,200		$ 30,800
Contract with Customer, Liability, Revenue Recognized			(20,200)
Increase (Decrease) in Unbilled Receivables			26,500
Unbilled Receivables Transferred To Accounts Receivables			(16,300)
Contract with Customer, Liability, Increase (Decrease)			15,600
Transferred at Point in Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	570,284	538,118	1,669,132	1,611,490
Transferred over Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	136,639	136,195	409,045	410,157
Americas [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	275,252	264,973	819,287	780,369
Europe [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	190,026	179,227	559,945	563,658
Asia [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	241,645	230,113	698,945	677,620
Discovery & Analytical Solutions [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	426,904	406,166	1,249,704	1,233,319
Discovery & Analytical Solutions [Member] | Transferred at Point in Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	311,123	290,929	903,274	886,007
Discovery & Analytical Solutions [Member] | Transferred over Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	115,781	115,237	346,430	347,312
Discovery & Analytical Solutions [Member] | Americas [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	178,493	169,366	518,884	497,833
Discovery & Analytical Solutions [Member] | Europe [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	119,801	110,747	351,216	357,766
Discovery & Analytical Solutions [Member] | Asia [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	128,610	126,053	379,604	377,720
Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	280,019	268,147	828,473	788,328
Diagnostics [Member] | Transferred at Point in Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	259,161	247,189	765,858	725,483
Diagnostics [Member] | Transferred over Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	20,858	20,958	62,615	62,845
Diagnostics [Member] | Americas [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	96,759	95,607	300,403	282,536
Diagnostics [Member] | Europe [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	70,225	68,480	208,729	205,892
Diagnostics [Member] | Asia [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	113,035	104,060	319,341	299,900
Life Sciences [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	243,167	222,191	702,406	675,807
Life Sciences [Member] | Discovery & Analytical Solutions [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	243,167	222,191	702,406	675,807
Life Sciences [Member] | Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	0	0	0	0
Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	280,019	268,147	828,473	788,328
Diagnostics [Member] | Discovery & Analytical Solutions [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	0	0	0	0
Diagnostics [Member] | Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	280,019	268,147	828,473	788,328
Applied Markets [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	183,737	183,975	547,298	557,512
Applied Markets [Member] | Discovery & Analytical Solutions [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	183,737	183,975	547,298	557,512
Applied Markets [Member] | Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	$ 0	$ 0	$ 0	$ 0

Changes in Accounting Policies

Changes in Accounting Policies (Details) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 29, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Jul. 01, 2018	Apr. 01, 2018	Sep. 29, 2019	Sep. 30, 2018	Dec. 30, 2018	Dec. 31, 2017
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Cost of Goods and Services Sold	$ (364,648)			$ (341,986)			$ (1,080,303)	$ (1,056,958)
Selling, general and administrative expenses	204,171			196,769			604,581	601,374
Research and development expenses	45,376			48,848			141,700	142,028
Restructuring and contract termination charges, net	14,068			6,508			27,868	13,086
Operating income (loss) from continuing operations	78,660			80,202			223,725	208,201
Nonoperating Income (Expense)	15,406			2,161			51,879	29,947
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest	63,254			78,041			171,846	178,254
Provision for income taxes	4,644			2,596			8,642	12,101
Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent	58,610			75,445			163,204	166,153
Loss on disposition of discontinued operations before income taxes	0			(308)			0	(859)
Cash and cash equivalents	392,969			149,513			392,969	149,513	$ 163,111
Accounts receivable, net	(646,286)						(646,286)		(632,669)
Inventories	391,820						391,820		338,347
Other current assets	(117,330)						(117,330)		(100,507)
Property, Plant and Equipment, Net	298,240						298,240		318,590
Intangible assets, net	1,199,461						1,199,461		1,199,667
Goodwill	2,987,541						2,987,541		2,952,608
Other assets, net	280,745						280,745		270,023
Assets	(6,489,081)						(6,489,081)		(5,975,522)
Current portion of long-term debt	506,650						506,650		14,856
Accounts payable	190,261						190,261		220,949
Accrued expenses and other current liabilities	16,923						16,923		4,834
Accrued expenses and other current liabilities	472,156						472,156		528,827
Current liabilities of discontinued operations	2,112						2,112		2,165
Long-term debt	1,750,925						1,750,925		1,876,624
Long-term liabilities	690,041						690,041		742,312
Liabilities	3,782,284						3,782,284		3,390,567
Preferred Stock, Value, Issued	0						0		0
Common Stock, Value, Issued	111,093						111,093		110,597
Capital in excess of par value	83,996						83,996		48,772
Retained earnings	2,755,165						2,755,165		2,602,067
Accumulated other comprehensive loss	(243,457)						(243,457)		(176,481)
Stockholders' Equity Attributable to Parent	2,706,797	$ 2,706,867	$ 2,638,472	2,572,469	$ 2,517,177	$ 2,555,252	2,706,797	2,572,469	2,584,955	$ 2,503,188
Liabilities and Equity	(6,489,081)						(6,489,081)		$ (5,975,522)
Discontinued Operation, Tax Effect of Discontinued Operation	52			(1,411)			147	(1,341)
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest	(52)			1,103			(147)	482
Net income	$ 58,558	$ 69,087	$ 35,412	$ 76,548	$ 64,063	$ 26,024	$ 163,057	$ 166,635

Business Combinations (Narrativ

Business Combinations (Narrative) (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018	Dec. 29, 2019	Dec. 30, 2018	Jan. 03, 2016	Jun. 30, 2019	Jul. 01, 2018	Dec. 31, 2017
Business Acquisition [Line Items]
Number of Years in Measurement Period from Acquisition Date to Change Underlying Assumptions			1 year
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	$ 28,000,000		$ 28,000,000
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	25,502,000	$ 67,126,000	$ 25,502,000	$ 67,126,000		$ 69,661,000		$ 34,261,000	$ 74,093,000	$ 65,328,000
Business Combination, Contingent Consideration Arrangements, Maximum Period			2 years 9 months 18 days
Business Combination, Contingent Consideration Arrangements, Weighted Average Period			9 years
Total transaction costs	800,000	1,700,000	$ 5,900,000	5,500,000
Business Combination, Contingent Consideration Arrangements, Description			Contingent consideration is measured at fair value at the acquisition date, based on the probability that revenue thresholds or product development milestones will be achieved during the earnout period, with changes in the fair value after the acquisition date affecting earnings to the extent it is to be settled in cash.
Goodwill	2,987,541,000		$ 2,987,541,000			2,952,608,000
Business Combination, Contingent Consideration, Liability, Current	21,600,000		21,600,000			67,000,000
Business Combination, Contingent Consideration, Liability, Noncurrent	3,900,000		3,900,000			2,700,000
Foreign Currency Transaction Gain (Loss), before Tax	(4,700,000)	(4,300,000)	(9,200,000)	8,800,000
Interest Expense	16,149,000	16,684,000	49,206,000	50,745,000
Fiscal Year 2019 Acquisitions [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost Of Acquired Entity, Working Capital Adjustments			(438,000)
Business Combination, Consideration Transferred			244,542,000
Cash Acquired			13,866,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets	46,003,000		46,003,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment	5,309,000		5,309,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets	529,000		529,000
Cash paid to the shareholders			$ 257,970,000
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life			10 years 1 month 6 days
Goodwill	79,659,000		$ 79,659,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Revenue	83,000		83,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt	8,264,000		8,264,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net	244,542,000		244,542,000
Cisbio Bioassays SAS [Member]
Business Acquisition [Line Items]
Foreign Currency Transaction Gain (Loss), before Tax			2,600,000
Fiscal Year 2018 Acquisitions [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost Of Acquired Entity, Working Capital Adjustments			(262,000)
Business Combination, Consideration Transferred						104,634,000
Cash Acquired						1,132,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets	6,079,000		6,079,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment						1,166,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets						891,000
Cash paid to the shareholders						95,950,000
Business Combination, Consideration Transferred, Liabilities Incurred						$ 3,354,000
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life						11 years 2 months 12 days
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value						$ 6,200,000
Goodwill	65,129,000		65,129,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt	4,412,000		4,412,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net						104,634,000
Vanadis Diagnostics AB [Member]
Business Acquisition [Line Items]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High							$ 93,000,000
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value			19,200,000				$ 56,900,000
Tulip Diagnostics Private Limited [Member]
Business Acquisition [Line Items]
Foreign Currency Transaction Gain (Loss), before Tax		$ (100,000)		$ (1,000,000)
Diagnostics [Member]
Business Acquisition [Line Items]
Goodwill	1,656,921,000		1,656,921,000			1,617,616,000
Discovery & Analytical Solutions [Member]
Business Acquisition [Line Items]
Goodwill	1,330,620,000		1,330,620,000			1,334,992,000
Core Technology [Member] | Fiscal Year 2019 Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	115,467,000		115,467,000
Core Technology [Member] | Fiscal Year 2018 Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles						34,021,000
Customer Relationships [Member] | Fiscal Year 2019 Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	40,200,000		40,200,000
Customer Relationships [Member] | Fiscal Year 2018 Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles						10,200,000
Trade Names [Member] | Fiscal Year 2019 Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	$ 5,600,000		5,600,000
Trade Names [Member] | Fiscal Year 2018 Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles						1,070,000
United States of America, Dollars | Fiscal Year 2019 Acquisitions [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments			258,400,000
United States of America, Dollars | Cisbio Bioassays SAS [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments			219,900,000
United States of America, Dollars | 2019 Acquisitions (excluding Cisbio) [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments			$ 38,500,000
United States of America, Dollars | Fiscal Year 2018 Acquisitions [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments						$ 105,800,000
United States of America, Dollars | Subsequent Event [Member] | Shangdong Meizheng [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments					$ 152,000,000
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High					$ 26,000,000

Business Combinations (Fair Val

Business Combinations (Fair Values of the Business Combinations and Allocations for the Acquisitions Completed) (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 29, 2019	Dec. 30, 2018
Business Acquisition [Line Items]
Goodwill	$ 2,987,541,000	$ 2,952,608,000
Fiscal Year 2019 Acquisitions [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid	257,970,000
Business Acquisition, Cost Of Acquired Entity, Working Capital Adjustments	(438,000)
Cash Acquired	13,866,000
Business Combination, Consideration Transferred	244,542,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets	46,003,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment	5,309,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets	529,000
Goodwill	79,659,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Total	(39,878,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Revenue	83,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net	244,542,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt	(8,264,000)
Fiscal Year 2018 Acquisitions [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid		95,950,000
Business Combination, Consideration Transferred, Liabilities Incurred		3,354,000
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value		(6,200,000)
Business Acquisition, Cost Of Acquired Entity, Working Capital Adjustments	(262,000)
Cash Acquired		1,132,000
Business Combination, Consideration Transferred		104,634,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets	6,079,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment		1,166,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets		891,000
Goodwill	65,129,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Total	(9,049,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities		(461,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net		104,634,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt	(4,412,000)
Core Technology [Member] | Fiscal Year 2019 Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	115,467,000
Core Technology [Member] | Fiscal Year 2018 Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles		34,021,000
Trade Names [Member] | Fiscal Year 2019 Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	5,600,000
Trade Names [Member] | Fiscal Year 2018 Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles		1,070,000
Customer Relationships [Member] | Fiscal Year 2019 Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	40,200,000
Customer Relationships [Member] | Fiscal Year 2018 Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles		10,200,000
Diagnostics [Member]
Business Acquisition [Line Items]
Goodwill	1,656,921,000	1,617,616,000
Discovery & Analytical Solutions [Member]
Business Acquisition [Line Items]
Goodwill	$ 1,330,620,000	$ 1,334,992,000

Discontinued Operations (Narrat

Discontinued Operations (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018	Dec. 30, 2018
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest	$ (52)	$ 1,103	$ (147)	$ 482
Pre-tax gain (loss) on disposal of business unit	0	(308)	0	(859)
Discontinued Operation, Tax Effect of Discontinued Operation	52	$ (1,411)	147	$ (1,341)
Current liabilities of discontinued operations	$ 2,112		$ 2,112		$ 2,165

Restructuring and Lease Charg_3

Restructuring and Lease Charges, Net (Narrative) (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 29, 2019	Dec. 30, 2018
Restructuring Cost and Reserve [Line Items]
Accrued restructuring and integration costs	$ 18,099	$ 6,180
Accrued expenses and other current liabilities	16,923	4,834
Restructuring Reserve, Noncurrent	1,200	$ 1,400
Restructuring Reserve, Accrual Adjustment	$ 619

Restructuring and Lease Charg_4

Restructuring and Lease Charges, Net (Schedule of Initial Charges) (Details) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 29, 2019USD ($)employees	Jun. 30, 2019USD ($)employees	Mar. 31, 2019USD ($)employees	Dec. 30, 2018USD ($)employees	Sep. 30, 2018USD ($)employees	Apr. 01, 2018USD ($)employees	Sep. 29, 2019USD ($)
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	$ 18,099			$ 6,180			$ 18,099
Restructuring and contract termination charges, net							27,249
Restructuring Reserve, Accrual Adjustment							619
Restructuring reserve Settled with Cash and Translation Adjustment							(15,949)
Q3 2019 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Number of Positions Eliminated | employees	259
Restructuring and contract termination charges, net	$ 13,797
Q2 2019 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Number of Positions Eliminated | employees		44
Restructuring and contract termination charges, net		$ 5,590
Q1 2019 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Number of Positions Eliminated | employees			105
Restructuring and contract termination charges, net			$ 7,460
Q4 2018 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Number of Positions Eliminated | employees				1
Restructuring and contract termination charges, net				$ 348
Q3 2018 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Number of Positions Eliminated | employees					61
Restructuring and contract termination charges, net					$ 1,764
Q1 2018 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Number of Positions Eliminated | employees						47
Restructuring and contract termination charges, net						$ 5,998
Employee Severance [Member] | Q3 2019 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	8,987			0			8,987
Restructuring and contract termination charges, net							13,797
Restructuring Reserve, Accrual Adjustment							0
Restructuring reserve Settled with Cash and Translation Adjustment							(4,810)
Employee Severance [Member] | Q2 2019 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	2,889			0			2,889
Restructuring and contract termination charges, net							5,590
Restructuring Reserve, Accrual Adjustment							0
Restructuring reserve Settled with Cash and Translation Adjustment							(2,701)
Employee Severance [Member] | Q1 2019 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	2,333			0			2,333
Restructuring and contract termination charges, net							7,460
Restructuring Reserve, Accrual Adjustment							23
Restructuring reserve Settled with Cash and Translation Adjustment							(5,150)
Employee Severance [Member] | Q4 2018 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	0			348			0
Restructuring and contract termination charges, net							0
Restructuring Reserve, Accrual Adjustment							0
Restructuring reserve Settled with Cash and Translation Adjustment							(348)
Employee Severance [Member] | Q3 2018 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	620			1,415			620
Restructuring and contract termination charges, net							0
Restructuring Reserve, Accrual Adjustment							401
Restructuring reserve Settled with Cash and Translation Adjustment							(1,196)
Employee Severance [Member] | Q1 2018 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	1,326			1,609			1,326
Restructuring and contract termination charges, net							0
Restructuring Reserve, Accrual Adjustment							0
Restructuring reserve Settled with Cash and Translation Adjustment							$ (283)
Diagnostics [Member] | Employee Severance [Member] | Q3 2019 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net	2,641
Diagnostics [Member] | Employee Severance [Member] | Q2 2019 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net		1,129
Diagnostics [Member] | Employee Severance [Member] | Q1 2019 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net			1,459
Diagnostics [Member] | Employee Severance [Member] | Q4 2018 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net				0
Diagnostics [Member] | Employee Severance [Member] | Q3 2018 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net					618
Diagnostics [Member] | Employee Severance [Member] | Q1 2018 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net						902
Discovery & Analytical Solutions [Member] | Employee Severance [Member] | Q3 2019 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net	$ 11,156
Discovery & Analytical Solutions [Member] | Employee Severance [Member] | Q2 2019 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net		$ 4,461
Discovery & Analytical Solutions [Member] | Employee Severance [Member] | Q1 2019 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net			$ 6,001
Discovery & Analytical Solutions [Member] | Employee Severance [Member] | Q4 2018 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net				$ 348
Discovery & Analytical Solutions [Member] | Employee Severance [Member] | Q3 2018 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net					$ 1,146
Discovery & Analytical Solutions [Member] | Employee Severance [Member] | Q1 2018 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net						$ 5,096

Restructuring and Lease Charg_5

Restructuring and Lease Charges, Net (Schedule of Restructuring Plan Activity) (Details) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 29, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 30, 2018	Sep. 30, 2018	Apr. 01, 2018	Sep. 29, 2019
Restructuring Reserve [Roll Forward]
Balance at beginning of period			$ 6,180				$ 6,180
Restructuring and contract termination charges, net							27,249
Restructuring Reserve, Accrual Adjustment							619
Restructuring reserve Settled with Cash and Translation Adjustment							(15,949)
Balance at end of period	$ 18,099			$ 6,180			18,099
Employee Severance and Facility Closing [Member]
Restructuring Reserve [Roll Forward]
Balance at beginning of period			6,043				6,043
Restructuring and contract termination charges, net							26,847
Restructuring Reserve, Accrual Adjustment							569
Restructuring reserve Settled with Cash and Translation Adjustment							(15,548)
Balance at end of period	17,911			6,043			17,911
Contract Termination [Member]
Restructuring Reserve [Roll Forward]
Balance at beginning of period			137				137
Restructuring and contract termination charges, net							402
Restructuring Reserve, Accrual Adjustment							50
Restructuring reserve Settled with Cash and Translation Adjustment							(401)
Balance at end of period	188			137			188
Q3 2019 Restructuring Plan [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net	13,797
Q3 2019 Restructuring Plan [Member] | Employee Severance [Member]
Restructuring Reserve [Roll Forward]
Balance at beginning of period			0				0
Restructuring and contract termination charges, net							13,797
Restructuring Reserve, Accrual Adjustment							0
Restructuring reserve Settled with Cash and Translation Adjustment							(4,810)
Balance at end of period	8,987			0			8,987
Q2 2019 Restructuring Plan [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net		$ 5,590
Q2 2019 Restructuring Plan [Member] | Employee Severance [Member]
Restructuring Reserve [Roll Forward]
Balance at beginning of period			0				0
Restructuring and contract termination charges, net							5,590
Restructuring Reserve, Accrual Adjustment							0
Restructuring reserve Settled with Cash and Translation Adjustment							(2,701)
Balance at end of period	2,889			0			2,889
Q1 2019 Restructuring Plan [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net			7,460
Q1 2019 Restructuring Plan [Member] | Employee Severance [Member]
Restructuring Reserve [Roll Forward]
Balance at beginning of period			0				0
Restructuring and contract termination charges, net							7,460
Restructuring Reserve, Accrual Adjustment							23
Restructuring reserve Settled with Cash and Translation Adjustment							(5,150)
Balance at end of period	2,333			0			2,333
Q4 2018 Restructuring Plan [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net				348
Q4 2018 Restructuring Plan [Member] | Employee Severance [Member]
Restructuring Reserve [Roll Forward]
Balance at beginning of period			348				348
Restructuring and contract termination charges, net							0
Restructuring Reserve, Accrual Adjustment							0
Restructuring reserve Settled with Cash and Translation Adjustment							(348)
Balance at end of period	0			348			0
Q3 2018 Restructuring Plan [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net					$ 1,764
Q3 2018 Restructuring Plan [Member] | Employee Severance [Member]
Restructuring Reserve [Roll Forward]
Balance at beginning of period			1,415				1,415
Restructuring and contract termination charges, net							0
Restructuring Reserve, Accrual Adjustment							401
Restructuring reserve Settled with Cash and Translation Adjustment							(1,196)
Balance at end of period	620			1,415			620
Q1 2018 Restructuring Plan [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net						$ 5,998
Q1 2018 Restructuring Plan [Member] | Employee Severance [Member]
Restructuring Reserve [Roll Forward]
Balance at beginning of period			1,609				1,609
Restructuring and contract termination charges, net							0
Restructuring Reserve, Accrual Adjustment							0
Restructuring reserve Settled with Cash and Translation Adjustment							(283)
Balance at end of period	1,326			1,609			1,326
Previous restructuring and integration plans [Member] | Employee Severance and Facility Closing [Member]
Restructuring Reserve [Roll Forward]
Balance at beginning of period			2,671				2,671
Restructuring and contract termination charges, net							0
Restructuring Reserve, Accrual Adjustment							145
Restructuring reserve Settled with Cash and Translation Adjustment							(1,060)
Balance at end of period	1,756			2,671			1,756
Diagnostics [Member] | Contract Termination [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net							200
Diagnostics [Member] | Q3 2019 Restructuring Plan [Member] | Employee Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net	2,641
Diagnostics [Member] | Q2 2019 Restructuring Plan [Member] | Employee Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net		1,129
Diagnostics [Member] | Q1 2019 Restructuring Plan [Member] | Employee Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net			1,459
Diagnostics [Member] | Q4 2018 Restructuring Plan [Member] | Employee Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net				0
Diagnostics [Member] | Q3 2018 Restructuring Plan [Member] | Employee Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net					618
Diagnostics [Member] | Q1 2018 Restructuring Plan [Member] | Employee Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net						902
Discovery & Analytical Solutions [Member] | Contract Termination [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net							$ 300
Discovery & Analytical Solutions [Member] | Q3 2019 Restructuring Plan [Member] | Employee Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net	$ 11,156
Discovery & Analytical Solutions [Member] | Q2 2019 Restructuring Plan [Member] | Employee Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net		$ 4,461
Discovery & Analytical Solutions [Member] | Q1 2019 Restructuring Plan [Member] | Employee Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net			$ 6,001
Discovery & Analytical Solutions [Member] | Q4 2018 Restructuring Plan [Member] | Employee Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net				$ 348
Discovery & Analytical Solutions [Member] | Q3 2018 Restructuring Plan [Member] | Employee Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net					$ 1,146
Discovery & Analytical Solutions [Member] | Q1 2018 Restructuring Plan [Member] | Employee Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net						$ 5,096

Interest and Other Expense (I_3

Interest and Other Expense (Income), Net (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018
Other Income and Expenses [Abstract]
Interest income	$ (292)	$ (316)	$ (925)	$ (754)
Interest expense	16,149	16,684	49,206	50,745
Gain on disposition of businesses and assets, net	0	(13,031)	2,469	(13,031)
Gain (Loss) on Extinguishment of Debt	471	0	471	0
Other expense, net	(922)	(1,176)	658	(7,013)
Total interest and other expense, net	15,406	2,161	51,879	29,947
Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments		(2,500)	(4,200)	9,800
Foreign Currency Transaction Gain (Loss), before Tax	(4,700)	(4,300)	(9,200)	8,800
Defined Benefit Plan, Other Cost (Credit)	$ (1,400)	$ (2,500)	$ (4,400)	$ (7,500)

Inventories, Net (Details)

Inventories, Net (Details) - USD ($) $ in Thousands	Sep. 29, 2019	Dec. 30, 2018
Inventory Disclosure [Abstract]
Raw materials	$ 136,102	$ 119,115
Work in progress	31,192	18,110
Finished goods	224,526	201,122
Total inventories, net	$ 391,820	$ 338,347

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018
Income Tax Contingency [Line Items]
Provision for income taxes	$ 4,644	$ 2,596	$ 8,642	$ 12,101
Unrecognized tax benefits, gross	31,100		31,100
Uncertain tax benefits if recognized that could affect the continuing operations effective tax rate	29,400		29,400
Uncertain tax positions including accrued interest, net of tax benefits and penalties, to be resolved within the next year	1,300		$ 1,300
Open Tax Years by Major Tax Jurisdiction, Begin Date			2009
Tax Adjustments, Settlements, and Unusual Provisions			$ (12,700)	(7,100)
Discontinued Operation, Tax Effect of Discontinued Operation	52	(1,411)	147	(1,341)
Income Tax Expense (Benefit), Intraperiod Tax Allocation	$ 4,696	$ 1,185	8,789	10,760
Excess Income Tax Benefit on Stock Compensation			(4,600)	(5,400)
Discrete Income Tax Expense (Benefit), Tax Reform Trueup			2,700	(5,400)
Discrete Income Tax Expense (Benefit), Sale of Business				$ 7,100
Discrete Income Tax Expense (Benefit), Tax Election			(3,700)
US Federal Return To Provision Adjustments			$ (6,500)

Debt (Details)

Debt (Details) € in Millions, $ in Millions	Oct. 13, 2019USD ($)	Sep. 12, 2019USD ($)	Apr. 11, 2018USD ($)	Jul. 19, 2016EUR (€)	Oct. 25, 2011USD ($)	Sep. 29, 2019USD ($)	Dec. 30, 2012USD ($)	Sep. 29, 2019EUR (€)	Dec. 30, 2018USD ($)	Dec. 30, 2018EUR (€)
Line of Credit, Maturing September 17, 2024 [Member]
Line of Credit Facility, Maximum Borrowing Capacity						$ 1,000
Letters of credit issued and outstanding						11.4
Line of Credit Facility, Remaining Borrowing Capacity						957.3
Aggregate borrowings under the amended facility						31.3
Unamortized Debt Issuance Expense						3.5
Line of Credit, Maturing September 17, 2024 [Member] | Significant Other Observable Inputs (Level 2) [Member]
Long-term Debt						$ 27.8
Other Secured Bank Loan [Member]
Interest rate terms under amended senior unsecured revolving credit facility						The secured bank loans of $0.3 million bear fixed annual interest rates between 1.95% and 5.0% and are required to be repaid in monthly installments until 2027.
Secured Debt | €								€ 0.3		€ 0.3
Line of Credit, Maturing August 11, 2021 [Member]
Aggregate borrowings under the amended facility									$ 418
Unamortized Debt Issuance Expense									2.4
Line of Credit, Maturing August 11, 2021 [Member] | Significant Other Observable Inputs (Level 2) [Member]
Long-term Debt									415.6
2021 Notes [Member]
Debt Instrument, Interest Rate, Stated Percentage					5.00%
Unsecured senior notes, face value					$ 500
Gross proceeds from the issuance of debt instrument					493.6
Senior unsecured notes issuance as percentage of principal amount		99.40%
Debt Instrument, Unamortized Discount					$ 3.1	$ 0.8			1.1
Unamortized Debt Issuance Expense						1.2			1.6
2021 Notes [Member] | Significant Other Observable Inputs (Level 2) [Member]
Long-term Debt						498			497.4
Financing Lease Obligations [Member]
Initial Fair Value of Other Long-term Debt Related to Financing Lease Obligations							$ 29.3
Additional Financing Lease Obligations, funded by lessors							$ 11.5
Other Long-term Debt, Current									1.5
Other Long-term Debt, Noncurrent									33
Financing Lease Obligations [Member] | Significant Other Observable Inputs (Level 2) [Member]
Other Long-term Debt									34.5
1.875 Percent Ten Year Senior Unsecured Notes [Member]
Debt Instrument, Interest Rate, Stated Percentage				1.875%
Unsecured senior notes, face value | €				€ 500
Gross proceeds from the issuance of debt instrument | €				€ 492.3
Senior unsecured notes issuance as percentage of principal amount				99.118%
Debt Instrument, Unamortized Discount				€ 4.4		3.5			4
Percentage of redemption upon a change of control and a contemporaneous downgrade of the Notes				101.00%
Unamortized Debt Issuance Expense						3.4			3.8
1.875 Percent Ten Year Senior Unsecured Notes [Member] | Significant Other Observable Inputs (Level 2) [Member]
Long-term Debt						$ 540.1			564.5
1.875 Percent Ten Year Senior Unsecured Notes [Member] | Treasury Rate [Member]
Basis spread on variable rate						0.35%
0.6 Percent Senior Unsecured Notes due in April 2021 [Member]
Interest rate terms under amended senior unsecured revolving credit facility						Interest on the April 2021 Notes is payable annually on April 9th each year.
Debt Instrument, Interest Rate, Stated Percentage			0.60%
Unsecured senior notes, face value			$ 300
Gross proceeds from the issuance of debt instrument			$ 298.7
Senior unsecured notes issuance as percentage of principal amount			99.95%
Debt Instrument, Unamortized Discount			$ 0.2			$ 0.1			0.1
Percentage of redemption upon a change of control and a contemporaneous downgrade of the Notes			101.00%
Unamortized Debt Issuance Expense						1.3			2
0.6 Percent Senior Unsecured Notes due in April 2021 [Member] | Significant Other Observable Inputs (Level 2) [Member]
Long-term Debt						$ 326.8			341.3
0.6 Percent Senior Unsecured Notes due in April 2021 [Member] | Treasury Rate [Member]
Basis spread on variable rate						0.15%
3.3 Percent Ten Year Senior Unsecured Notes due in Sept 2029 [Member]
Interest rate terms under amended senior unsecured revolving credit facility						Interest on the 2029 Notes is payable semi-annually on March 15th and September 15th each year
Debt Instrument, Interest Rate, Stated Percentage		3.30%
Unsecured senior notes, face value		$ 850
Gross proceeds from the issuance of debt instrument		$ 847.2
Senior unsecured notes issuance as percentage of principal amount		99.67%
Debt Instrument, Unamortized Discount		$ 2.8				$ 2.8
Percentage of redemption upon a change of control and a contemporaneous downgrade of the Notes		101.00%
Unamortized Debt Issuance Expense						8.1
3.3 Percent Ten Year Senior Unsecured Notes due in Sept 2029 [Member] | Significant Other Observable Inputs (Level 2) [Member]
Long-term Debt						$ 839.1
3.3 Percent Ten Year Senior Unsecured Notes due in Sept 2029 [Member] | Treasury Rate [Member]
Basis spread on variable rate						0.25%
Other Debt Facilities - EUROIMMUN [Member]
Interest rate terms under amended senior unsecured revolving credit facility						Of these bank loans, loans in the aggregate amount of $25.3 million bear fixed interest rates between 1.1% and 4.5% and a loan in the amount of $0.1 million bears a variable interest rate based on the Euribor rate plus a margin of 1.5%..
Long-term Debt, Percentage Bearing Variable Interest, Amount | €								0.1
Long-term Debt, Percentage Bearing Fixed Interest, Amount | €								25.6
Other Debt Facilities - EUROIMMUN [Member] | Significant Other Observable Inputs (Level 2) [Member]
Other Long-term Debt | €								€ 25.7		38.2
Other Debt Facilities - EUROIMMUN [Member] | Euribor Rate [Member]
Basis spread on variable rate						1.50%
Other Unsecured Revolving Debt Facilities [Member]
Other Unsecured Revolving Credit Facilities									$ 5.8
Interest rate terms under amended senior unsecured revolving credit facility						The unsecured revolving debt facilities had fixed interest at a rate of 2.3%.
Debt Instrument, Interest Rate, Stated Percentage						2.30%		2.30%
Unsecured Revolving Credit Facility [Member] | Line of Credit, Maturing September 17, 2024 [Member]
Interest rate terms under amended senior unsecured revolving credit facility						The interest rates on the Eurocurrency Rate loans are based on the Eurocurrency Rate at the time of borrowing, plus a percentage spread based on the credit rating of the Company's debt. The interest rates on the US Dollar Base Rate loans are based on the US Dollar Base Rate at the time of borrowing, plus a percentage spread based on the credit rating of the Company's debt. The base rate is the higher of (i) the Federal Funds Rate (as defined in the new credit agreement) plus 50 basis points (ii) the rate of interest in effect for such day as publicly announced from time to time by Bank of America as its "prime rate," or (iii) the Eurocurrency Rate plus 1.00%. The Eurocurrency margin as of September 29, 2019 was 101.5 basis points.
Weighted average interest rates under amended senior unsecured revolving credit facility						The weighted average Eurocurrency interest rate as of September 29, 2019 was 0.75%, resulting in a weighted average effective Eurocurrency Rate, including the margin, of 1.77%, which was the interest applicable to the borrowings outstanding as of September 29, 2019.
Unsecured Revolving Credit Facility [Member] | Line of Credit, Maturing September 17, 2024 [Member] | Base Rate Option Two [Member]
Basis spread on variable rate						0.50%
Unsecured Revolving Credit Facility [Member] | Line of Credit, Maturing September 17, 2024 [Member] | Base Rate Option Three [Member]
Basis spread on variable rate						1.05%
Subsequent Event [Member] | 2021 Notes [Member]
Debt Redemption, Pre-tax Non-operating Charges	$ 32.3
Debt Redemption, Make-whole	31.3
Debt Redemption, Deferred costs and Original Issue Discount	2
Reverse Treasury Rate Lock Settlement	$ 1
United States of America, Dollars | Other Debt Facilities - EUROIMMUN [Member]
Unsecured Debt | €								€ 21.4
Secured Debt | €								4
Other Long-term Debt | €								25.4		32.1
Long-term Debt, Percentage Bearing Fixed Interest, Amount | €								25.3
Euro Member Countries, Euro | Other Debt Facilities - EUROIMMUN [Member]
Other Long-term Debt | €								€ 23.2		€ 28
Minimum [Member] | Other Secured Bank Loan [Member]
Debt Instrument, Interest Rate, Stated Percentage						1.95%		1.95%
Minimum [Member] | Other Debt Facilities - EUROIMMUN [Member]
Debt Instrument, Interest Rate, Stated Percentage						1.10%		1.10%
Minimum [Member] | United States of America, Dollars | Other Debt Facilities - EUROIMMUN [Member]
Debt Instrument, Interest Rate, Stated Percentage						1.10%		1.10%
Maximum [Member] | Other Secured Bank Loan [Member]
Debt Instrument, Interest Rate, Stated Percentage						5.00%		5.00%
Maximum [Member] | Other Debt Facilities - EUROIMMUN [Member]
Debt Instrument, Interest Rate, Stated Percentage						4.50%		4.50%

Earnings Per Share (Schedule of

Earnings Per Share (Schedule of Reconciliation of Number of Shares Utilized in Earnings Per Share Calculations) (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018
Earnings Per Share [Abstract]
Number of common shares-basic	110,946	110,724	110,778	110,499
Effect of dilutive securities, Stock options	484	791	558	813
Effect of dilutive securities, Restricted stock	129	232	124	198
Number of common shares-diluted	111,559	111,747	111,460	111,510
Number of potentially dilutive securities excluded from calculation due to antidilutive impact	413	358	396	346

Industry Segment Information In

Industry Segment Information Industry Segment Information Narrative (Details)	3 Months Ended
	Sep. 29, 2019segments
Segment Reporting Information [Line Items]
Number of Operating Segment	2

Industry Segment Information (S

Industry Segment Information (Schedule of Sales and Operating Income by Operating Segment, Excluding Discontinued Operations) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018
Segment Reporting Information [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	$ 706,923	$ 674,313	$ 2,078,177	$ 2,021,647
Operating income (loss) from continuing operations	78,660	80,202	223,725	208,201
Interest and other expense, net	15,406	2,161	51,879	29,947
Income from continuing operations before income taxes	63,254	78,041	171,846	178,254
Product [Member]
Segment Reporting Information [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	493,320	474,523	1,434,156	1,417,739
Service [Member]
Segment Reporting Information [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	213,603	199,790	644,021	603,908
Corporate [Member]
Segment Reporting Information [Line Items]
Operating income (loss) from continuing operations	(21,130)	(15,590)	(51,422)	(45,627)
Diagnostics [Member]
Segment Reporting Information [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	280,019	268,147	828,473	788,328
Operating income (loss) from continuing operations	47,443	47,411	128,184	104,585
Diagnostics [Member] | Product [Member]
Segment Reporting Information [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	237,202	227,273	695,734	669,469
Diagnostics [Member] | Service [Member]
Segment Reporting Information [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	42,817	40,874	132,739	118,859
Discovery & Analytical Solutions [Member]
Segment Reporting Information [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	426,904	406,166	1,249,704	1,233,319
Operating income (loss) from continuing operations	52,347	48,381	146,963	149,243
Discovery & Analytical Solutions [Member] | Product [Member]
Segment Reporting Information [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	256,118	247,250	738,422	748,270
Discovery & Analytical Solutions [Member] | Service [Member]
Segment Reporting Information [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	$ 170,786	$ 158,916	$ 511,282	$ 485,049

Stockholders' Equity (Narrative

Stockholders' Equity (Narrative) (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended						9 Months Ended	12 Months Ended
	Dec. 29, 2019	Sep. 29, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 30, 2018	Sep. 30, 2018	Sep. 29, 2019	Dec. 29, 2019	Jul. 23, 2018
Schedule of Shareholders' Equity [Line Items]
Stock Repurchase Program, Remaining Authorized Repurchase Amount		$ 197.8					$ 197.8
Repurchased Common Shares For Activity Pursuant to Equity Incentive Plans		1,654					67,222
Aggregate Cost of Repurchased Common Shares for Activity Pursuant to Equity Incentive Plans		$ 0.1					$ 6.2
Cash dividends (per share)		$ 0.07	$ 0.07	$ 0.07	$ 0.07	$ 0.07
Dividends Payable, Amount		$ 7.8					$ 7.8
Dividends Payable, Date Declared		Jul. 25, 2019
Repurchase Program, 07/23/2018 [Member]
Schedule of Shareholders' Equity [Line Items]
Stock Repurchase Program, Authorized Amount									$ 250
Subsequent Event [Member]
Schedule of Shareholders' Equity [Line Items]
Cash dividends (per share)	$ 0.07
Dividends Payable, Date Declared								Oct. 24, 2019

Stockholders' Equity (Component

Stockholders' Equity (Components Of Accumulated Other Comprehensive Loss) (Details) - USD ($) $ in Thousands	Sep. 29, 2019	Dec. 30, 2018
Stockholders' Equity Note [Abstract]
Foreign currency translation adjustments, net of income taxes	$ (243,413)	$ (176,459)
Unrecognized losses and prior service costs, net of income taxes	245	245
Unrealized net losses on securities, net of income taxes	(289)	(267)
Accumulated other comprehensive loss	$ (243,457)	$ (176,481)

Stock Plans (Narrative) (Detail

Stock Plans (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018	Dec. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total income tax benefit recognized for stock-based compensation	$ 2,800	$ 6,100	$ 10,000	$ 10,600
Stock-based compensation costs capitalized as part of inventory			400
Proceeds from issuance of common stock under stock plans			17,563	19,484
Total pre-tax stock-based compensation expense	12,304	$ 11,127	$ 25,105	$ 23,275
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant-date fair value of options		$ 18.65	$ 22.64	$ 17.56
Total intrinsic value of options exercised	600	$ 18,900	$ 17,300	$ 25,300
Proceeds from issuance of common stock under stock plans			17,600	19,500
Total pre-tax stock-based compensation expense	3,100	1,400	5,700	4,000
Total unrecognized compensation cost, net of estimated forfeitures, related to nonvested stock, granted	7,700		$ 7,700
Weighted-average period for recognition of unrecognized compensation cost, years			1 year 10 months 24 days
Restricted Stock Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total pre-tax stock-based compensation expense	4,700	3,000	$ 10,200	8,700
Total unrecognized compensation cost, net of estimated forfeitures, related to nonvested stock, granted	$ 18,200		$ 18,200
Weighted-average period for recognition of unrecognized compensation cost, years			1 year 6 months
Awards/units outstanding	355,000		355,000		465,000
Number of Shares, Granted			161,000
Weighted-average grant-date fair value of stock granted (per share)			$ 94.88
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period			57,000
Fair value of restricted stock awards vested	$ 400	1,100	$ 11,700	10,000
Performance Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total pre-tax stock-based compensation expense	$ 1,300	5,300	$ 3,700	7,600
Awards/units outstanding	71,213		71,213
Number of Shares, Granted			0
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period			10,116
Deferred Compensation Share-based Arrangements, Liability, Current and Noncurrent	$ 8,500		$ 8,500
Stock Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total pre-tax stock-based compensation expense			$ 700	$ 800
Number of Shares, Granted			7,301
Weighted-average grant-date fair value of stock granted (per share)			$ 95.84
Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized under plan	5,000,000		5,000,000
Number of Shares, Granted			33,843	21,321
Weighted-average grant-date fair value of stock granted (per share)			$ 82.25	$ 69.57
Shares available for grant under employee stock purchase plan	800,000		800,000
Performance Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total pre-tax stock-based compensation expense	$ 3,200	$ 1,300	$ 4,800	$ 2,200
Awards/units outstanding	145,114		145,114
Number of Shares, Granted			76,218
Weighted-average grant-date fair value of stock granted (per share)			$ 92.95
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period			18,777
2019 Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized under plan	6,250,000		6,250,000

Stock Plans (Summary of Total C

Stock Plans (Summary of Total Compensation Recognized Related to Outstanding Stock Options) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total pre-tax stock-based compensation expense	$ 12,304	$ 11,127	$ 25,105	$ 23,275
Cost of sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total pre-tax stock-based compensation expense	477	430	1,188	1,093
Research and development expenses [Member ]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total pre-tax stock-based compensation expense	178	335	802	1,029
Selling, general and administrative and other expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total pre-tax stock-based compensation expense	$ 11,649	$ 10,362	$ 23,115	$ 21,153

Stock Plans (Weighted-Average A

Stock Plans (Weighted-Average Assumptions Used in the Black-Scholes Option Pricing Model) (Details)	9 Months Ended
	Sep. 29, 2019	Sep. 30, 2018
Share-based Payment Arrangement [Abstract]
Risk-free interest rate	1.90%	2.90%
Expected dividend yield	0.30%	0.40%
Expected lives, years	5 years	5 years
Expected stock volatility	22.80%	20.70%

Stock Plans (Summary of Stock O

Stock Plans (Summary of Stock Option Activity) (Details) $ / shares in Units, shares in Thousands, $ in Millions	9 Months Ended
	Sep. 29, 2019USD ($)$ / sharesshares
Stock option activity
Number of Shares, Outstanding at beginning of period | shares	1,765
Number of Shares, Granted | shares	302
Number of Shares, Exercised | shares	(371)
Number of Shares, Forfeited | shares	(112)
Number of Shares, Outstanding at end of period | shares	1,584
Number of Shares, Exercisable at end of period | shares	997
Weighted-Average Price, Outstanding at beginning of period | $ / shares	$ 52.91
Weighted-Average Price, Granted | $ / shares	93.67
Weighted-Average Price, Exercised | $ / shares	47.30
Weighted-Average Price, Forfeited | $ / shares	78.29
Weighted-Average Price, Outstanding at end of period | $ / shares	60.20
Weighted-Average Price, Exercisable at end of period | $ / shares	$ 48.75
Weighted-Average Remaining Contractual Term in Years, Outstanding at end of period	4 years
Weighted-Average Remaining Contractual Term in Years, Exercisable at end of period	3 years 1 month 6 days
Total Intrinsic Value, Outstanding at end of period | $	$ 39.5
Total Intrinsic Value, Exercisable at end of period | $	$ 36.3

Stock Plans (Summary of Restric

Stock Plans (Summary of Restricted Stock Award Activity) (Details) - Restricted Stock Awards [Member] shares in Thousands	9 Months Ended
	Sep. 29, 2019$ / sharesshares
Restricted stock award activity
Number of Shares, Nonvested at beginning of period | shares	465
Number of Shares, Granted | shares	161
Number of Shares, Vested | shares	(214)
Number of Shares, Forfeited | shares	(57)
Number of Shares, Nonvested at end of period | shares	355
Weighted-Average Grant-Date Fair Value, Nonvested at beginning of period | $ / shares	$ 61.72
Weighted-Average Grant-Date Fair Value, Granted | $ / shares	94.88
Weighted-Average Grant-Date Fair Value, Vested | $ / shares	54.91
Weighted-Average Grant-Date Fair Value, Forfeited | $ / shares	75.90
Weighted-Average Grant-Date Fair Value, Nonvested at end of period | $ / shares	$ 78.57

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets, Net (Narrative) (Details) - USD ($) $ in Thousands	Jan. 01, 2019	Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018	Dec. 30, 2018
Goodwill and Intangible Assets Net [Line Items]
Change in any one of the input assumptions for the various reporting units	10.00%
Goodwill		$ 2,987,541		$ 2,987,541		$ 2,952,608
Total amortization expense related to finite-lived intangible assets		41,300	$ 35,300	121,200	$ 100,700
Future Amortization Expense, Year One		40,500		40,500
Future Amortization Expense, Year Two		172,100		172,100
Future Amortization Expense, Year Three		157,200		157,200
Future Amortization Expense, Year Four		141,600		141,600
Future Amortization Expense, Year Five		118,600		118,600
Finite-Lived Intangible Assets, Net		1,128,877		1,128,877		1,129,083
Intangible assets, net		1,199,461		1,199,461		1,199,667
Minimum [Member]
Goodwill and Intangible Assets Net [Line Items]
Long-term terminal growth rates for reporting units	3.00%
Discount rates for reporting units	10.50%
Maximum [Member]
Goodwill and Intangible Assets Net [Line Items]
Long-term terminal growth rates for reporting units	5.00%
Discount rates for reporting units	15.00%
Patents [Member]
Goodwill and Intangible Assets Net [Line Items]
Gross amortizable intangible assets		30,816		30,816		42,646
Less: Accumulated amortization		27,136		27,136		37,753
Finite-Lived Intangible Assets, Net		3,680		3,680		4,893
Trade Names And Trademarks [Member]
Goodwill and Intangible Assets Net [Line Items]
Gross amortizable intangible assets		81,103		81,103		78,146
Less: Accumulated amortization		38,138		38,138		33,801
Finite-Lived Intangible Assets, Net		42,965		42,965		44,345
Licensing Agreements [Member]
Goodwill and Intangible Assets Net [Line Items]
Gross amortizable intangible assets		58,728		58,728		53,305
Less: Accumulated amortization		48,664		48,664		45,550
Finite-Lived Intangible Assets, Net		10,064		10,064		7,755
Core Technology [Member]
Goodwill and Intangible Assets Net [Line Items]
Gross amortizable intangible assets		637,051		637,051		540,911
Less: Accumulated amortization		302,709		302,709		265,744
Finite-Lived Intangible Assets, Net		334,342		334,342		275,167
Customer Relationships [Member]
Goodwill and Intangible Assets Net [Line Items]
Gross amortizable intangible assets		1,084,801		1,084,801		1,089,527
Less: Accumulated amortization		348,275		348,275		293,964
Finite-Lived Intangible Assets, Net		736,526		736,526		795,563
In-process Research and Development [Member]
Goodwill and Intangible Assets Net [Line Items]
Gross amortizable intangible assets		$ 1,300		$ 1,300		$ 1,360

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets, Net (Changes in the Carrying Amount of Goodwill) (Details) $ in Thousands	9 Months Ended
	Sep. 29, 2019USD ($)
Changes in the carrying amount of goodwill
Balance at beginning of period	$ 2,952,608
Foreign currency translation	(50,283)
Goodwill, Acquisition, Earn Outs and Other Adjustments	85,216
Balance at end of period	2,987,541
Diagnostics [Member]
Changes in the carrying amount of goodwill
Balance at beginning of period	1,617,616
Foreign currency translation	(27,941)
Goodwill, Acquisition, Earn Outs and Other Adjustments	67,246
Balance at end of period	1,656,921
Discovery & Analytical Solutions [Member]
Changes in the carrying amount of goodwill
Balance at beginning of period	1,334,992
Foreign currency translation	(22,342)
Goodwill, Acquisition, Earn Outs and Other Adjustments	17,970
Balance at end of period	$ 1,330,620

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets, Net (Identifiable Intangible Asset Balances) (Details) - USD ($) $ in Thousands	Sep. 29, 2019	Dec. 30, 2018
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Net amortizable intangible assets	$ 1,128,877	$ 1,129,083
Intangible assets, net	1,199,461	1,199,667
Patents [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	30,816	42,646
Less: Accumulated amortization	(27,136)	(37,753)
Net amortizable intangible assets	3,680	4,893
Trade Names And Trademarks [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	81,103	78,146
Less: Accumulated amortization	(38,138)	(33,801)
Net amortizable intangible assets	42,965	44,345
Trade names and trademarks	70,584	70,584
Licensing Agreements [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	58,728	53,305
Less: Accumulated amortization	(48,664)	(45,550)
Net amortizable intangible assets	10,064	7,755
Core Technology [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	637,051	540,911
Less: Accumulated amortization	(302,709)	(265,744)
Net amortizable intangible assets	334,342	275,167
Customer Relationships [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	1,084,801	1,089,527
Less: Accumulated amortization	(348,275)	(293,964)
Net amortizable intangible assets	736,526	795,563
In-process Research and Development [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	$ 1,300	$ 1,360

Warranty Reserves (Details)

Warranty Reserves (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018
Warranty reserve activity
Balance beginning of period	$ 7,985	$ 8,943	$ 8,393	$ 9,050
Provision charged to income	2,899	3,327	8,601	10,012
Payments	(3,999)	(3,547)	(10,536)	(10,514)
Adjustments to previously provided warranties, net	1,239	(226)	1,658	110
Foreign currency translation and acquisitions	(169)	(49)	(161)	(210)
Balance end of period	$ 7,955	$ 8,448	$ 7,955	$ 8,448

Employee Benefit Plans (Compone

Employee Benefit Plans (Components of Net Periodic Benefit Cost (Credit)) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018
Defined Benefit Pension Benefits [Member]
Components of net periodic benefit cost (credit)
Service cost	$ 1,698	$ 1,712	$ 4,960	$ 5,180
Interest cost	4,136	4,051	12,445	12,212
Expected return on plan assets	(6,132)	(7,270)	(18,469)	(21,926)
Amortization of prior service	(38)	(41)	(115)	(123)
Net periodic benefit cost (credit)	(336)	(1,548)	(1,179)	(4,657)
Postretirement Medical Benefits [Member]
Components of net periodic benefit cost (credit)
Service cost	22	27	66	80
Interest cost	29	30	87	90
Expected return on plan assets	(294)	(314)	(882)	(941)
Amortization of prior service	0	0	0	0
Net periodic benefit cost (credit)	$ (243)	$ (257)	(729)	(771)
Foreign Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Plan Assets, Contributions by Employer			$ 6,100	$ 6,400

Derivatives And Hedging Activ_2

Derivatives And Hedging Activities (Details) $ in Thousands, € in Millions	Oct. 13, 2019USD ($)	Sep. 29, 2019USD ($)	Sep. 30, 2018USD ($)	Sep. 29, 2019USD ($)	Sep. 30, 2018USD ($)	Sep. 29, 2019EUR (€)	Dec. 30, 2018USD ($)	Dec. 30, 2018EUR (€)	Jul. 01, 2018USD ($)	Jul. 01, 2018EUR (€)
Derivative [Line Items]
Company's business conducted outside United States				70.00%
Payments for Hedge, Financing Activities				$ 1,600
Payments for (Proceeds from) Hedge, Financing Activities				1,587	$ 30,285
Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net		$ 0		0
Foreign Currency Transaction Gain (Loss), before Tax		(4,700)	$ (4,300)	(9,200)	8,800
2021 Notes [Member]
Derivative [Line Items]
Notional Amount of Nonderivative Instruments				500,000
Unrealized Gain (Loss) on Derivatives				$ 200
European And Asian Currencies [Member]
Derivative [Line Items]
Maximum maturity period for foreign exchange contracts, in months				12 months
Duration Of Foreign Currency Derivatives				30 days
Fair Value Hedging [Member]
Derivative [Line Items]
Derivative, Notional Amount		282,300		$ 282,300			$ 223,300		$ 180,400
Notional Amount of Euro Derivatives [Member]
Derivative [Line Items]
Derivative, Notional Amount | €						€ 14.9		€ 37.3		€ 48.7
Notional Amount of US Dollar Derivatives [Member] | Cash Flow Hedging [Member]
Derivative [Line Items]
Derivative, Notional Amount		8,700		8,700			$ 5,700		$ 28,000
Net Investment Hedging [Member] | 1.875 Percent Ten Year Senior Unsecured Notes [Member]
Derivative [Line Items]
Notional Amount of Nonderivative Instruments				134,300
Unrealized Gain (Loss) on Net Investment Hedge in AOCI		5,800	800	8,900	7,700
Net Investment Hedging [Member] | 0.6 Percent Senior Unsecured Notes due in April 2021 [Member]
Derivative [Line Items]
Notional Amount of Nonderivative Instruments				299,900
Unrealized Gain (Loss) on Net Investment Hedge in AOCI		$ 12,800	$ 1,800	$ 15,100	$ 22,600
Subsequent Event [Member] | 2021 Notes [Member]
Derivative [Line Items]
Reverse Treasury Rate Lock Settlement	$ 1,000
United States of America, Dollars | Cross-currency Swap [Member]
Derivative [Line Items]
Derivative, Fixed Interest Rate		5.00%		5.00%		5.00%
United States of America, Dollars | Net Investment Hedging [Member] | Cross-currency Swap [Member]
Derivative [Line Items]
Notional Amount of Nonderivative Instruments				$ 220,000
Fair Value of Cross-currency Swap		$ 4,700		$ 4,700
Euro Member Countries, Euro | Cross-currency Swap [Member]
Derivative [Line Items]
Derivative, Fixed Interest Rate		2.47%		2.47%		2.47%
Euro Member Countries, Euro | Net Investment Hedging [Member] | Cross-currency Swap [Member]
Derivative [Line Items]
Notional Amount of Nonderivative Instruments				$ 197,400

Fair Value Measurements (Narrat

Fair Value Measurements (Narrative) (Details) $ in Thousands, € in Millions

9 Months Ended

12 Months Ended

Sep. 29, 2019USD ($)

Sep. 30, 2018USD ($)

Jan. 03, 2016USD ($)

Sep. 29, 2019EUR (€)

Sep. 12, 2019USD ($)

Jun. 30, 2019USD ($)

Dec. 30, 2018USD ($)

Dec. 30, 2018EUR (€)

Jul. 01, 2018USD ($)

Apr. 11, 2018USD ($)

Dec. 31, 2017USD ($)

Jul. 19, 2016EUR (€)

Oct. 25, 2011USD ($)

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High

$ 28,000

Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value

$ 25,502

$ 67,126

$ 34,261

$ 69,661

$ 74,093

$ 65,328

Business Combination, Contingent Consideration Arrangements, Description

Contingent consideration is measured at fair value at the acquisition date, based on the probability that revenue thresholds or product development milestones will be achieved during the earnout period, with changes in the fair value after the acquisition date affecting earnings to the extent it is to be settled in cash.

Business Combination, Contingent Consideration Arrangements, Maximum Period

2 years 9 months 18 days

Business Combination, Contingent Consideration Arrangements, Weighted Average Period

9 years

Payments for acquisition related contingent consideration

$ (28,200)

$ (12,800)

Line of Credit, Maturing September 17, 2024 [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Line of Credit Facility, Maximum Borrowing Capacity

1,000,000

Revolving credit facility outstanding balance

31,300

Unamortized Debt Issuance Expense

3,500

Line of Credit, Maturing August 11, 2021 [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Revolving credit facility outstanding balance

418,000

Unamortized Debt Issuance Expense

2,400

1.875 Percent Ten Year Senior Unsecured Notes [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Unamortized Debt Issuance Expense

3,400

3,800

Unsecured senior notes, face value | €

€ 500

Debt Instrument, Unamortized Discount

(3,500)

(4,000)

€ (4.4)

1.875 Percent Ten Year Senior Unsecured Notes [Member] | Euro Member Countries, Euro

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Unsecured senior notes, fair value

526,000

496,100

0.6 Percent Senior Unsecured Notes due in April 2021 [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Unamortized Debt Issuance Expense

1,300

2,000

Unsecured senior notes, face value

$ 300,000

Debt Instrument, Unamortized Discount

(100)

(100)

$ (200)

Unsecured senior notes, fair value

302,800

300,500

2021 Notes [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Unamortized Debt Issuance Expense

1,200

1,600

Unsecured senior notes, face value

$ 500,000

Debt Instrument, Unamortized Discount

(800)

(1,100)

$ (3,100)

Unsecured senior notes, fair value

526,200

516,100

3.3 Percent Ten Year Senior Unsecured Notes due in Sept 2029 [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Unamortized Debt Issuance Expense

8,100

Unsecured senior notes, face value

$ 850,000

Debt Instrument, Unamortized Discount

(2,800)

$ (2,800)

Unsecured senior notes, fair value

851,000

Other Debt Facilities - EUROIMMUN [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Long-term Debt, Percentage Bearing Fixed Interest, Amount | €

€ 25.6

Other Debt Facilities - EUROIMMUN [Member] | Euro Member Countries, Euro

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Other Long-term Debt | €

€ 23.2

€ 28

Vanadis Diagnostics AB [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Payments to Acquire Businesses, Net of Cash Acquired

$ 32,000

Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value

19,200

56,900

Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High

$ 93,000

Vanadis Diagnostics AB & Shanghai Spectrum Instruments Co., Ltd [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Payments for acquisition related contingent consideration

48,500

Payment for Contingent Consideration Liability, Operating Activities

20,300

Payment for Contingent Consideration Liability, Financing Activities

$ 28,200

Minimum [Member] | Vanadis Diagnostics AB [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Conditional probability of success

95.00%

95.00%

Measurement Inputs, Discount Rate

0.60%

Maximum [Member] | Vanadis Diagnostics AB [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Projected milestone date

2020

Conditional probability of success

98.00%

98.00%

Measurement Inputs, Discount Rate

1.60%

Significant Other Observable Inputs (Level 2) [Member] | Line of Credit, Maturing September 17, 2024 [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Long-term Debt

$ 27,800

Significant Other Observable Inputs (Level 2) [Member] | Line of Credit, Maturing August 11, 2021 [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Long-term Debt

415,600

Significant Other Observable Inputs (Level 2) [Member] | 1.875 Percent Ten Year Senior Unsecured Notes [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Long-term Debt

540,100

564,500

Significant Other Observable Inputs (Level 2) [Member] | 0.6 Percent Senior Unsecured Notes due in April 2021 [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Long-term Debt

326,800

341,300

Significant Other Observable Inputs (Level 2) [Member] | 2021 Notes [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Long-term Debt

498,000

497,400

Significant Other Observable Inputs (Level 2) [Member] | 3.3 Percent Ten Year Senior Unsecured Notes due in Sept 2029 [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Long-term Debt

$ 839,100

Significant Other Observable Inputs (Level 2) [Member] | Financing Lease Obligations [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Other Long-term Debt

$ 34,500

Significant Other Observable Inputs (Level 2) [Member] | Other Debt Facilities - EUROIMMUN [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Other Long-term Debt | €

€ 25.7

€ 38.2

Fair Value Measurements (Assets

Fair Value Measurements (Assets and Liabilities Carried at Fair Value Measured on a Recurring Basis) (Details) - USD ($) $ in Thousands	Sep. 29, 2019	Jun. 30, 2019	Dec. 30, 2018	Sep. 30, 2018	Jul. 01, 2018	Dec. 31, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	$ 25,502	$ 34,261	$ 69,661	$ 67,126	$ 74,093	$ 65,328
Fair Value, Recurring [Member] | Carrying (Reported) Amount, Fair Value Disclosure [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	2,708		2,447
Foreign exchange derivative assets, net	(272)		(750)
Foreign exchange derivative liabilities, net	(646)		(594)
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	25,502		69,661
Fair Value, Recurring [Member] | Quoted Prices In Active Markets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	2,708		2,447
Foreign exchange derivative assets, net	0		0
Foreign exchange derivative liabilities, net	0		0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	0		0
Fair Value, Recurring [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	0		0
Foreign exchange derivative assets, net	(272)		(750)
Foreign exchange derivative liabilities, net	(646)		(594)
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	0		0
Fair Value, Recurring [Member] | Significant Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	0		0
Foreign exchange derivative assets, net	0		0
Foreign exchange derivative liabilities, net	0		0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	$ 25,502		$ 69,661

Fair Value Measurements (Reconc

Fair Value Measurements (Reconciliation of Beginning and Ending Level 3 Net Liabilities) (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018
Fair Value Disclosures [Abstract]
Balance beginning of period	$ (34,261,000)	$ (74,093,000)	$ (69,661,000)	$ (65,328,000)
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases	0	(5,800,000)	0	(7,500,000)
Payments	9,997,000	16,507,000	48,558,000	16,507,000
Change in fair value (included within selling, general and administrative expenses)	(1,238,000)	(3,740,000)	(4,399,000)	(10,805,000)
Balance end of period	$ (25,502,000)	$ (67,126,000)	$ (25,502,000)	$ (67,126,000)

Contingencies (Details)

Contingencies (Details) $ in Millions	9 Months Ended
	Sep. 29, 2019USD ($)years
Commitments and Contingencies Disclosure [Abstract]
Management's estimate of total cost of ultimate disposition | $	$ 7.9
Number of years over which estimated environmental cost will be paid | years	10

Leases (Details)

Leases (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 29, 2019	Sep. 29, 2019
Leases [Abstract]
Operating Lease, Cost	$ 14,846	$ 44,766
Schedule Of Supplemental Cash Flow Information Related To Leases [Line Items]
Operating Lease, Payments	$ 12,938	$ 37,663

Leases Supplemental Balance She

Leases Supplemental Balance Sheet Information Related to Leases (Details) - USD ($) $ in Thousands	Sep. 29, 2019	Dec. 31, 2018	Dec. 30, 2018
Schedule of Supplemental Balance Sheet Information Related To Leases [Line Items]
Operating Lease, Right-of-Use Asset	$ 174,689	$ 199,500	$ 0
Operating Lease, Liability, Current	37,453
Operating Lease, Liability, Noncurrent	153,216		$ 0
Operating Lease, Liability	$ 190,669	$ 147,100
Operating Lease, Weighted Average Remaining Lease Term	7 years 7 months 6 days
Operating Lease, Weighted Average Discount Rate, Percent	3.30%

Leases Lessee, Operating Lease,

Leases Lessee, Operating Lease, Liability, Maturity (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 29, 2019	Sep. 29, 2019	Dec. 31, 2018
Operating Lease Liabilities, Maturity [Line Items]
Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year	$ 12,284	$ 12,284
Lessee, Operating Lease, Liability, Payments, Due Year Two	43,049	43,049
Lessee, Operating Lease, Liability, Payments, Due Year Three	35,771	35,771
Lessee, Operating Lease, Liability, Payments, Due Year Four	24,964	24,964
Lessee, Operating Lease, Liability, Payments, Due Year Five	20,021	20,021
Operating Lease, Payments	12,938	37,663
Lessee, Operating Lease, Liability, Payments, Due Year Six	17,843	17,843
Lessee, Operating Lease, Liability, Payments, Due After Year Six	65,505	65,505
Lessee, Operating Lease, Liability, Payments, Due	219,437	219,437
Lessee, Operating Lease, Liability, Undiscounted Excess Amount	(28,768)	(28,768)
Operating Lease, Liability	$ 190,669	$ 190,669	$ 147,100

Leases Minimum Rental Commitmen

Leases Minimum Rental Commitments Under Noncancelable Operating Leases, Under ASC 840 (Details) $ in Millions	Dec. 30, 2018USD ($)
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
Operating Leases, Future Minimum Payments, Remainder of Fiscal Year	$ 56.4
Operating Leases, Future Minimum Payments, Due in Two Years	46.6
Operating Leases, Future Minimum Payments, Due in Three Years	33.5
Operating Leases, Future Minimum Payments, Due in Four Years	22.1
Operating Leases, Future Minimum Payments, Due in Five Years	15.6
Operating Leases, Future Minimum Payments, Due Thereafter	$ 67.6

Uncategorized Items - pki-09292

Label	Element	Value
Restricted Cash	us-gaap_RestrictedCash	$ 3,008,000
Restricted Cash	us-gaap_RestrictedCash	3,204,000
Accounting Standards Update 2014-09 [Member] | Retained Earnings [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	10,209,000
Accounting Standards Update 2016-16 [Member] | Retained Earnings [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ (2,062,000)